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General Abstract 
Introduction: Chapter 1 
Chronic liver disease causes 1.75 million deaths globally and is within the top 10 leading causes of 
death in middle income countries. Chronic liver injury occurs via a process of inflammation and 
fibrosis formation. Patients often do not present to healthcare until advanced stages of disease and 
when there is already decompensated cirrhosis. Liver biopsy has been used to identify earlier stages 
of fibrosis, but it is poorly accepted by patients and has limitations. Transient Elastography (TE) using 
Fibroscan ® is a non-invasive tool for the diagnosis liver fibrosis. The clinical application of Fibroscan 
in non-alcoholic fatty disease (NAFLD), chronic hepatitis B (CHB), and methotrexate induced liver 
fibrosis were examined.  
Clinical Utility of Transient Elastography in non-alcoholic fatty liver disease: Chapters 2, 3 and 4 
Non-alcoholic fatty liver disease affects 20-35% of the global population, but only a small subset 
develop the histological subtype of non-alcoholic steatohepatitis (NASH), which can lead to 
progressive liver disease by causing fibrosis and eventually cirrhosis. Fibroscan can potentially 
identify those patients who have fibrosis and are at increased risk of further progression. Patients 
with type 2 diabetes, who are at high risk of NASH, were assessed. A liver stiffness measurement 
(LSM) ≥9.8 kPa, used as a cut-off for advanced fibrosis (1), was found in 12% (10/77) of subjects. 
Higher LSM readings correlated with higher BMI and the use of insulin therapy. Patients on insulin 
had LSM ≥9.8 kPa with likelihood ratio (LR): 12.3, p=0.002 (Chapter 2). The study was limited by a 
small sample size, and a high failure rate as the medium (M) probe was only available. 
A systemic review evaluating all non-invasive methods for diagnosing NASH and NAFLD fibrosis was 
undertaken. This included a meta-analysis that focused on what was found to be the most widely 
studied markers of NASH and NAFLD fibrosis: cytokeratin-18 (CK-18) fragments and transient 
elastography respectively (Chapter 3). Not only was TE found to be the most extensively studied, it 
had also one of the highest diagnostic accuracies with pooled sensitivities and specificities to 
diagnose F≥2, 3 and 4 to be: 79% and 75%, 85% and 85%, and 92% and 92% respectively.  
We then proceeded to perform a much larger study in diabetic subjects using the latest generation 
of Fibroscan ® 502 touch model (Chapter 4). This included the extra-large (XL) probe for obese 
subjects and also featured the novel Controlled Attenuation Parameter (CAP), which assesses liver 
steatosis. A total of 1918 diabetes patients at Prince of Wales Hospital, Hong Kong were recruited. 
Each had a TE and CAP to assess liver stiffness and steatosis. Reliable scans were achieved in 98.2% 
of patients using the M or XL probes. The proportion of patients with increased CAP (suggestive of 
steatosis) and increased LSM (suggestive of advanced fibrosis) were 72.8% and 17.7% respectively. 
By multivariate analysis, female gender, higher body mass index, triglycerides, fasting plasma 
glucose and alanine aminotransferase, and non-insulin use were associated with increased CAP. 
Longer duration of diabetes, higher body mass index, alanine aminotransferase, spot urine albumin-
creatinine ratio, and lower high-density lipoprotein-cholesterol were associated with increased LSM. 
The17.7% prevalence of advanced fibrosis suggests type 2 diabetic patients would benefit from 
routine screening for liver disease.   
Clinical Utility of Transient Elastography in chronic hepatitis B: Chapters 5 and 6 
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Transient elastography was initially applied for staging patients with chronic hepatitis C (CHC) with 
data rapidly growing on its utility for the assessment in patients with CHB infection. Our study 
contributes to this by further evaluating the diagnostic accuracy and usefulness of TE, and also 
comparing its performance against the FIB4 index, Aspartate Platelet Ratio Index (APRI), Aspartate 
Alanine Aminotransferase Ratio (AAR), Age Platelet Index (API), Fibrosis Index (FI) and Caffeine 
Breath Test (CBT) (Chapter 5).  
In 71 CHB patients, the diagnostic performance of the LSM for Metavir fibrosis stage F≥1, 2, 3 and 4 
were: Area under Receiver Operator Characteristic (AUROC) = 0.825, 0.792, 0.874 and 0.945 
respectively. Patients with high ALT required higher LSM cut-offs. Dual cut-offs are needed to “rule 
in” and to “rule out” stage of fibrosis with a high level of certainty. Using normal vs high ALT specific 
cut-offs, F≥2 and F≥3 can be “ruled in” or “ruled out” with certainty in 49.3% and 57.7% of CHB 
patients respectively. TE was the superior non-invasive test when compared with FIB4-I, APRI, API, 
AAR and FI. Caffeine breath test compared well against TE in a small cohort, but is not as practical. 
Liver histology is limited by interobserver variability, with 44% of liver biopsies being classified a 
different stage on second evaluation, and the intraclass correlation coefficient showing moderate 
agreement (K =0.457). Although routinely compared, this highlights the limitations of assessing the 
accuracy of TE and other non-invasive tests against a reference standard that has such a degree of 
variation.   
The use of TE in the longitudinal monitoring of fibrosis is important in the follow up of patients with 
CHB (Chapter 6). Current literature was conflicting and seemed to suggest that decline in LSM was 
influenced more by the fall in ALT with decline in necroinflammatory activity, rather than fibrosis 
regression. We sought to evaluate the factors that affected LSM change and assess which clinical 
subgroups experienced an LSM decline.  
In 124 CHB patients who were followed for 31.2 months (SD 13.1), LSM decline was greatest in those 
who had active disease and were subsequently treated with antivirals. This is associated with ALT 
normalization, HBeAg seroconversion and viral suppression. In CHB patients with quiescent disease - 
ie did not require antiviral treatment, or who had persistently normal ALT irrespective of treatment - 
only a small or non-significant decline in LSM was observed. The change in LSM was strongly 
correlated with length of time and may suggest fibrosis regression. Further studies are required, as 
our findings are limited by a lack of correlation with liver biopsy, and the low baseline levels of liver 
stiffness in those with inactive CHB.  
Clinical Utility of Transient Elastography in methotrexate induced liver fibrosis: Chapter 7  
Long term use of methotrexate has been associated with risk of liver fibrosis and the role of TE in 
this cohort was evaluated. The relationship between liver fibrosis and methotrexate dose, and other 
factors associated with moderate fibrosis (F2) using an LSM cut-off of ≥7.1 kPa were examined. 
In 39 patients with a mean intake dose of 5.3g of methotrexate, no correlation was found between 
the LSM and the cumulative dose or duration of treatment. Of the 7/39 cases of LSM≥7.1 kPa 
(17.9%), BMI≥30 was the only risk factor with a likelihood ratio (LR) of 4.442, p=0.029. One patient 
had cirrhosis (2.6%). This is much lower than rates reported from early studies [26% (2, 3)], and 
more in line with recent data [around 2% (4)], and lends support to the suggestion that early studies 
overestimated the risk of methotrexate induced fibrosis due to lack of controls for pre-existing liver 
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disease (5). There was also no difference in the LSM of methotrexate subjects and matched 
population controls. 
Conclusion 
Our studies lend further support to the utility of LSM on identifying those at increased risk of liver 
fibrosis progression, which will continue to remain a significant clinical challenge in both individuals 
and as a public health burden. In particular we feel that major contributions have been made on the 
subject of screening for advanced fibrosis in a high-risk population of type II diabetic patients. Our 
longitudinal studies on the role of using TE in follow up and comparing its performance in CHB 
patients are also significant. Despite the small cohort of methotrexate users, this further supports 
the utility of TE in a wide range of liver diseases that manifest with progressive fibrosis. The next 
area of further development in the clinical use of TE is as a stand-alone marker that has prognostic 
significance.  
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CHAPTER 1:    GENERAL INTRODUCTION 
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1.1 The global burden of chronic liver disease 
 
Chronic liver disease is a common disorder that causes significant health and economic burdens.  
Patients are susceptible to a variety of complications and their life expectancy can be markedly reduced. 
Irrespective of the aetiology, liver damage is insidious, with most patients experiencing no symptoms. 
Approximately 40% of patients with cirrhosis are asymptomatic and are identified only through 
incidental abnormalities on laboratory or radiographic studies (6). Often, the first symptoms 
experienced are that of decompensated cirrhosis, whereby it is generally too late for the condition to be 
reversed and life expectancy is limited.   
Chronic liver disease is one of the major causes of death worldwide. The WHO Global Burden of Disease 
Study estimated there were 1.75 million deaths - 752 000 from liver cancer and 1.03 million from 
cirrhosis - in 2010 (7). Liver cancer and cirrhosis each ranked within the top 10 leading causes of death in 
upper and lower middle income countries in 2012 (Figure 1 and Figure 2) (8).  
The top 3 aetiologies of chronic liver disease that cause liver related mortality and morbidity are chronic 
hepatitis B (CHB), chronic hepatitis C (CHC) and alcohol abuse. On a global scale, CHB is estimated to be 
responsible for 45% of liver cancer deaths and 30% of cirrhosis related deaths. Chronic hepatitis C 
causes 26% and 28% of liver cancer and cirrhosis related deaths, while alcohol abuse accounts for 25% 
of liver cancer and cirrhosis deaths. Variations across different regions are seen. CHC was the 
predominant cause of liver cancer and cirrhosis related deaths in the USA (40 and 41% respectively) and 
Western Europe (36 and 40% respectively). Chronic hepatitis B is the predominant cause of liver cancer 
and cirrhosis related deaths in China (54 and 46% respectively) and India (48 and 35% respectively). In 
Australia, alcohol is the leading cause of cirrhosis related death (33%), but CHB is the leading cause of 
liver cancer deaths (41%)(7). 
Non-alcoholic fatty liver disease (NAFLD) is imminently the next major cause of liver disease burden.  
Increasing worldwide obesity rates (9) has led to doubling of NAFLD over the past 20 years, with 
prevalence ranging from 6.3 to 33% with a median of 20% (10). This increase has been observed not just 
in Western countries, but in the Middle East, Far East, Africa, the Caribbean and Latin America. The 
World Gastroenterology Organisation (WGO) has identified NAFLD as a worldwide pandemic (11).  
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Figure 1: Top 10 causes of death in upper-middle income countries in 2012 
 
Figure 1 taken from “WHO fact sheet #310” 
http://www.who.int/mediacentre/factsheets/fs310/en/index1.html (8) 
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Figure 2: Top 10 causes of death in lower-middle income countries in 2012  
 
Figure 2 taken from “WHO fact sheet #310” 
http://www.who.int/mediacentre/factsheets/fs310/en/index1.html (8)   
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1.2 Liver related mortality and economic burden in Australia 
 
According to the Australian Bureau of Statistics data, 7266 liver related deaths occurred in 2012, ranking 
it as the 19th leading cause. Other diseases such as cardiovascular, respiratory and cancer contribute a 
much greater proportion of mortality, but the median age for death is much younger in liver disease. For 
instance, in alcoholic cirrhosis, the median age at death was 58.3 years and 56.3 years for males and 
females respectively. The overall impact to society is under-represented than what mortality statistics 
suggests because there are greater impacts due to premature loss of life and associated social and 
economic costs (12). 
To demonstrate the total economic burden of liver disease, the Gastroenterological Society of Australia 
(GESA) and Australian Liver Association (ALA) commissioned a Deloitte Access Economics report (13). 
Several findings were of note. Firstly, a staggering 6,179,285 persons had liver disease (approximately 
28% of the population). NAFLD accounted for an estimated 90% (Table 1). Secondly, the total financial 
impact (including health system costs, loss of productivity due to inability to be employed, absenteeism, 
premature death, care giver costs, program and welfare payments, funeral costs and taxation foregone) 
was a massive $5.4 billion. Burden of disease quantifies the impact in terms of disability adjusted life 
years, and is a better reflection of the greater loss in function seen in liver disease patients who are 
generally younger and within working age. This was calculated to an estimated $50.7 billion (Table 2). 
The total economic burden of chronic liver disease is 40% greater than that from diabetes and chronic 
kidney disease combined, and it is two fifths of the cost of cardiovascular disease, which has the 
greatest economic burden.  Alarmingly, the prevalence of liver disease is projected to affect 8,092,339 
persons by 2030 (Table 1) (13).   
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Table 1: Prevalence of liver disease Australia 2012 
 
Prevalence of liver disease in Australia by gender in 2012 and 2030 – taken from “The economic cost and health burden of 
liver disease in Australia” (13) 
 
 
Table 2: Cost of Liver Disease Australia 2012 
 
Total costs of liver disease, by type and bearer in 2012 ($ million) – taken from  “The economic cost and health burden of 
liver disease in Australia” (13) 
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1.3 Fibrosis in chronic liver injury 
 
The response to liver injury is a ubiquitous process of inflammation and fibrosis regardless of the cause. 
Fibrosis develops in all patients with chronic liver injury at variable rates depending upon the aetiology 
and host factors (14). There is collapse of hepatic lobules, formation of fibrous septae, and hepatocyte 
regeneration with nodular formation. This diffuse process may ultimately progress to cirrhosis with its 
accompanying consequences of portal hypertension and impaired hepatic function.  Cirrhosis represents 
a late stage of progressive hepatic fibrosis characterized by distortion of the hepatic architecture and 
the formation of regenerative nodules.  
Once thought of as irreversible, hepatic fibrosis is now recognized as a dynamic process with the 
potential for significant resolution. However, late stage cirrhosis with profuse fibrous nodules, severe 
portal hypertension and grossly impaired synthetic function is generally thought of as irreversible. The 
exact point of no return is not well defined.  Evidence suggests that early cirrhosis is reversible when the 
offending agent is removed. In chronic hepatitis B, patients  experience a regression of cirrhosis in 74% 
of cases after 5 years of  viral suppression with tenofovir disoproxil fumerate (15). Chronic hepatitis C 
patients who achieve a sustained virological response (SVR) after antiviral therapy undergo cirrhosis 
regression in 61% after 61 months (16). NAFLD patients observed over 3 years had fibrosis regression in 
25%, associated with corresponding reductions in waist circumference and low density lipoprotein 
cholesterol (17).    
Regression of hepatic fibrosis is possible with specific disease targeted treatment. Further, antifibrotic 
therapy may be available as we gain new molecular insights into fibrogenesis. Hence accurate evaluation 
of liver fibrosis remains an important clinical tool. 
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1.4 Cellular and molecular mechanisms of fibrosis progression and regression 
 
Activated hepatic stellate cell (HSC) and their transformation into myofibroblasts is the main driver of 
liver fibrogenesis (18). The transition of HSCs into myofibroblasts is regulated by their interaction with 
several other cell types and the activation of specific pathways (19). Injured hepatocytes, hepatic 
macrophages (Kupffer cells), endothelial cells, and lymphocytes drive HSC activation. The death of 
hepatocytes leads to the release of cellular contents and reactive oxygen species that activate Kupffer 
cells to release pro-inflammatory factors such as TNFα, IL-1b, IL-6, CCL2, TLR4 and pro-fibrogenic factors 
TGFβ (20, 21).  
Kupffer cells drive fibrosis progression in chronic injury, but also coordinate the regenerative response in 
acute injury.  They stimulate the influx of bone marrow derived immune cells via release of CCL2 and 
CCL5 recruitment of immature monocyte-derived Ly6Chi macrophages. In mouse models, the absence of 
Ly6Chi macrophages results in inhibition of the pro-fibrogenic response in carbon tetrachloride injury 
suggesting that Ly6Chi macrophages are central to the fibrosis mechanism and activation (22).  Ly6Chi 
macrophages can differentiate into pro-resolution (restorative) Ly6Clo macrophages which secrete large 
quantities of fibrolytic matrix metalloproteinases such as MMP-9 and MMP-13, and the anti-
inflammatory cytokine IL-10, which are all implicated in fibrosis resolution (23). This may involve the 
fractalkine receptor CX3CR1 (24), but further research is needed.   These pathways may be potential 
targets for antifibrotic therapy and remain of intense interest (20).  
Oxidative stress may also be an important aspect of fibrogenesis.  Reactive oxygen species causing 
oxidative stress in chronic tissue damage can lead to the overexpression of critical genes related to 
extracellular matrix remodeling, inflammation and fibrogenesis, especially in alcoholic hepatitis and non-
alcoholic steatohepatitis (NASH) (25, 26). Other factors that have been implicated include the intestinal 
microbiota (27), tissue hypoxia (28), epigenetic modification in conditioning the progression of fibrosis 
(29) and the mechanical properties of the underlying matrix on the progression of the fibrogenic process 
(30).  
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1.5 Liver biopsy and the histological staging of liver fibrosis 
 
Liver biopsy is the reference standard for the assessment of hepatic fibrosis. There are several 
histological scoring systems used to stage liver fibrosis.  The most common include the Metavir, Knodell, 
Ishak, Scheuer, and Laennac scores (31-35). All scoring systems provide a semi-quantitative score based 
on the distribution and extent of fibrosis. Each was developed originally for chronic viral hepatitis, and 
also includes an assessment of necroinflammatory activity. In general they describe increasing severity 
of each stage based on the location of fibrosis within the hepatic lobule. Fibrosis begins around the 
portal triad, then extend to septations which later connect and form bridges between the triads. Finally, 
the fibrous septations becomes so numerous and prominent that discrete nodules are formed which is 
the basis of histological cirrhosis. In studies of non-invasive assessment of liver fibrosis, Metavir score is 
the most commonly used system, and hence adopted in our research.  The description and typical 
appearance of each Metavir stage is provided in Figure 3. 
 
 
 
Figure 3: Metavir Fibrosis Score  
Adopted from Asselah 2008 (36) 
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Although liver biopsy is considered the reference standard for fibrosis assessment, there are several 
limitations. The decision to proceed with a liver biopsy between the clinician and the patient is usually 
not a trivial one.  It is a painful invasive procedure that is associated with uncommon, but serious 
complications (see 1.5.1). Patients are reluctant to submit to repeated biopsies which limit the ability to 
monitor disease progression and treatment response. Interpretation requires expertise, and remains 
subject to variability as well as sampling error. As such, liver biopsies cannot be used on a large scale.  
 
1.5.1 Complications of liver biopsy 
Complications from liver biopsies are overall uncommon, with large retrospective studies reporting a 
risk of bleeding of approximately 0.3-1.7% and a risk of death of 0.09 -0.33% (37-39). 
In a British nationwide audit of 1500 cases across 189 health institutions (37), bleeding complicated 26 
procedures (1.7%), and transfusion was required in 11 (0.73%). There were two definite and three 
possible procedure related deaths, giving an overall mortality of 0.13-0.33% (37). 
In a retrospective study of 9212 liver biopsies over 21 years, there were 10 fatal and 22 non-fatal 
haemorrhages (0.11% and 0.24%, respectively) (38). Risk factors were malignancy, age, sex, and the 
number of biopsy needle passes. The rate of fatal and non-fatal haemorrhage were 0.4% and 0.57% 
compared with 0.04% and 0.16% respectively (38). 
The largest review comprised of 68,276 biopsies over 10 years across 36 Italian institutions (39) . A total 
of 147 (2.2%) complications were found. Complications related to bleeding occurred in 30 (0.44%), 
inadvertent puncture into the chest cavity in 51 (0.75%), puncture of other viscous in 13 (0.19%) and 
others (such as sepsis, shock, biliary peritonitis, reaction to anaesthetic) in the remaining 53 (0.78%). 
Fatal complications occurred in 6 (0.09%), all due to bleeding and in which 3 patients had cirrhosis (39).   
Pain is a very common side effect. A study showed that pain is experienced in 87% of cases and extend 
beyond the day of the procedure in 20% (40). Observation for at least 6 hours post procedure is required 
by most protocols to monitor for complications and adds inconvenience to patients. For all the 
aforementioned reasons, liver biopsy has a poor patient acceptance and tolerance.   
 
1.5.2 Sampling error 
A biopsy represents approximately 1/50000th volume of the liver, so that sampling error can occur 
where disease distribution is uneven or when the size of the biopsy inadequate. In a study of 124 
hepatitis C patients, 33.1% had a difference of at least 1 stage of fibrosis in biopsy samples taken 
laporascopically simultaneously from the left and right lobe, leading to an under-diagnosis of cirrhosis in 
14.5% (41).   
Length of biopsy is important, with inadequate samples being associated with greater variability. One 
study of 17 liver samples demonstrated 65% of biopsies 15 mm in length were categorized correctly 
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according to the reference value. However this increased to 75% for a 25-mm liver biopsy specimen 
(42). 
In a study of 161 liver biopsies, assessors were blinded and specimens were repeatedly examined after 
shortening the visible length from ≥3cm to 1.5cm and then to 1cm. Shorter length was associated with 
reporting of mild fibrosis. They also reported that 11-15 portal tracts were required for accurate staging. 
The authors concluded that to achieve 11-15 portal tracts, a biopsy at least 2cm in length would be 
adequate in 94% of specimens (43). 
This standard of a 2cm biopsy length however, may be unrealistic. A meta-analysis of 32 studies with 
10027 liver biopsies showed that the mean length was 17.7mm and mean number of portal tracts was 
7.5. Only 8 studies had a mean length of at least 20mm (44) . These biopsies were performed in research 
studies, where strict study criteria for minimum biopsy length were required. Having adequate length 
liver biopsy (>2cm) is unlikely to be achievable in the real world, and would be difficult to enforce 
because of concern with the additional risks of bleeding and other complications. 
1.5.3 Variability of histology interpretation 
Interobserver variability is a well described issue in histological fibrosis staging. It is generally 
reproducible amongst pathologists in academic centres or who are specialised in hepatic histopathology. 
A high level of concordance in 30 liver biopsies  specimens examined by  10 specialist liver pathologist in 
the METAVIR study group was found for portal fibrosis (K=0.80) and cirrhosis (K=0.91)(32). Another 
study of 95 liver biopsies showed an 84% agreement across 3 observers in an academic centre (45). 
Outside of academic settings, the variability of interpretation is significantly higher. In 391 biopsies, 
there was complete agreement between specialist liver pathologists and community pathologists in only 
49.9% of cases. Across all stages of fibrosis, the correlation (K) coefficient was 0.41 which is considered 
only to be a poor to fair level of agreement,  with 73% cases understaged by community pathologists 
(46).  
 
1.5.4 Barriers for use in large numbers of patients  
Most protocols for post liver biopsy care requires monitoring for several hours after the procedure to 
ensure there has been no serious side effects. This usually requires a full day commitment from the 
patient. For liver biopsy to be performed safely, skilled operators, and a facility for monitoring post 
procedure are necessary. Use of imaging to safely guide the location of biopsy is now common practice 
and necessitates ultrasound imaging equipment.  Furthermore, for liver histology to be interpreted with 
a high level of accuracy, it is best examined by specialist liver pathologists. Liver biopsy and assessment 
is thus is a resource intense procedure. It is impractical to be used as routine tool on a large numbers of 
patients.  
Given the limitations of liver biopsy and combined with the increasing burden of liver disease, the need 
for alternative methods of assessment is accentuated.  
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1.5.5 Transient Elastography as an alternative to liver biopsy   
There has been much research in non-invasive measures of hepatic fibrosis. At the time of this thesis’ 
conception in 2009, an emerging method for liver fibrosis evaluation was Transient Elastography (TE).    
Transient elastography assesses the elasticity of tissue in the liver. Fibroscan ® is a non-invasive device 
developed by Echosens ® (Paris, France) that applies TE to measure liver fibrosis. Fibroscan overcomes 
the drawbacks of liver biopsy with regards to complications, pain, poor patient acceptance, and high 
resource demand. It also assesses a much greater volume of liver compared to liver biopsy.   
Fibroscan is rapidly performed with each case requiring around 10 or fewer minutes to complete.  
Results are displayed immediately after each scan. The patient feels a soft tap on the skin surface from 
the probe. There is no pain or complications. There is negligible operator dependence after a short 
period of training and supervision.  The volume of liver assessed by Fibroscan is approximately 4cm3. 
This is 100 to 200 times greater than that of a liver biopsy, and potentially reduces sample variation.  
Fibroscan has been widely accepted by patients and physicians because it is safe, painless, rapid, and 
produces results that are instantly available.   
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1.6 Transient Elastography: basic principle and the concept of the Liver 
Stiffness Measurement  
 
1.6.1 Concept of Transient Elastography 
Transient Elastography characterizes the elasticity of soft tissues. Using this method, an imaging system 
follows in real time, the propagation of a low frequency shear wave. The displacement of the 
propagating shear wave is measured as a function of time and space. The aim of tissue elastography is 
to create high-resolution shear stiffness images of human tissue for diagnostic purposes (47).  
The shear stiffness of any material refers to its propensity to deform under mechanical stress. It is 
known as the Young’s Modulus or Elastic Modulus and is measured in units of Pascals (Pa).  The concept 
is commonly applied in engineering and was first described by 18th century scientists Leonhard Euler and 
Giordano Riccati, and was further developed by Thomas Young in the 19th century (48).  
The stiffness of human tissue has long been utilized in medicine as a method of distinguishing different 
pathological states. For instance, the ‘hardness’ of a lump is traditionally taught in clinical examination 
to medical students to help determine the likelihood of a lesion being benign or malignant. In the case 
of liver fibrosis, the progressive deposition of collagen leads to a “stiffer” liver. The goal of transient 
elastography is to utilise this property to generate high-resolution images. The expectation is that shear 
stiffness images will identify abnormal tissue not identified by standard ultrasound techniques. 
 
1.6.2 What is Fibroscan® and Liver Stiffness Measurement? 
Fibroscan® is a non-invasive medical device developed by Echosens® (Paris, France) that applies the 
principles of transient elastography to diagnose the magnitude of fibrosis in the liver. It was first 
introduced in 2003 in Europe when it received European Medical Association approval.  In Australia, 
Fibroscan® was registered with the Therapeutic Goods Administration on 28th April 2008.  
Fibroscan consists of a specialised ultrasound probe and an integrated computer (Figure 4 and Figure 5). 
The specialised probe has an ultrasound transducer fitted on the axis of an electrodynamic transducer. 
The electrodynamic transducer creates a low-amplitude mechanical pulse and generates a low 
frequency (50 Hz) elastic wave, also known as a shear wave, which propagates throughout the liver 
tissue.   
The ultrasound transducer transmits and senses radiofrequency signals during the shear wave. 
Comparison of consecutive signals allows for the mapping of the local strain of the medium. A strain rate 
image is then generated by the integrated computer. The strain rate image reflects rates of deformation 
generated in the liver by the propagation of the elastic wave as a function of time (horizontal axis in 
milliseconds) and of depth (vertical axis in millimeters) (Figure 6). The colour scale indicates the sign of 
the deformations (compression or dilatation) and their amplitude. The speed of the propagation of this 
elastic wave is proportional to the slope. The greater the slope, the greater the propagation speed, 
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known formally as the shear wave velocity. The square of the shear velocity (Vs) is proportional to the 
elastic modulus (E):  E  VS2. Consequently the elastic modulus of the liver can then be derived.   
The elastic modulus of the liver has been coined as the Liver Stiffness Measurement (LSM) and thus 
from here on will be referred to as such.    
 
 
 
 
 
Figure 4: The Fibroscan probe  
Figure obtained and used with permission from UITC, distributor of Fibroscan.  
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Figure 5: The Fibroscan Chassis  
Figure obtained and used with permission from UITC, distributor of Fibroscan.  
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Figure 6: Strain Rate Images  
The vertical axis represents the depth of measurement (millimetres), while the horizontal axis 
represents time (milliseconds). The deformation caused by the shear wave is the prominent diagonal 
dark stripe. The slope of this stripe, as indicated by the dotted white line, represents the shear wave 
velocity. Below each strain rate image is the corresponding shear wave velocity (Vs) in metres per 
second, and the derived elastic modulus (E) in kilopascals. Figure obtained and used with permission 
from UITC, distributor of Fibroscan.  
 
1.7 Performing and Interpreting a Fibroscan 
 
1.7.1 Performing a Fibroscan 
 
Patient preparation and positioning 
Portal blood flow increases after a meal and this has been found to increase the LSM (49-51). 3 hours 
fast prior to performing the Fibroscan is recommended. 
The measurement of the stiffness of the liver is carried out on the right lobe of the liver at the 
intercostal spaces in the mid-axillary line. The patient is instructed to be lying down on the examination 
table in supine position with the right arm in maximum abduction.  
 
Taking measurements 
Ultrasound gel is applied on the tip of the probe sensor and placed in contact with the skin of the 
patient. As soon as the probe is in contact with the patient's skin, a pressure variation is detected which 
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initiates the ultrasonic sensor functions in ultrasound mode. The ultrasound signal is represented by the 
display in mode A and the display as function of time in M Mode. These two modes allow verification 
that the measurement zone includes the liver only. The manufacturer recommends choosing a liver zone 
at least 7cm thick, away from the liver edges and large vascular structures. The measurement can only 
be triggered within a specific range of pressure applied as indicated by a green zone. Once the 
measurement has been chosen, and the probe is kept perpendicular to the patient's skin with an 
appropriate pressure, the measurement of the stiffness can be triggered by pressing on one of the 
probe buttons. The vibrator generates a low frequency (50Hz) elastic wave, and the acquisition lasts less 
than a tenth of a second. A progression bar appears in the information window while the acquisition 
data are transferred and processed. The results are then displayed. The images generated for the signals 
in A mode, M mode and the strain rate image are known as the elastogram (Figure 7).     
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Figure 7: The Elastogram  
(A) Represents the M mode. (B) Represents the A mode and (C) is the strain rate image. Figure 
obtained and used with permission from UITC, distributor of Fibroscan.  
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1.7.2 Correct evaluation of liver stiffness by interpreting elastograms 
 
 A correct evaluation of the liver requires the elastogram to meet three quality criteria.  
The A mode signal needs to be linear. This means that the region of measurement is uniform and 
suggests there is only one type of tissue being evaluated.  
The M mode image needs to show the characteristic layer structure of the liver at all the depths. The 
image pattern should be homogenous, suggesting that only liver parenchyma is being measured. 
Heterogeneous patterns that feature white bands may represent the liver border with the lung and 
vascular structures. Patterns with dark bands represent ribs.  
The third criterion is that the elastogram is free of defects. Fibroscan’s internal software automatically 
rejects and cancels elastograms when the signal detected and strain rate image produced are not 
satisfactory. However not all defective elastograms are correctly filtered by the software and liver 
stiffness results for these inaccurate elastograms are still calculated and displayed.  These defects need 
to be correctly recognized by the operator and the corresponding LSM results should be disregarded. 
The known defects that can occur are “A” waves, “E” waves and angled waves (52). 
“A” waves are dual shear waves. They form due to shear waves emerging from the same point and then 
diverge, which then creates the appearance of the capital letter “A”. The steeper shear wave being 
detected by the software instead of the shallower wave causes an over-estimation (Figure 8). 
“E” waves are enlarged waves. These are similar to “A” waves, where dual shear waves emerge from the 
same point and diverge, but are so close together that they coalesce forming the shape of a wedge.  If 
the steeper slope is detected by the software as being the liver stiffness, this results in an over-
estimation (Figure 9). 
A waves and E waves are due to shear waves arising from ribs. Since the hardness of bone is much 
greater than that of the liver, this leads to an overestimation. “A” waves and “E” waves can be avoided 
by finding a larger intercostal space.  
Angled waves describe the shear wave seen as having a point of inflection at the proximal depths of 
measurement, causing an angled appearance (Figure 10). The corresponding A mode will show a non-
linear signal, and TM mode non-homogenous saturation. Angled waves occur when the distance 
between the liver capsule and skin surface, called the skin capsule distance (SCD) is within the probe’s 
region of measurement.  Structures between the liver surface and the skin, such as the fibrous liver 
capsule may be included in the interpretation of liver stiffness, and can cause an over estimation.  
Angled waves can be avoided by finding a measurement spot where the liver is closer to the skin 
surface.  
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Figure 8: “A” wave  
The left image shows the steeper shear wave being interpreted by Fibroscan software as the shear 
velocity (as indicated by the dotted white line), which leads to an overestimation of the liver stiffness. 
The right image shows the shallower shear wave being interpreted as the shear velocity, which is the 
correct estimation of liver stiffness.   Figure obtained and used with permission from UITC, distributor of 
Fibroscan.  
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Figure 9: “E” wave  
The shear wave becomes gradually larger at deeper levels from the coalescence of 2 shear waves. The 
slope of the steeper shear wave is interpreted as the shear wave velocity leading to an overestimation.  
Figure obtained and used with permission from UITC, distributor of Fibroscan.  
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Figure 10: Angled wave elastograms 
The shear wave appears to have an inflection point at approximately 35mm depth. This leads to an 
overestimation if the slope of the shear wave prior to the inflection point (represented in red) in 
measured, as opposed to the slope of the shear wave beyond the inflection point (represented in 
green). At depths between 20-30mm, the corresponding A mode and M mode shows a non-linear signal 
and a much brighter saturation respectively.  Figure obtained and used with permission from UITC, 
distributor of Fibroscan.  
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1.7.3 Calculation of the Liver Stiffness Measurement 
 
The final Liver Stiffness Measurement (in kPa) is represented by the median value of all the valid 
stiffness measurements. The interquartile range (IQR, in kPa) represents the interval around the median 
(m) containing the measurements that are between the 25th to 75th percentiles. If the measurement is 
not valid, the current stiffness is not defined. The software calculates a "success rate" in % to express 
the number of valid measurements in relation to the number of attempted measurements and shows 
this information in the display.  
 
 
1.7.4 Requirements for a reliable stiffness examination: changing definitions 
When this study began in 2009, a “reliable” stiffness examination was based on 3 criteria (52): 
1. At least 10 valid measurements performed at the same spot in the right lobe of the liver 
2. A Success Rate (SR) ≥60% 
3. An IQR/Median Ratio of liver stiffness ≤ 0.30 
Excellent interobserver agreement is observed when the IQR to median ratio (IQR/M) is ≤ 30%. A study 
of 800 TE examinations performed on 200 patients by 4 operators revealed the intraclass correlation 
coefficient to be excellent (K= 0.98) (53). From this study, the term “reliable” LSM became synonymous 
with reproducibility.  
A lower IQR/M ratio may even reduce discordance further. In a study of 254 patients, the most 
discriminant cutoff value for discordance was IQR/M = 0.21. When IQR/M  ≤ 0.21, discordance was 
observed in in 10/135 cases (7.4%) as compared to 18/119 (15.1%), p≤0.05 when IQR/M > 0.21 (54).  
Subsequently, a study of 1165 patients in 2013 challenged the usual definitions for LSM reliability which 
led to the criteria being refined (55).  In this study, TE findings were compared to liver biopsy. Using the 
usual definition of a “reliable” LSM, cirrhosis was not diagnosed any more accurately than in those with 
an “unreliable” LSM.  When the LSM was < 7.1kPa, there was no difference in the accuracy of fibrosis 
stage classification regardless of the IQR/M ratio. When the LSM was 7.1-12.5 kPa, the accuracy was 
significantly superior if the IQR/M ≤ 0.30. When the LSM was ≥12.5 kPa, accuracy was superior if 
IQR/M< 0.10. Thus the investigators proposed new system of definitions. Instead of “reliable” vs 
“unreliable”, the new classification included ‘‘very reliable’’ (IQR/M <0.10); ‘‘reliable’’ (IQR/M 0.10-0.30, 
or IQR/M >0.30 with LSM median <7.1 kPa), and ‘‘poorly reliable’’ (IQR/M >0.30 with LSE median ≥7.1 
kPa). Using this new classification, 74.3% of scans were now considered “reliable” and 16.6% of scans 
were “very reliable”.  Scans that were “unreliable” accounted for 9.1% of total cases. In contrast, the 
previous definition would classify 24.3% of scans as “unreliable” (55).  
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In addition, the LSM success rate in the study was not found to have any influence on diagnostic 
accuracy and the authors concluded that success rate is irrelevant. The same conclusion was made in 
another study of 251 patients which also found that success rate has no bearing on the accuracy of TE 
(56).   
The following are revised definition of reliable LSM based on the following criteria (57): 
1. A minimum of ten valid measurements  
2. An IQR/median ratio of ≤ 30%. This is not required if final stiffness result is < 7.1kpa 
These were adopted for all analyses in this thesis. 
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1.8 Histological scoring systems for the diagnosis of non-alcoholic fatty liver 
disease and non-alcoholic steatohepatitis 
 
A diagnosis of Non-alcoholic fatty liver disease (NAFLD) can be made simply based on the presence of 
>5% steatosis on liver biopsy, and after secondary causes (e.g. alcohol) have been clinically excluded. 
However, there is a wide spectrum of other histological features that may be present, including varying 
degrees of inflammation, liver injury, fibrosis and cirrhosis. Early studies suggest that Non-alcoholic 
steatohepatitis (NASH), is much more likely to progress to cirrhosis and hepatocellular carcinoma 
compared to bland steatosis (17, 58, 59). Since liver biopsy is the gold standard for the diagnosis of 
NASH, it is therefore important that histological interpretation is accurate and reproducible. Histology 
based scoring systems have been proposed make the diagnosis of NASH more objective and less prone 
to interobserver variance. The first large collaboration to address this was by the Pathology Committee 
of the NASH Clinical Research Network (NASH CRN), which designed and validated a histological scoring 
system to address the full spectrum of lesions of NAFLD, and to propose a NAFLD activity score (NAS) for 
use in clinical trials. The NAS comprised of a total score calculated from grade of steatosis (0 pts: < 5%, 1 
pt: 5-33%, 2 pt: 33-66%, 3 pt: >66%), lobular inflammation (0 pts: 0, 1 pt: 1-2. 2 pt: 2-4, 3pt: > 4 foci/20x 
power field), and ballooning (0 pts: none, 1 pt: mild/few, 2 pts: moderate/many). The NAS score would 
thus range 0-8 points. A score of 1-2 would be considered no NASH, 3-4 borderline NASH and 5-8 
definite NASH. Fibrosis staging was based on the Brunt’s or Kleiner’s system: F0 = no fibrosis; F1 = 
perisinusoidal or portal; F2 = perisinusoidal and portal/periportal; F3 = septal or bridging fibrosis; and F4 
= cirrhosis (60, 61).  
However, the NAS score was not an ideal a diagnostic tool. It was designed more to provide a 
continuous scale for activity assessment, which would be useful in clinical trials. A notable issue was that 
a significant proportion of patients that would be classified as borderline NASH under NAS, would be 
considered definite NASH or definite non-NASH by consensus expert opinion (62).  
To address some of these issues, a new system known as the Steatosis Activity Fibrosis (SAF) score was 
developed by Bedossa et al. (63) and validated by the Fatty Liver Inhibition of Progression (FLIP) 
consortium. Like the NAS, the SAF comprises a score for each of the main components of NAFLD: 
steatosis, ballooning, lobular inflammation, and fibrosis. However, disease activity is determined by the 
sum of ballooning (0-2) and lobular inflammation (0-2) only. Steatosis is excluded as a factor in 
determining disease severity in the SAF score, of which its inclusion was among the chief criticisms of 
the NAS score. In addition, the SAF proposes an algorithm for determining NAFLD vs NASH. Essentially, 
the presence of any steatosis (grade 1,2 or 3) in association with both ballooning (grade 1 or 2) and 
lobular inflammation (grade 1 or 2) would be classified as NASH. NAFLD is the diagnosis instead of NASH 
when there is absence of ballooning or lobular inflammation (either being grade 0). The absence of 
steatosis (grade 0) would preclude a diagnosis NAFLD altogether.  
Agreement between expert liver pathologists and general pathologists on the diagnosis of NASH was 
found to improve after applying the SAF score algorithm (64). Despite this, the NAS and SAF scores are 
both tools that are mostly used in research. Greater validation in the hands of non-expert pathologists 
 51 
 
are required. Furthermore, while it is important to differentiate NASH from simple steatosis, recent 
studies have revealed that ultimately, the degree of fibrosis has the greatest prognostic influence (65).   
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1.9 Rationale for examining the clinical utility of transient elastography in 
nonalcoholic fatty liver disease, chronic hepatitis B and long term 
methotrexate patient populations  
 
At the time of this study’s conception, few publications existed for TE. Most research focused on 
hepatitis C, with scarce data for other patient populations. We identified nonalcoholic fatty liver disease, 
hepatitis B and methotrexate induced liver fibrosis as areas requiring further study. 
A systematic web-based literature search of all publications in MEDLINE (via OvidSP), PUBMED (NLM) 
and EMBASE was conducted on 10th January 2009 from the date of inception for each of the databases. 
Our primary search strategy for identifying studies used the following free-text words: “transient 
elastography”, “Fibroscan” and “liver stiffness measurement”. Search limits included abstracts and 
publication in peer-reviewed journals. This list of articles was corroborated with the latest official 
summary of “Publications and Communications for Fibroscan” provided by Echosens (66).   A secondary 
search of the reference lists of the articles that were identified on the primary search was performed to 
locate any studies missed by electronic search strategies.  
A total of 88 publications were found. The vast majority were from Europe where Fibroscan originated. 
23 articles were in a non-English language and 36 articles were identified to be reviews, comments, 
letters or editorials. The remaining 29 articles were original research studies. The main aetiology of liver 
disease studied in each publication is broken down as follows:  
• 13 publications focusing mainly on the hepatitis C population. 4 of these studies examined 
HIV/HCV co-infection and one reported the use of TE in liver transplantation for HCV patients 
(67-79).  
• 6 publications examining the use of TE in chronic liver disease of multiple aetiologies. However, 
in every study, the majority of the patients had hepatitis C (80-84). 
• 3 studies focused on the reliability and reproducibility of TE (53, 85, 86).  
• 2 studies that examined TE for use in chronic hepatitis B or predominantly chronic hepatitis B 
(87, 88)  
• 2 studies of liver fibrosis in patients on methotrexate (89, 90) 
• 1 study of TE in HIV infected patients (91)  
• 1 study of TE in primary biliary cirrhosis and primary sclerosing cholangitis (92) 
• 1 study of TE in nonalcoholic fatty disease (1).   
The studies which established TE as a promising non-invasive device and gave it prominence were 3 
validation studies that compared the LSM with liver biopsy (77, 78, 84). 
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Two of these were studies in HCV patients and were published in 2005. The other assessed chronic liver 
disease patients of multiple aetiologies and was published in 2006. These landmark studies are 
summarized as follows: 
Ziol et al. correlated TE with liver biopsy in a multicenter French study of 327 chronic hepatitis C 
patients.  LSM correlated well with fibrosis stage. Areas under the receiver operator characteristics 
(AUROC) curves were 0.79 for F≥2, 0.91 for F≥3, and 0.97 for F= 4. Optimal stiffness cutoff values of 8.7 
and 14.5 kPa were found for F≥2 and F= 4 respectively (77).  
Castera et al. assessed the performance of Fibroscan in patients with chronic hepatitis C, in comparison 
against and in combination with Fibrotest and the aspartate transaminase to platelets ratio index [APRI]. 
One hundred and eighty three consecutive patients with chronic hepatitis C were recruited at a single 
centre. Optimal LSM Cut-off values were 7.1 kPa for F≥2, 9.5 kPa for F≥3, and 12.5 kPa for F=4. The 
diagnostic performance of Fibroscan and Fibrotest were similar, but both superior to APRI. The AUROCS 
for Fibroscan, Fibrotest and APRI were: 0.83, 0.85, and 0.78, respectively, for F≥ 2; 0.90, 0.90, and 0.84, 
respectively, for F≥ 3; and 0.95, 0.87, and 0.83, respectively, for F=4. The best performance was 
obtained by combining the Fibroscan and Fibrotest, with an AUROC of 0.88 for F≥ 2, 0.95 for F≥ 3, and 
0.95 for F= 4. When the Fibroscan and Fibrotest results agreed, liver biopsy examination confirmed them 
in 84% of cases for F≥2, 95% for F≥3, and in 94% for F=4 (78). 
Foucher et al. examined 711 patients with chronic liver disease of multiple aetiologies at a single centre.  
The accuracy of TE compared to liver biopsy, and the ability of LSM to correlate with clinical outcomes 
were assessed.  LSM significantly correlated with fibrosis stage. AUROC curves were 0.80 for F≥2, 0.90 
for F≥3, and 0.96 for F=4. Using a cut off value of 17.6 kPa, patients with cirrhosis were detected with a 
positive predictive value (PPV) and a negative predictive value (NPV) of 90%. Liver stiffness significantly 
correlated with clinical, biological, and morphological parameters of liver disease. With an NPV >90%, 
the cut off values for the presence of oesophageal varices grade 2 or 3, cirrhosis Child-Pugh B or C, past 
history of ascites, hepatocellular carcinoma, and oesophageal bleeding were 27.5, 37.5, 49.1, 53.7, and 
62.7 kPa, respectively (84). 
Our literature review on TE at the time demonstrated that the majority of research had focused on the 
chronic hepatitis C population, with very little data on other populations with chronic liver disease.  
However, on a worldwide scale, nonalcoholic fatty liver disease and chronic hepatitis B are both more 
prevalent (10, 93, 94). Long term methotrexate was thought for a very long time to cause liver fibrosis 
and required rigorous monitoring with repeated liver biopsies but data from small studies using TE 
demonstrated contrary evidence suggesting that methotrexate induced liver fibrosis is not as common 
as previously thought (89, 90). We sought to explore the clinical utilities of TE in the patient populations 
of NAFLD, CHB and long term methotrexate use.  
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CHAPTER 2:   ASSESSING LIVER STIFFNESS USING 
TRANSIENT ELASTOGRAPHY IN PATIENTS WITH 
TYPE 2 DIABETES – A PILOT STUDY 
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2.0 CHAPTER SUMMARY 
 
Introduction: The development of liver fibrosis from NAFLD is associated with an increased risk of 
mortality. Fibroscan ® measures the liver stiffness measurement (LSM) and has been demonstrated to 
assess liver fibrosis. We measured the LSM using Fibroscan in a cohort of patients with type II diabetes 
who are at risk of developing progressive liver disease and compared them with non-diabetic controls.  
Methods: Subjects with type II diabetes, no prior documented liver disease and alcohol intake < 
140g/week were recruited from outpatient specialist clinics. Demographic, clinical history and 
laboratory data were collected. Fibroscan ® was performed with the M probe. At least 10 successful 
measurements were required for a valid LSM. An interquartile range to median ratio of < 30% was 
required when the LSM≥7.1 kPa for a reliable LSM. The cutoff of ≥9.8 kPa was used to indicate advanced 
fibrosis.   
Results: Valid scans were obtained in 88/97 (90.7%), while valid and reliable scans were obtained in 
77/97 (79.4%) of subjects.  A cut-off ≥9.8 kPa was present in 12% (10/77) diabetes subjects. The LSM 
was significantly correlated with BMI and the need for insulin therapy. Patients requiring insulin had 
LSM≥9.8 kPa with likelihood ratio (LR): 12.3, p=0.002. Obesity was associated with invalid scans and was 
also probably the cause of unreliable scans. The mechanism is thought to be due to greater 
subcutaneous adiposity and hence higher skin to liver capsule distance (SCD).  
Conclusions: The 12% prevalence of high LSM in type II diabetes suggests that this is an at risk group for 
developing progressive liver disease. This is likely to be an under representation given that those who 
were obese were unable to have successful readings.  Those who are obese and are on insulin therapy 
may represent a particularly high risk group.  There is a high failure rate for obtaining valid and reliable 
scans which stems from using the M probe in obese patients. Further studies with larger sample size and 
using newer generations of Fibroscan with the XL probe are needed.   
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2.1 BACKGROUND 
 
2.1.1 Non-alcoholic fatty liver disease and the spectrum of histological changes 
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide, with a 
prevalence of 20-35% in the general population (10, 95-97). NAFLD is defined as the presence of 
steatosis after alcohol and other secondary causes of fat accumulation in the liver have been excluded 
(98).  NAFLD has a spectrum of distinct histological changes, which include simple steatosis (SS), non-
alcoholic steatohepatitis (NASH) and fibrosis which may progress to cirrhosis.   
Simple steatosis is described when there is greater than 5% of hepatocytes affected by steatosis, 
without any features of hepatocellular injury (98). The extent of steatosis can be mild (5 to 33% of 
hepatocytes are steatotic), moderate (34 to 66%), or severe (>66%). The pattern of steatosis typically is 
macrovesicular, though mixed micro and macrovesicles may also be seen (98). NASH features steatosis 
as well as hepatocyte injury (such as ballooning degeneration and fibrosis), and lobular inflammation 
(99-101). Liver fibrosis may eventually develop, but is not a required diagnostic feature of NASH (99-
101). Non-NASH is used to describe SS, and “borderline NASH” - biopsies which feature mild 
inflammation but without enough features of hepatocyte injury to diagnose as “definite” NASH (99-101) 
.  
 
2.1.2 Natural history and prognosis of non-NASH, NASH and NAFLD fibrosis 
The understanding of the natural history and prognosis of NAFLD comes mostly from longitudinal case 
control and cohort studies. Liver biopsy data is scarce and no large series that have assessed paired 
biopsies.  
Patients with NAFLD are at risk of higher mortality compared to the general population. A study of 420 
NAFLD patients in Olmsted County, Minnesota reported a standardized mortality ratio (SMR) of 1.34 
after a median follow up of 7.6 years (102). Liver related mortality was the 3rd leading cause of death in 
this group of patients behind malignancy and ischaemic heart disease (102).  
NAFLD is associated with metabolic syndrome, and when cohorts are compared in studies that have 
controlled for metabolic risk factors, the difference in mortality is not so profound. The US National 
Health and Nutrition Examination Survey (NHANES) of 14000 patients reported that after metabolic 
syndrome and other confounders are matched, mortality in NAFLD has a Hazards Ratio (HR) of only 
1.038 (103).  However, liver related mortality remained much higher: HR=9.32 (103).  
Several studies have demonstrated that within groups of patients who have NAFLD, those with the 
NASH subtype have greater mortality compared with Non-NASH. In a study 129 NAFLD subjects 
compared with matched controls, survival after a median 13.7 years follow up was reported to be lower 
in NASH (70% versus 80% p=0.01), but was not significantly different in non-NASH subjects (104). 
Cleveland clinic registry data reported NASH vs Non-NASH liver related mortality to be 11% compared to 
2% over a median follow up of 8 years (105), and 18% compared to 3% over a median of 18.5 years 
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respectively (106).   A Swedish study of 256 NAFLD patients reported an SMR of 1.55 for SS and an SMR 
of 1.86 for NASH over a median follow up of 28 years (107).  
Recent data suggests liver fibrosis may be the most important histological feature when it comes to 
predicting poor liver related outcomes in NAFLD. An international study of 619 NAFLD patients followed 
over a median of 12.6 years reported that fibrosis was the only histological feature of liver biopsies 
significantly associated with death or liver transplantation (108). The hazard ratio calculated against 
those with no fibrosis, increased progressively with the Metavir fibrosis stage (see section 1.5 for 
description of the Metavir stages): F1 HR=1.88 (95% confidence interval [CI], 1.28–2.77), F2 HR= 2.89 
(95% CI, 1.93–4.33), F3 HR=3.76 (95% CI, 2.40–5.89), and F4 HR=10.9 (95% CI, 6.06–19.62). The presence 
of fibrosis was associated with lower survival regardless of the presence of NASH and furthermore, 
NASH was not associated with lower survival compared with non-NASH unless fibrosis was present 
(108). 
 
2.1.3 Non-invasive assessment of NAFLD and fibrosis 
As NASH and NAFLD with fibrosis are associated with increased liver related mortality, patients who 
have developed either of these conditions should be the considered for monitoring and interventions. 
Liver biopsy is traditionally considered the reference standard for diagnosis and is recommended by 
international and regional guidelines (11, 97), but is not an ideal method of assessment for liver fibrosis. 
Pain and risk of complications make it poorly accepted by patients. In addition, liver biopsy has resource 
intensive requirements, and can produce variable results due to interobserver interpretation.  
A pertinent need arises for non-invasive methods to diagnose NAFLD fibrosis and NASH. Transient 
Elastography with Fibroscan ® allows for rapid and non-invasive measurement of the tissue stiffness. 
Most data on its utility was in those with chronic hepatitis C. (77, 78, 84). In contrast, only 1 study was 
published in 2009 in its role in NAFLD (1). Thus we sought to further explore the use of Fibroscan in 
NAFLD.  
Subsequent to this study, we performed a systematic review  of all non-invasive measures of NASH and 
NAFLD fibrosis with a meta-analysis focusing on the 2 modalities that had been the most widely studied: 
TE and CK-18(109). This meta-analysis and review is presented in detail in chapter 3.  
 
2.1.4 Epidemiology of fibrosis in NAFLD is unknown   
The overall prevalence of NAFLD is reported to be 20-35%, but the epidemiology of the more severe 
disease phenotypes of NASH and NAFLD with fibrosis is incomplete due to the difficulty of obtaining 
liver biopsies in large series. No data exists for the prevalence of steatohepatitis and NAFLD fibrosis for 
the general population. A recent review estimated the prevalence of NASH to be 3-5%, but provided 
none for fibrosis in NAFLD (10). 
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Type 2 Diabetes is a major risk factor for NAFLD, with prevalence rates of 63 -70% based on ultrasound 
(110-112). A study of asymptomatic mostly male middle aged and overweight adults reported NAFLD 
and NASH respectively in 46% and 12.2% overall, but was higher in diabetics with 74% and 22.2% 
respectively (95). Fibrosis occurred in 9 subjects (2.7%) overall.  
 
2.1.5 Study goals, hypothesis and specific objectives 
 
Given the gap in data on liver fibrosis in NAFLD patients, we sought to explore the use of TE in assessing 
liver stiffness as a surrogate marker of liver fibrosis in a cohort of patients with type II diabetes who are 
at higher risk for NAFLD and NAFLD fibrosis. Based on previous studies, we estimate the rate of 
advanced fibrosis to be 5% in this cohort (95).  
 
• Objective 1: To determine the rate of advanced fibrosis in type II diabetes by using the cutoff of 
LSM ≥9.8kpa established by Yoneda et al. (1).  
• Objective 2: To compare the LSM in type II diabetes patients and matched healthy controls 
without diabetes or known liver disease.   
• Objective 3: To identify factors associated with high LSM results  
• Objective 4: To determine the success rate of obtaining valid and reliable Fibroscans and factors 
that influences this.     
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2.2 METHODS 
 
2.2.1 Patient Selection and data collection 
Consecutive type II diabetic patients who attended the Diabetes and Endocrinology outpatient clinics at 
Concord Repatriation Hospital (Concord Sydney, Australia) from June 2009 to November 2009 were 
recruited into the study.   Patients who were younger than 18 years or were pregnant were excluded 
from the study. Patients with a history of alcohol intake of greater than 20g per day, or had prior 
diagnosed chronic liver disease other than NAFLD were excluded from the study. These included viral 
hepatitis B or C, recent viral hepatitis A or E (within 1 year of recruitment), haemachromatosis, cardiac 
hepatic congestion, autoimmune hepatitis, primary or secondary biliary cirrhosis, primary or secondary 
sclerosing cholangitis, Wilson’s disease and alpha-antitrypsin deficiency.  Patients with prior diagnosis of 
secondary causes of fatty liver (steroids, tamoxifen, amiodarone, thyroid disease) were also excluded. 
All patients gave informed written consent. A total of 101 subjects were enrolled.  
Clinical assessment was performed using a standardized questionnaire. Age, gender, duration of 
diabetes, pharmacological treatment, alcohol intake, diagnosis of any pre-existing liver disease and 
other co-morbid medical history were recorded.  Height, weight were measured and BMI calculated.  
Biochemistry results within 1 month to the date of the Fibroscan were recorded including : bilirubin 
(BR), alkaline phosphatase (ALP), gamma-glutamyl transpeptidase (GGT), alanine aminotransferase 
(ALT), aspartate aminotransferase (AST), albumin (ALB), platelet count, international normalized ratio 
(INR) alpha fetal protein (αFP) and HbA1c.  
Non diabetic controls with no known liver disease were recruited from staff at the clinics and from 
persons accompanying patients who attended the outpatient clinic. After matching for age, sex, height, 
weight, body mass index (BMI) and weekly alcohol intake, 26 controls were included in the analysis.  
Fibroscan was performed as previously described (section 1.7). The author performed all the TE scans.    
 
2.2.2 Statistical analysis 
Statistical analysis was performed using the Statistical Package for Social Sciences (SPSS) version 17.0. 
Continuous variables were expressed as the mean ± standard deviation where appropriate. LSM 
between groups were compared using Independent samples T-test. Categorical variables were 
compared using the chi-square test and Fisher’s exact test when appropriate. Multivariate analysis was 
performed using multiple stepwise linear or logistic regression on variables where appropriate. The LSM 
cut-off values used for advanced fibrosis (F≥3) was 9.8 kPa, as reported from the validation study by 
Yoneda (1).  
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2.3 RESULTS 
 
2.3.1 Characteristics of the study population 
Table 3 shows the characteristics of the study population. The mean age was 60.8 years (yrs), Standard 
Deviation (SD) 11.4 yrs with 40.3% being female. The mean duration of diabetes was 9.5 (SD 7.8) yrs 
with a mean HbA1c of 8.2% (SD 1.8) with 32.5% of patients on insulin therapy. The mean BMI was 
elevated: 30.6 SD 7.1 kgm-2. Mean alcohol intake was 15 (SD 42) g/week (range 0-140 g/week). Apart 
from mildly elevated GGT (64 SD 104 IU/L), The mean of all other biochemical parameters were all 
within the normal reference range.  
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Table 3: Clinical and biochemical characteristics of the Study Population 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Characteristic  Mean (SD)a 
Age (yrs) 60.8 (11.4) 
Female 31/77 (40.3%) 
Duration of Diabetes (yrs) 9.5 (7.8) 
HbA1c (%) 8.2 (1.8) 
Insulin therapy 25/77 (32.5%) 
Cholesterol (mmol/L) 4.2 (1.0) 
HDL (mmol/L) 1.2 (0.3) 
LDL (mmol/L) 2.2 (0.8) 
Triglycerides (mmol/L) 1.8 (1.0) 
Height (m) 1.64 (0.11) 
Weight (kg) 82.5 (22.1) 
BMI (kgm-2) 30.6 (7.1) 
Alcohol intake (g/wk) 15 (42) 
BR (µmol/L) 9 (4) 
ALB (g/L) 44 (4) 
ALP (IU/L) 92 (73) 
GGT (IU/L) 62 (104) 
ALT (IU/L) 32 (21) 
AST (IU/L) 28 (21) 
PLT (x109/L) 272 (107) 
INR  1.0 (0.2) 
αFP (ug/L) 1.9 (1.0) 
  
a. The mean and standard deviation is shown 
except for female and insulin therapy where 
the frequency is represented  
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2.3.2 Patient recruitment, invalid and reliable Liver Stiffness Measurements 
 
One hundred and one consecutive patients were identified as potential candidates for the study.  After 
screening, 4 were ineligible. Two patients had type I diabetes, one patient excessive alcohol and one had 
haemachromatosis. Ninety seven patients were recruited for the study and had fibroscan performed. 
There were 9 subjects who had invalid LSM, defined as less than 10 measurements acquired. Out of the 
88/97 (90.7%) subjects remaining, 11 subjects had unreliable results, defined by an IQR/M ratio of 
greater than 30% when the LSM≥7.1 kPa. This left 77/97 (79.4%) subjects with valid and reliable scans 
(Figure 11) 
A comparison of the factors between those who had valid LSM versus invalid LSM was performed. The 
mean BMI was significantly greater in those with an invalid LSM:  36.7 (SD 6.3) kgm-2 vs 30.1 (SD 6.9) 
kgm-2, p=0.044. No other factors were found to be significant and a summary of the comparison is 
shown in Table 4.  
A comparison of the factors between subjects who had a reliable LSM versus an unreliable LSM was 
performed.  In univariate analysis, LDL, LSM, IQR/M ratio and success rate were statistically significant.  
In multivariate analysis using a validated binary logistic regression model (Hosmer and Lemeshow test 
p=0.492), the only significant difference was a greater mean LSM in subjects with unreliable LSMs:  13.7 
(SD 8.6) kPa vs 6.8 (SD 2.8) kPa (B coefficient 0.518, Wald statistic p = 0.049).  A summary of the 
comparison is shown in Table 5. 
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Figure 11: Patient recruitment flow chart          
 
 
  
101 patients identified for the study at 
Diabetes Clinic 
97 patients eligible with Fibroscan 
performed 
4 excluded due to failing exclusion 
criteria 
- 2 patients type 1 DM 
- 1 alcohol >140g/wk 
- 1 haemachromatosis 
88 subjects valid LSM 
(>10 valid measurements) 
77 subjects reliable and successful LSM 
(IQR/M ratio≤30% when LSM≥7.1kpa) 
9 subjects unsuccessful LSM  
(<10 valid measurements) 
11 subjects unreliable LSM  
(IQR/M ratio >30% when LSM≥7.1kpa) 
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Table 4: Comparison of valid versus invalid Liver Stiffness Measurement subjects 
Patient Characteristic Valid LSM (n=88) Invalid LSM (n=9) P value 
Age (yrs) 60.6 (11.6) 62.0 (9.9) 0.734 
Gender Femalea 36/88 (40.9%) 6/9 (66.6%) 0.137 
Duration of Diabetes (yrs) 9.1 (7.3) 15.0 (12.3) 0.055 
HbA1c (%) 8.2 (1.8) 8.5 (0.5) 0.754 
Insulin therapya 31/88 (35.2%) 6/9 (66.6%) 0.069 
Cholesterol (mmol/L) 4.2 (1.0) 4.0 (0.6) 0.710 
HDL (mmol/L) 1.2 (0.3) 1.1 (0.1) 0.627 
LDL (mmol/L) 2.2 (0.8) 1.7 (0.2) 0.298 
Triglycerides (mmol/L) 1.8 (1.0) 2.8 (2.0) 0.464 
Height (m) 1.64 (0.11)  1.63 (0.08) 0.847 
Weight (kg) 81.1 (21.6) 98.6 (23.7) 0.044 
BMI (kgm-2) 30.1 (6.9) 36.7 (6.3) 0.016 
Alcohol intake (g/wk) 15.5 (42.7) 0 0.471 
BR (mmol/L) 9 (4) 13 (7) 0.108 
ALB (g/L) 44 (4) 45 (2) 0.565 
ALP (IU/L) 92 (74) 82 (12) 0.820 
GGT (IU/L) 62 (105) 70 (71) 0.891 
ALT (IU/L) 31 (21) 46 (16) 0.232 
AST (IU/L) 27 (21) 42 (21) 0.242 
PLT (x109/L) 270 (108)  327 (65) 0.371 
INR  1.0 (0.2) 1.0 (0.1) 0.944 
αFP (ug/L) 1.9 (1.0) 2.4 (0.5) 0.620 
a. Chi square test applied to gender female and insulin therapy variables. All other variables are 
continuous and were compared using the independent samples  t-test.  
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Table 5: Comparison of reliable versus unreliable Liver Stiffness Measurement subjects 
Patient Characteristic Reliable LSM (n=77) Unreliable LSM (n=11) P value 
Age (yrs) 60.0 (11.5) 65.1 (11.6) 0.173 
Femalea 31/77(40.3%)  5/11(45.5%) 0.315 
Duration of Diabetes (yrs) 8.6 (7.3) 12.2 (6.6) 0.125 
HbA1c (%) 8.2 (1.8) 8.1 (1.8) 0.890 
Insulin therapya 24/77(31.2%) 4/11(36.4%) 1.000 
Cholesterol (mmol/L) 4.1 (1.0) 4. (1.0) 0.089 
HDL (mmol/L) 1.2 (0.3) 1.4 (0.4) 0.108 
LDL (mmol/L) 2.2 (0.7) 2.7 (0.9) 0.072b 
Triglycerides (mmol/L) 1.8 (1.0) 1.7 (0.7) 0.807 
Height (m) 1.64 (0.11) 1.65 (0.12) 0.748 
Weight (kg) 79.7 (20.7) 90.7 (25.6) 0.114 
BMI (kgm-2) 29.6 (6.7) 33.1 (7.7) 0.121 
Alcohol intake (g/wk) 14.9 (42.8) 19.5 (43.7) 0.741 
BR (mmol/L) 9 (4) 9 (3) 0.680 
ALB (g/L) 44 (4) 43 (3) 0.641 
ALP (IU/L) 91 (76) 104 (55) 0.541 
GGT (IU/L) 52 (92) 131 (163) 0.025 
ALT (IU/L) 30 (19) 39 (31) 0.205 
AST (IU/L) 26 (19) 40 (29) 0.034b 
PLT (x109/L) 270 (112) 270 (79) 0.994 
INR  1.0 (0.2) 1.0 (0.1) 0.682 
αFP (ug/L) 1.8 (1.0) 2.1 (1.1) 0.409 
LSM (kPa) 6.8 (2.8) 13.7 (8.6) <0.001b 
IQR/median 0.22 (0.14) 0.53 (0.25) <0.001b 
Scan Success Rate 79.1 (22.8) 62.5 (22.0) 0.029b 
a. Chi square test applied to gender female and insulin therapy variables. All other variables are continuous and 
were compared using the independent samples  t-test. 
b. Only the LSM value was significant in multivariate analysis 
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2.3.3 Distribution of liver stiffness measurements in the diabetes subjects  
Using the LSM cutoffs derived from Yoneda’s study (1), 45 /77 (58%) of subjects had at least Metavir 
fibrosis stage 1(F≥1). The number of subjects with F≥2 was 36/77 (47%), F≥ 3 was 9/77 (12%), and F4 
1/77 (1%). This is summarized in Table 6. The distribution of the LSM scores and their frequencies are 
shown in Figure 12.  
 
 
Table 6: Distribution of LSM and in diabetes subjects  
 
LSM (kpa)(1) Derived F Stage N (total = 77) 
≥5.9 ≥1 45 (58%) 
≥6.7 ≥2 36 (47%) 
≥9.8 ≥3 9 (12%) 
≥17.5 4 1 (1%) 
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Figure 12: Distribution of Liver Stiffness in Diabetes subjects  
Red line indicates LSM=9.8 kPa, the cutoff used for F≥3 
 
 
Figure 13: Distribution of Liver Stiffness in Controls:   
Red line indicates LSM=9.8 kPa, the cutoff used for F≥3 
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2.3.4 Type II diabetes patients and non-diabetic controls 
A comparison between type II diabetes patients in the cohort and non-diabetic controls with no known 
history of chronic liver disease was performed. Twenty six matched control subjects were included in 
the analysis. The LSM range for controls was 2.9-8.9 kPa (Figure 13). The mean LSM was found to be 
greater in type II diabetes cohort: 6.8 (SD 2.8) kPa versus 5.0 (SD 1.3) kPa, p= 0.002. No significant 
differences were found for age, gender, BMI, alcohol intake or IQ R/median ratio. The scan success rate 
was higher in type II diabetes 79.1% (SD 22.8%) versus controls 66.7% (SD 30.4%), p= 0.029. However, 
scan success is not a significant factor in the accuracy of readings (see 1.7.4). These findings are 
summarized in Table 7.  
 
 
 
 
Table 7: Comparison of characteristics between type II diabetes patients and healthy controls 
 Type II Diabetes (n=77) Non-diabetic controls 
(n=26) 
P value 
Age (yrs) 60.0 (11.5) 55.5 (13.3) 0.101 
Femalea 31/77 (40%)  15/26 (58%) 0.122 
BMI (kgm-2) 29.6 (6.7) 28.3 (6.4) 0.379 
Alcohol intake (g/wk) 14.9 (42.8) 25.0 (61.0) 0.370 
LSM (kPa) 6.8 (2.8) 5.0 (1.3) 0.002 
LSM ≥ 9.8 kPa 9/77 (12%) 0/26 (0%) 0.068 
IQR/median 0.21 (0.14) 0.25 (0.15) 0.371 
Scan Success Rate 79.1 (22.8) 66.7 (30.4) 0.029 
c. Chi square test applied to gender and LSM≥9.8 kPa with the proportions and percentages in parenthesis 
reported. All other variables are continuous in which the mean value and standard deviation in parenthesis 
were reported. Comparisons were performed using the independent samples t-test. 
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2.3.5 BMI and insulin use are associated with liver stiffness in diabetes  
In the diabetes cohort, univariate and multivariate regression analysis was performed to determine 
associations with liver stiffness. The factors found to have a significant association with LSM in 
univariate analysis include insulin therapy (r=-0.190, p<0.001); weight (r=0. 393, p= 0.001); BMI (r= 
0.349, p= 0.002); and ALT (r=0.281, p= 0.016). In multivariate analysis, the only remaining associations 
with LSM were BMI and insulin therapy. These findings are shown in Table 8.  
 
Table 8: Correlations of patient characteristics with liver stiffness in diabetes patients 
Patient Characteristic Correlation (r) P value 
Age (yrs) 0.168 0.145 
Femalea -0.201 0.098 
Duration of Diabetes (yrs) 0.105 0.376 
HbA1c (%) 0.101 0.395 
Insulin therapya -0.190 <0.001b 
Cholesterol (mmol/L) 0.061 0.624 
HDL (mmol/L) -0.016 0.906 
LDL (mmol/L) 0.080 0.543 
Triglycerides (mmol/L) 0.090 0.477 
Height (m) 0.178 0.133 
Weight (kg) 0.393 0.001b 
BMI (kgm-2) 0.349 0.002b 
Alcohol intake (g/wk) -0.036 0.763 
BR (mmol/L) -0.043 0.720 
ALB (g/L) 0.026 0.826 
ALP (IU/L) 0.039 0.745 
GGT (IU/L) 0.095 0.423 
ALT (IU/L) 0.281 0.016b 
AST (IU/L) 0.216 0.067 
PLT (x109/L) -0.172 0.160 
INR -0.116 0.375 
αFP (ug/L) -0.202 0.131 
a. Categorical variables were converted to continuous variables to enable multiple regression 
b. Only BMI and use of insulin therapy were significant in the multivariate model 
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2.3.6 Comparison of factors in diabetes patients with LSM<9.8 kPa versus LSM≥ 9.8 kPa (cut-
off indicative of F≥3) 
 A comparison of the clinical factors was performed in those with an LSM <9.8 kPa versus ≥9.8 kPa. The 
only significant difference was that the greater proportion of those who use insulin therapy in those 
with LSM≥ 9.8 kPa group: 77.8% versus 25%, likelihood ratio (LR) 12.3, p= 0.002.These findings are 
shown in Table 9.   
 
Table 9: Comparison of characteristics between diabetic patients with LSM < 9.8 kPa and subjects with ≥ 9.8 kPa   
Patient Characteristic LSM<9.8kPa (n=68) LSM≥9.8 kPa (n=9) P value 
Age (yrs) 59.8 (11.8) 61.8 (8.8) 0.625 
Femalea 28/68 (41.2%) 3/9 (33.3%) 0.652 
Duration of Diabetes (yrs) 8.6 (7.5) 8.8 (5.8) 0.947 
HbA1c (%) 8.1 (1.9) 8.7 (1.3) 0.399 
Insulin therapya 17/68 (25.0%) 7/9 (77.8%) 0.002 (LR 12.3)b 
Cholesterol (mmol/L) 4.2 (1.1) 4.0 (0.6) 0.601 
HDL (mmol/L) 1.2 (0.3) 1.2 (0.4) 0.835 
LDL (mmol/L) 2.2 (0.8) 2.1 (0.5) 0.629 
Triglycerides (mmol/L) 1.8 (1.0) 1.7 (1.0) 0.609 
Height (m) 1.63 (0.11) 1.67 (0.12) 0.383 
Weight (kg) 78.4 (20.2) 90.3 (23.7) 0.125 
BMI (kgm-2) 29.3 (6.7) 32.2 (7.0) 0.258 
Alcohol intake (g/wk) 15.3 (44.7) 11.9 (23.9) 0.832 
BR (mmol/L) 9 (4) 9 (2) 0.645 
ALB (g/L) 44 (4) 44 (2) 0.905 
ALP (IU/L) 91 (81) 85 (14) 0.804 
GGT (IU/L) 53 (98) 44 (25) 0.785 
ALT (IU/L) 28 (19) 42 (20) 0.056 
AST (IU/L) 25 (19) 34 (18) 0.145 
PLT (x109/L) 273 (120) 251 (36) 0.602 
INR  1.0 (0.2) 1.0 (0.0) 0.677 
αFP (ug/L) 1.9 (1.1) 1.4 (0.4) 0.181 
a. Chi square test applied to categorical variables. All other variables were continuous and the independent 
samples t-test was applied 
b. The likelihood ratio (LR) was calculated for insulin therapy use in those with LSM≥9.8 kPa vs < 9.8 kPa.  
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2.3.7 Summary of the results  
In this cohort of type 2 diabetes patients: 
• 12% had an LSM of ≥ 9.8 kPa indicative of at least advanced fibrosis (F≥3) 
• The mean LSM was significantly higher in diabetics compared with non-diabetic matched 
controls: 6.8 (SD 2.8) kPa versus 5.0 (SD 1.3) kPa, p= 0.002 
• The LSM was associated with insulin therapy (r=-0.190, p<0.001) and BMI (r= 0.349, p= 0.002). 
• Diabetes patients with an LSM ≥ 9.8 kPa were significantly more likely to be on insulin therapy, 
with a likelihood ratio of 12.3 (p=0.002) 
• Valid LSM was obtained in 90.7%, while a valid and reliable LSM were obtained in 79.4% of all 
subjects 
• Subjects with invalid scans had a significantly higher BMI:  36.7 (SD 6.3) kgm-2 vs 30.1 (SD 6.9) 
kgm-2, p=0.044 
• Subjects with unreliable scans had a significantly higher LSM: 13.7 (SD 8.6) kPa vs 6.8 (SD 2.8) 
kPa (B coefficient 0.518, Wald statistic p = 0.049) 
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2.4 DISCUSSION 
 
2.4.1 Rate of advanced fibrosis (as indicated by LSM≥9.8 kPa) in diabetes subjects 
 
In our study cohort, 12% of type II diabetes patients had an LSM of ≥ 9.8 kPa consistent with at least F3 
or advanced fibrosis. In contrast, the highest LSM reading in a non-diabetic control was 8.9 kPa. The LSM 
was significantly higher in diabetes patients:  6.8 (SD 2.8) kPa versus 5.0 (SD 1.3) kPa, p= 0.002. This 
result suggests that diabetes is associated with the development of progressive liver damage as a 
consequence of NAFLD, and is consistent with other studies (95, 110-112). The high rate of 12% with 
elevated LSM indicative of advanced fibrosis suggests that this group of patients should be routinely 
screened for liver disease. 
A point of contention of the findings may be that they are somewhat limited by the accuracy of TE and 
that the LSM cutoffs adopted were derived from a single study of Japanese patients which may not be 
generalizable.  At the time of the research, the only available data was from Yoneda’s study, in which 
the LSM cutoff of ≥9.8 kPa for F≥3 was reported to have high sensitivity (85%) and specificity (81%), with 
an overall excellent AUROC of 0.904. In the later meta-analysis (chapter 3), pooled sensitivity and 
specificity for F≥3 to both be 85%, with the LSM cut-offs used in studies ranging from 8.0-10.4 kPa (109).  
Therefore, the chosen cutoff of 9.8 kPa for this study was reasonable and a reliable reflection of F≥3 
advanced fibrosis.   
 
Whether NAFLD is the only cause of fibrosis in this group of type 2 diabetic patients could be 
questioned. Due to the cross sectional nature of the study, we were only able to rule out other causes of 
chronic liver disease with clinical history and medical records. Not every patient had full serological or 
biochemical tests to exclude viral hepatitis, hemochromatosis, Wilson’s disease and other causes of 
chronic liver disease. However the assumption that these patients with type 2 diabetes develop liver 
fibrosis because of NAFLD is still a sound one to make. It is established that 63-70% of type II diabetes 
patients have NAFLD, making it by far the most likely cause of liver fibrosis in this population (110-112). 
Meanwhile in our local setting, other causes of chronic liver disease are uncommon. The prevalence of 
chronic hepatitis B and C are each estimated to be 1% (113, 114). The next most common liver disorder 
is hemochromatosis in which the homozygous state has a prevalence of 0.5% (115). Therefore even if 
there were patients with undiagnosed chronic liver disease from these other etiologies, the background 
prevalence would only be around 2-3% compared to the 63-70% probability of having NAFLD. Patients 
with excessive alcohol intake were excluded as per study criteria. The contribution to fibrosis prevalence 
from other causes rather than NAFLD would therefore be minimal.    
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2.4.2 Liver Stiffness is associated with BMI and insulin therapy 
 
Our results show BMI and need for insulin therapy are correlated with the LSM, and that patients on 
insulin therapy is associated with LSM ≥ 9.8, with a likelihood ratio of 12.3 (p=0.002)   
Obesity and insulin resistance are key components of the metabolic syndrome. The need for insulin 
therapy probably implies a state of increase insulin resistance, in which endogenous insulin is 
insufficient for glycaemic control, thereby necessitating exogenous insulin administration. Our findings 
are unsurprising given that obesity, insulin resistance and metabolic syndrome are recognized as key 
features in the pathogenesis of NASH and fibrosis in NAFLD (116). Our observations are compatible with 
reports of LSM being associated with the HOMA-IR score (117, 118) and obese patients having very high 
rates (57-98%) of NAFLD (119-121). Furthermore, advanced liver fibrosis has been linked with the 
presence of diabetes and obesity in biopsy series (122, 123).  BMI in the obese range and the need for 
insulin therapy are clinical features that could be used to further stratify diabetes patients who are at 
high risk of progressive liver disease for screening.  
 
2.4.3 LSM has no association with ALT, AST and lipid levels, duration of diabetes or HbA1c 
 
Our study found no correlation between LSM with ALT, AST and lipid levels.  
LSM has been shown to be affected by elevated ALT levels in studies of TE in the viral hepatitis 
population (88) . While some biopsy series have reported an association between raised transaminases 
and advanced fibrosis (122, 123), the majority of the TE literature that feature liver biopsy (7 out of 9 
studies) have found no association (1, 117, 118, 124-129). This suggests that ALT may have minimal 
effect on LSM reading in the setting of NAFLD. This could be explained by hepatic necroinflammation not 
being as severe as that are seen in those underlying viral hepatitis flares.   
Hyperlipidaemia is associated with liver fibrosis (130) while statin use has been found to have a 
protective effect (108) in other studies. No correlations between LSM and lipid levels were found in our 
study, probably because patients were mostly on pharmacological treatment. The use of lipid lowering 
therapy was not closely examined in this cross sectional analysis, and may be addressed in future 
studies.  
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2.4.4 Overestimations of liver stiffness can occur when using the M probe in obese patients 
with excessive skin capsule distance 
 
At the time of writing, 9 studies had compared liver histology with LSM in NAFLD patients while also 
examining factors which were associated with LSM (1, 117, 118, 124-129). These were also the studies 
that met QUADAS criteria and analysed in the meta-analysis to be presented in chapter 3.  
There were reports by 3 of these studies that obese range BMI was a confounding variable for liver 
stiffness (117, 124, 126).  In patients who were obese, the LSM was inaccurate for assessing fibrosis 
stage. Obese BMI patients often had a high LSM, but a lower degree of fibrosis severity found on biopsy 
compared to non-obese individuals. Mechanisms postulated include greater steatosis itself causing high 
liver stiffness, leading to overestimation of the liver fibrosis stage (117, 124, 126).  
However, the 6 other studies reported no association between the LSM and obese range BMI or 
steatosis that was independent or separate to liver fibrosis (1, 118, 125, 127-129). Without comparison 
to liver biopsy, is not possible in our study to clarify whether high liver stiffness in obese BMI patients is 
due to fibrosis, or due to an alternate confounding mechanism associated with obesity. It would appear 
unlikely obesity is a confounder given the majority of the literature has not reproduced similar findings.  
There may be a simpler reason why obese patients have less accurate Fibroscans. It is well established 
that inaccurate LSMs can occur in patients who have an excessive skin to liver capsule distance (SCD) 
that is greater than the depth of measurement that the Fibroscan probe allows (see 1.4.7) (52). The 
main reason for an excessive SCD is subcutaneous fat, and hence obese individuals are most likely to 
have inaccurate scans.  
The M probe has a measurement depth from 25 mm to 65 mm beneath the skin. When the SCD is less 
than 25mm, the measured region will contain liver tissue only, and so an accurate assessment occurs.  
But if the SCD is greater than 25mm, the measured region will contain non-liver tissue that is between 
the skin and the liver. This might include: the liver capsule, which is fibrous and likely to produce higher 
stiffness values compared to the liver parenchyma; the bony ribs and intercostal muscles, which would 
similarly produce higher stiffness results; and the subcutaneous fat, which probably has lower stiffness 
compared to liver leading to an underestimation. The effect is that the LSM will be assessed based on 
the stiffness of these non- liver tissues, leading to inaccurate results.  
When non-liver tissue is measured, typical elastograms may contain A waves, E waves and angled waves 
(see section 1.7.2). These are sometimes undetected by the internal quality control software algorithm 
of the Fibroscan. Thus, achieving accurate measurements is reliant upon the operator to recognize 
incorrect scans when they are not automatically detected and discarded by the Fibroscan.  
This issue may be resolved by using a probe that can obtain measurements to a greater depth 
underneath the skin. It is notable that the 3 aforementioned studies that reported inaccurate LSMs in 
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obese patients had only the M probe available for use. It is probable that the routine use of the M probe 
on obese subjects, who would tend to have excessive SCD, resulted in numerous occasions where non 
liver tissue was measured instead of the liver, resulting in systematic overestimation or 
underestimation. In the 6 other studies that did not find LSM to be overestimated in obese patients, 
their operators may have been more able to limit excessive overestimation/underestimation. The 
operator’s experience, technique and ability to identify aberrant waves on the elastogram when the 
software fails to reject them are important factors in obtaining accurate Fibroscans.   
 
2.4.5 Invalid and unreliable measurements can occur when using the M probe in obese 
patients with excessive skin to liver capsule distance  
 
The M probe being insufficient for obese patients also provides an explanation for the occurrence of 
invalid scans (defined as unable to obtain minimum 10 measurements) and unreliable scans (defined as 
the IQR/M ratio ≤ 30% required if final stiffness result is < 7.1kpa) in our study.  
Our findings of invalid scans being associated with a higher mean BMI: 36.7 (SD 6.7) kgm-2 vs 30.1 (SD 
6.9) kgm-2, p=0.016, is consistent with other studies (1, 117, 118, 124-129).  This can be explained by 
obese patients having an excessive SCD. Scans were invalid because the measurement region of the M 
probe was not deep enough to measure the liver parenchyma only. This would be reflected as a non-
linear A mode signal, leading to rejection of the elastogram by the internal software (see 1.7.2).  
Unreliable scans were associated with having a much higher mean LSM: 13.7 (SD 8.6) kPa vs 6.8 (SD 2.8). 
The higher value of the LSM is not causative of unreliable scans, but rather a manifestation of the 
underlying reason. By definition, unreliable scans occur when the set of measurements for the LSM have 
a wide range, specifically when the interquartile range is greater than 30% of the median measurement. 
Nearby tissue types (such as ribs and the fibrous liver capsule) are much “harder” than the liver. There is 
a bigger difference in elasticity between the liver and these tissue types than compared to the different 
regions within the liver itself. Thus a wide range of measurements likely indicates that non liver tissues 
along with liver tissue are being concurrently scanned. These measurements are included within the set 
of valid measurements and contribute to calculating the median score. As hard structures will have high 
stiffness measurements, this leads to a higher median score being assigned as the LSM, along with a 
wider range of values within the set of measurements taken. The result is that the LSM is overestimated 
and has high IQR/M ratio more likely to be greater than 30% - the exact scenario that was observed in 
unreliable scans.  
Unreliable scans due to measuring non-liver tissue is again most likely related to obese patients who 
have an excessive SCD. Those with unreliable scans were 11kg heavier (90.7kg vs 79.7kg) and BMI 3.5 
kgm-2 greater (33.1 kgm-2 vs 29.6 kgm-2). This difference is probably great enough to systematically cause 
an excessive SCD leading to unreliable scans, in spite of the difference not being statistically significant. 
Small numbers in the unreliable scan group (n=11) probably prevented statistical significance being 
reached.  
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2.4.6 Study limitations and further research with the XL probe 
 
The rates of an invalid scan or an unreliable scan in our study were 9% and 11% respectively. Scans were 
both valid and reliable only in 79.4% of subjects. Other studies have reported similar rates of invalid 
scans using the M probe: 8 – 14% (1, 117, 118, 124-129). None have highlighted the rate of obtaining 
both a valid and reliable scan. The low rate means inaccurate assessments occur in approximately 1 in 5 
patients which severely limits the usefulness of Fibroscan in NAFLD. Obese patients are more likely to be 
affected by NAFLD, but are also the group of patients in which Fibroscan is least able to obtain valid, 
reliable and accurate readings.   
The limits of the M probe in inadequate measurement depth for obese individuals was recognized and 
addressed by development of the XL probe. The XL probe had not yet been developed at the time of this 
study, nor was available for any of the publications that reported high failure rates.  The measurement 
depth for the M probe is 25-65mm beneath the skin, while the XL probe is able to measure between 35-
75mm underneath the skin (131).  The potential advantages of the XL probe are reviewed in the meta-
analysis presented in the next chapter.  
This study has several limitations including small number of patients, absence of reference liver biopsy, 
and other relevant clinical data, such as fasting insulin and glucose levels to calculate the HOMA-IR. 
Limitations of the use of the M probe in this cohort are also recognized.  
Nonetheless at the time of research, little data existed for the use of Fibroscan for NAFLD. The study was 
intended to be used as a pilot to determine further studies, and a much larger and comprehensive study 
of TE in diabetic patients was later performed (132) which overcame many of the limitations of this pilot 
including the lack of XL probe, while also assessing the controlled attenuation parameter (CAP) a novel 
feature of Fibroscan that assesses steatosis. This is presented in chapter 4 of this thesis.  
 
2.5 CONCLUSION 
 
The prevalence of advanced fibrosis in patients with type II diabetes appears to be high. Higher liver 
stiffness was observed in diabetics with obese range BMI and who required insulin therapy. These 
clinical features could be used to target at risk patients for screening.  Fibroscan may be of limited use in 
obese individuals due to overestimation of high liver stiffness values and a high rate of invalid and 
unreliable scans. Further studies with a larger study population and use of the XL probe are needed to 
clarify these issues.  
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CHAPTER 3:   SYSTEMATIC REVIEW WITH META-
ANALYSIS: NON-INVASIVE ASSESSMENT OF NON-
ALCOHOLIC FATTY LIVER DISEASE-THE ROLE OF 
TRANSIENT ELASTOGRAPHY AND PLASMA 
CYTOKERATIN-18 FRAGMENTS 
 
 
This chapter was published as: 
Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease - 
the role of transient elastography and plasma cytokeratin-18 fragments.  
Kwok R, Tse YK, Wong GL, Ha Y, Lee AU, Ngu MC, Chan HL, Wong VW 
Alimentary pharmacology & therapeutics 2014; 39(3):254-69. 
Raymond Kwok is the corresponding author and was primarily responsible for the literature review, data 
extraction, and writing the drafts. The study was co-designed and analysis co-interpreted with the co-
authors.  
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3.0 CHAPTER SUMMARY 
 
Background: Non-alcoholic fatty liver disease (NAFLD) affects 15-40% of the general population. Those 
who have steatohepatitis (NASH) and progressive fibrosis and would be candidates for monitoring and 
treatment. 
Aims: To review current literature on the use of non-invasive tests to assess the severity of NAFLD. 
Methods: Systematic literature searching identified studies evaluating non-invasive tests of NASH and 
fibrosis using liver biopsy as the reference standard. Meta-analysis was performed for areas with 
adequate number of publications. 
Results: Serum tests and physical measurements like transient elastography (TE) have high negative 
predictive value in excluding advanced fibrosis in NAFLD patients. The NAFLD fibrosis score comprise 6 
routine clinical parameters and has been endorsed by current AASLD guidelines as a screening test to 
exclude low-risk individuals. The pooled sensitivities and specificities for TE to diagnose F≥2, F≥3 and F4 
disease were 79% and 75%, 85% and 85%, and 92% and 92%, respectively. Liver stiffness measurement 
often fails in obese patients, but the success rate can be improved with the use of the XL probe. A 
number of biomarkers have been developed for the diagnosis of NASH, but few were independently 
validated. Serum/plasma cytokeratin-18 fragments have been most extensively evaluated and have a 
pooled sensitivity of 66% and specificity of 82% in diagnosing NASH. 
Conclusions: Current non-invasive tests are accurate in excluding advanced fibrosis in NAFLD patients 
and may be used for initial assessment. Further development and evaluation of NASH biomarkers are 
needed. 
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3.1 INTRODUCTION 
 
Non-alcoholic fatty liver disease (NAFLD) is currently the most common chronic liver disease worldwide, 
affecting 15-40% of the general population (95, 133). Depending on the presence of necroinflammation 
and hepatocyte ballooning, NAFLD is further divided into non-alcoholic fatty liver (NAFL) and non-
alcoholic steatohepatitis (NASH) (97). NASH is the active form of NAFLD. It occurs in 10-20% of NAFLD 
patients and may progress to cirrhosis and hepatocellular carcinoma (HCC) (17, 58, 59). Since NAFLD is 
highly prevalent but the majority of patients only has NAFL and run a benign course, it is important to 
identify patients with NASH and NAFLD fibrosis efficiently. 
 
Traditionally, liver biopsy is the primary method to assess the severity of NAFLD. However, it is an 
invasive procedure and carries a small but definite risk of complications. Furthermore, it is unrealistic to 
perform liver biopsy for 15-40% of the general population. In recent years, a number of blood tests and 
physical assessments have been developed to aid evaluation of NAFLD patients. Therefore, it is timely to 
appraise the diagnostic performance of these non-invasive tests. 
Our review will focus on the diagnosis of fibrosis and NASH in the NAFLD spectrum. The diagnosis of 
simple steatosis was not chosen as a primary focus of review because of its generally innocuous nature. 
Some non-invasive tests have been much more widely studied and used compared with others. After 
considering expert opinion and existing reviews on the topic, an in-depth assessment on the 
performances of transient elastography (TE), cytokeratin-18 fragments (CK18) and acoustic radiation 
force impulse (ARFI) was deemed appropriate. TE and CK18 are amongst the most widely studied 
modalities in NAFLD fibrosis and NASH, while ARFI has generated much recent interest. Thus in addition 
to a systematic review of the variety of non-invasive diagnostic methods in NAFLD fibrosis and NASH, we 
performed a meta-analysis on the use of TE, CK18 and ARFI.  
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3.2 METHODS 
 
3.2.1 Literature Search 
A systematic web-based literature search of all publications in MEDLINE (via OvidSP), PUBMED (NLM) 
and EMBASE was conducted on 13th June 2013 from the date of inception for each of the databases. Our 
primary search strategy for identifying studies comprised of using free-text words (fatty liver, non-
alcoholic fatty liver disease, non-alcoholic steatohepatitis, transient elastography, Fibroscan, liver 
stiffness measurement, elastography imaging techniques, acoustic radiation force impulse, keratin 18, 
cytokeratin 18). Two reviewers (RK and VWSW) performed literature search separately and agreed upon 
the final selection of studies. Search limits included English language, abstracts, and publication in peer-
reviewed journals. A secondary search was performed to locate any potential studies missed by 
electronic search strategies. A comprehensive search of MEDLINE was performed for locating any 
existing systematic reviews on transient elastography, ARFI and CK18 in the diagnosis of NAFLD. Manual 
searching of reference lists from relevant reviews and primary studies and was performed. No additional 
suitable studies were found. 
 
3.2.2. Meta-analysis 
All candidate articles from our primary search had its abstract or full text scrutinized to determine 
whether it was a primary study. Subsequently the full text was further assessed to check for fulfillment 
of the inclusion/exclusion criteria. Disagreements were resolved through consensus. Inclusion/exclusion 
criteria for primary studies required the following features: 
 
(1) Detailed description of adult human subjects under study 
(2) Description of TE, ARFI or CK18 as an index test 
(3) Description of liver biopsy as the reference standard. The definition of NASH was taken as the 
NALFD activity score ≥ 5. Fibrosis staging based on the Brunt’s or Kleiner’s system: F0 = no 
fibrosis; F1 = perisinusoidal or portal; F2 = perisinusoidal and portal/periportal; F3 = septal or 
bridging fibrosis; and F4 = cirrhosis (60, 61). 
(4) A minimum number of NAFLD subjects ≥ 20 
(5) Results describe number of cases of fibrosis for each stage or NASH using liver biopsy, the 
sensitivity, specificity and nominated cut off values of the index test so that a 2x2 table could be 
created. Corresponding authors were asked to provide study level data if adequate information 
could not be extracted from the published article. 
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(6) Different articles from a primary study that contained overlapping data cohorts were only 
counted once. The most suitable article to use was determined by seeking clarification from the 
authors, or by using the most updated manuscript that contained all the required data.   
 
Both prospective and retrospective studies were acceptable. Studies in which subjects had other causes 
of chronic liver disease apart from NAFLD were included so long as discrete data for NAFLD population 
could be extracted. Studies which reported other noninvasive comparators were also allowed if the 
discrete data for TE, ARFI and CK18 could be extracted. 
A final number of 9 articles for TE (1, 117, 118, 124-129), 11 articles for CK18 (134-144) and 2 articles for 
ARFI (128, 145) were assessed to be suitable for inclusion in the meta-analysis.  There were too few 
studies for statistical analysis on the ARFI data.  
 
 
 
 
 
Figure 14 outlines the stepwise evaluation and selection process for all the candidate studies.  
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Figure 14: Summary of literature search and selection 
Articles identified with text word search 
MEDLINE/PUBMED/EMBASE 
TE – 119 
CK18 - 64 
ARFI - 8 
Articles identified as primary studies 
TE – 24 
CK18 – 22 
ARFI - 6 
 
ARFI 
Excluded 95 TE, 48 CK18 and 2 ARFI studies 
- Did not report primary data 
(reviews, editorials) 
- Did not report outcome of interest 
- Paediatric population (age<12yrs) 
 
Studies that met inclusion criteria 
TE – 9  
CK18 – 11  
ARFI – 2  
Excluded 15 TE studies 
- 1 not applied as a diagnostic test for fibrosis  
- 4 Incomplete data for 2x2 table 
- 5 Overlapping data cohorts 
- 5 Did not meet minimal required of 20 NAFLD 
patients 
Excluded 12 CK18 studies 
- 5 not applied as diagnostic test for NASH 
- 4 incomplete data for 2x2 table 
- 3 Overlapping data cohorts 
Excluded 4 ARFI studies 
- 2 data incomplete for 2x2 table 
- 1 not applied as a diagnostic test for fibrosis 
- 1 did not meet minimum required of 20 
NAFLD patients 
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3.2.3 Quality assessment 
Each study’s quality was analyzed by independent reviewers (RK, YKT). A modified version of the 
QUADAS (146) was used to assess the quality of the studies included for meta-analysis (Table 
12/Supplementary Table 1). Consensus was reached in disagreements by referral to a third reviewer 
(VWSW). 
TE studies overall scored highly on the QUADAS assessment (Figure 17/Supplementary Figure 1). Two 
studies scored 12/13 whereas the rest scored 13/13. CK18 studies had a mean QUADAS score of 11.2 
(range 9-13) (Figure 18/Supplementary Figure 2). The most common components in which studies lost 
points were an unclear description of the quality of liver biopsies (36% studies had high quality data), 
whether the histopathologist was blinded to other results (45%), and unclear descriptions of when 
serum was obtained for CK18 analysis in relation to the timing of liver biopsy (64%). 
 
3.2.4 Data extraction 
Two reviewers (RK, YJH) independently extracted the required information from primary studies. A data 
extraction pro-forma was created and variables included for collection were: patient age, sex, ethnicity, 
BMI, transaminase levels, results of the index and reference tests and accompanying diagnostic 
thresholds (cut-offs). Where available, other biochemical and blood parameters, presence of metabolic 
syndrome components and risk factors (other anthropometric measures, diabetes, hypertension, 
hypercholesterolemia and hypertriglyceridemia) were recorded. A 2×2 table was created for each 
modality and its reported cut-off for diagnosing each category. 
 
3.2.5 Data synthesis and statistical analysis 
From the 2×2 tables we calculated sensitivity and specificity. The estimates of sensitivity and specificity 
and their associated 95% confidence intervals (CIs) were presented graphically by plotting in paired 
forest plots. Summary estimates of sensitivity and specificity, along with 95% CIs, were obtained by 
using the bivariate random-effects modeling approach (minimum 4 studies) (147). Besides accounting 
for study size and between-study heterogeneity using a random effects model, the bivariate analyses 
enable correctly dealing with any possible negative correlation that might arise between the sensitivity 
and specificity. Moreover, we constructed a hierarchical summary receiver operating characteristic 
(HSROC) curve plotting sensitivity versus specificity (148). The HSROC curve illustrates the summary 
tradeoff between sensitivity and specificity across the studies.  
To examine the potential sources of heterogeneity, we predefined the following covariates: body mass 
index (< 30kg/m2 vs ≥ 30kg/m2, for TE), and study quality factors (yes vs unclear vs no, for individual 
QUADAS item as described above). Separate bivariate models were simply performed to different 
subgroups of studies because sufficient data were not available (at least 10 studies) to allow adding 
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covariates to the hierarchical model by means of meta-regression. The two studies by Yoneda et al. had 
much higher cutoffs for F4, compared with the other studies included in the meta-analysis (Figure 16). 
In order to assess the effect on the pooled results, a post-hoc sensitivity analyses was conducted to 
calculate pooled estimates of sensitivity and specificity in the bivariate model by excluding these two 
studies. Statistical analyses were performed using STATA 10.0 (StataCorp, College Station, TX, USA), 
particularly the metandi (149) commands and Review Manager (150) software. All statistical tests were 
two-sided, with a p value < 0.05 indicating statistical significance. 
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3.3 NON-INVASIVE DIAGNOSIS OF NASH 
 
NASH is the active form of NAFLD with necroinflammation and hepatocyte ballooning. With ongoing 
liver injury, NASH may progress to cirrhosis and HCC. In long-term follow-up studies, histological 
features of NASH predict future liver complications (104, 151). Previously, NAFL and NASH were 
considered distinct entities. However, recent longitudinal studies with paired liver biopsies suggest that 
some patients with NAFL may progress to NASH (17, 152). In any case, assessment of disease severity is 
important for prognostication and treatment monitoring. 
 
3.3.1 Serum biomarkers 
3.3.1.1 Cytokeratin-18 fragments 
Cytokeratins are keratin-containing proteins that form intermediate filaments and comprise the 
structure of cytoskeletons of epithelial cells. CK18 is found predominantly in glandular epithelia of the 
digestive, respiratory and urogenital tracts. It is the major intermediate filament protein of the liver. 
During apoptosis of hepatocytes, capsases cleave CK18 generating fragments that can be detectable 
using immunoassays (153). It is one of the most widely investigated biomarkers for NASH as a standalone 
test or as part of prediction models. The two main enzyme assays of CK18 that have been studied are 
M30 and M65, which supposedly measure hepatocyte apoptosis and total cell death, respectively. 
Meta-analysis on CK18 
We performed a meta-analysis of 11 studies with a total pool of 822 patients, in which 389 had 
histological NASH (Table 13/Supplementary Table 2). Since M30 and M65 had similar performance and 
M30 was more widely studied, we decided to focus on M30. The studies were further grouped according 
to whether a separate ‘high sensitivity’ and ‘high specificity’ cut-off (6 studies) was chosen, and/or a 
single ‘best’ overall cut-off level (7 studies) was used to diagnose NASH. In the 6 studies that chose 
separate cut-offs, for ‘high sensitivity’, the CK 18 cut-off chosen ranged 111.6 – 380.0 U/L (77-90% 
sensitivity and 34-94% specificity) (Figure 15). For ‘high specificity’, the cut-offs chosen ranged 261.4 – 
670 U/L (24-86% sensitivity and 91-100% specificity). The AUROC for these 6 studies were 0.71-0.93. For 
the 7 studies that reported a single ‘best’ overall cut-off, the range of chosen cut-offs was 121.6-338.0 
U/L, with 60-88% sensitivity, 66-97% specificity and AUROC 0.70-0.87. 
In the pooled estimates of diagnostic accuracy, the 7 studies which used a single ‘best’ overall cut-off 
level showed 66% sensitivity and 82% specificity. In the 6 studies using separate ‘high sensitivity’ and 
‘high specificity’ cut-offs, the pooled estimates were 82% sensitivity, 65% specificity and 58% sensitivity 
and 98% specificity, respectively. Pooled estimates of diagnostic accuracies remained stable when only 
studies with high quality were analyzed (Table 14/Supplementary Table 3). Figure 19/Supplementary 
Figure 3 showed the HSROC plots of CK18.  
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Discussion on CK18 
 Our findings suggest that CK18 has moderate accuracy overall for diagnosing NASH (66% sensitivity, 
82% specificity). When optimal cut-offs are used, sensitivity improves to 82%, while specificity is 98%. 
However, there is considerable variability in the suggested cut-offs and their respective diagnostic 
accuracy among studies. In clinical practice, this makes choosing which threshold to use very difficult. 
The variability may be partly explained as by choosing an optimal threshold to maximise either 
sensitivity or specificity, the accuracy of the other is greatly sacrificed. Other possible causes of 
heterogeneity include intervals between blood tests and liver biopsy, inadequate description of liver 
biopsy assessment and blinding, and inadequate reference test description. However, none of these was 
found to be significant, with only small differences in overall sensitivities and specificities in these 
subgroups (Table 14/Supplementary Table 3). 
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Figure 15: Forest plot from meta-analysis for CK18 
Forest plot from meta-analysis of sensitivities and specificities for CK18 to diagnose NASH using a 
random-effect model. Cutoffs with the best overall accuracy, sensitivity and specificity in individual 
studies were adopted. TP:True Positives, FP: False Positives, FN: False Negatives, TN: True Negatives.  
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3.3.1.2 Other biomarkers 
Soluble sFas (sFAS) is a death receptor from the TNFR family that has been implicated in apoptosis and is 
upregulated in NASH in animal models. An apoptosis panel combining CK18 with sFAS was found to have 
greater AUROC than either alone (154).  
Tumor necrosis factor-alpha (TNF-α) is a proinflammatory cytokine which has been proven to play 
important roles in pathogenesis of NAFLD. Several studies demonstrated that TNF-α contributed to 
NASH development in that NASH patients or animal models exhibit elevated serum TNF-α (155-158). 
However, its diagnostic performance of differentiating NASH from NAFL has not been fully elucidated.  
Another cytokine, interleukin-6 (IL-6) was elevated or upregulated in serum or liver tissue of NASH 
patients as stated by some independent studies (155, 159, 160), but did not show any difference 
between NASH and NAFL in other studies (161, 162). Grigorescu et al evaluated the accuracy of IL-6 as a 
noninvasive test for discriminating NASH from 79 NAFLD patients (160). At a cut-off of 6 pg/ml, the 
sensitivity and specificity were reported as 64% and 80%, respectively. However, the clinical utility of 
sole measurement of IL-6 for NASH diagnosis is probably of little value because of the discrepancies 
above mentioned. 
Concerning insulin resistance which characterizes NASH (163), Shimada et al conducted accuracy 
analyses of homeostasis model assessment of insulin resistance (HOMA-IR). In accordance with the fact 
that HOMA-IR could be normal in the early stage NASH, they reported that HOMA-IR differentiated early 
stage NASH from NAFL with a sensitivity of 51% at a cut-off of 3 (specificity of 95%, PPV 98%, NPV 31%, 
and AUROC 0.76). In another study, HOMA-IR was found to be significantly associated with NASH and 
was an independent predictor (164). However, there was no baseline difference in HOMA-IR between 
normal versus NAFLD and NAFL versus NASH; only between normal subjects and NASH was significant 
difference. 
High-sensitivity C-reactive protein (hsCRP) is an acute phase reactant which can detect lower grade 
inflammation. Yoneda et al was the first to show the usefulness of elevated hsCRP in distinguishing 
biopsy-proven NASH patients with nonprogressive steatosis subjects at an AUROC of 0.83 (165). 
However, the results were not reproduced by others (162, 166). In particular, Haukeland et al 
demonstrated that CC-chemokine ligand-2 (CCL2) but not hsCRP was elevated in NAFLD and was 
significantly higher in NASH than NAFL (162).  
CCL2, also known as monocyte chemoattractrant protein-1 (MCP-1) is a potent chemokine which is 
responsible for hepatic recruitment of macrophages during liver inflammation (167). In other study of 
104 subjects, high CCL2 level was associated with elevated ALT (168). In addition, CCL2 level was 
significantly higher in patients diagnosed with NAFLD by ultrasound. However, there are no studies 
which have validated CCL2 with liver biopsy and so further research is required before. 
 
In a series of 70 patients with biopsy-proven NAFLD and 10 healthy controls, significantly higher 
pentraxin-3 level was found in NASH than non-NASH cases (169).  The AUROC for separating NASH from 
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non-NASH with pentraxin-3 was 0.76. The sensitivity, specificity, PPV, and NPV were 66.7%, 78.6%, 
82.4%, and 61.1%, respectively at the cut-off of 1.6 ng/mL. There is a possibility of utilization of 
pentaxin-3 for not only differentiating NASH from non-NASH but also assessing degree of fibrosis, in that 
there was a stepwise increase in the level of this marker according to the histological stage of fibrosis. 
However, because pentraxin-3 is primarily an acute phase reactant responding inflammation, the sole 
measurement of this marker may not represent underlying pathology. 
Serum prolidase enzyme activity (SPEA) reflects hepatic prolidase enzyme activity (170). Kayadibi et al 
reported that SPEA was significantly elevated in patients with NASH than NAFL with an AUROC of 0.85, a 
sensitivity of 84%, a specificity of 82%, a PPV of 82%, and a NPV of 84% (cut off 1134 u/l) (171). Potential 
advantage is that SPEA could predict fibrosis as well as steatohepatitis. However, further investigation 
and validation is needed as for other biomarkers. 
Soluble receptor for advanced glycation endproducts (sRAGE) has been known to be associated with 
some components of metabolic syndrome (172, 173). A case control study involving 57 NAFLD patients 
and 14 healthy controls showed significantly decreased level of sRAGE in NASH group (174). In 
differentiating NASH from NAFL, the AUROC of sRAGE was 0.77. The sensitivity was 75.0% and specificity 
was 71.4% at a cut-off of 1309 pg/mL. Although the level of sRAGE might be decreased in NASH, it is not 
unique to NASH (175). Hence, they would possibly be useful when added to NASH diagnostic panels 
after further investigations. 
Oxidative stress has been recognized as an important mechanism in the pathogenesis of NASH. Markers 
from different oxidation pathways were investigated for use in NASH diagnosis but failed to show solid 
and consistent results (176-179). In addition, the serum or plasma measurement of oxidative markers 
may not necessarily reflect the activity of different oxidation pathways in the liver. Therefore, the use of 
oxidative stress markers in clinical practice is still questionable.  
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3.3.2 Clinical Models 
 
A thorough medical history to assess for metabolic syndrome risk factors and exclude alcohol and 
secondary causes of fatty liver is crucial in establishing NAFLD. However  symptoms are not helpful in 
discerning which patients have NASH,  as there is usually an absence until a considerable degree of 
cirrhosis develops (180).  As for physical examination, a specific pattern of fat distribution, dorsocervical 
lipohypertrophy, was shown to be associated with severity of steatohepatitis but this sign is non-specific 
and consistent recognition can be difficult when it is subtle (181). In addition, the performance of 
routine laboratory parameter has not reached satisfactory levels of sensitivity and specificity (182).  
Diagnostic performance can be improved when clinical and laboratory parameters are incorporated into 
prediction models (Table 10). Poynard’s NashTest consists of 13 parameters including some metabolic 
factors (183). From a cohort of patients diagnosed with NAFLD via the SteatoTest (also developed by 
Ponyard), NashTest, was assessed in its ability to differentiate NASH from simple steatosis. A specificity 
of 94% but the sensitivity only reached 33%. A later attempt was performed to validate this test in 
another French cohort (184). However, there were only 15 NashTest-positive cases and 19 biopsy-
confirmed NASH among more than 250 patients, hence further study is warranted. 
NASH Diagnostics, which incorporates cleaved cytokeratin-18 (CK-18), intact CK-18 minus cleaved CK-18, 
adiponectin, and resistin yielded a sensitivity of 72.1%, specificity of 91.4%, and overall area under the 
receiver-operating curve (AUROC) of 0.85 (137). A later study conducted by the same group however, 
demonstrated lower AUROC of 0.70 for the same panel (185). In that study, the authors newly 
constructed a model called the NASH model as a part of the NAFLD Diagnostic Panel. It consists of 6 
clinical or apoptosis- and necrosis-related parameters: type 2 diabetes mellitus, gender (male being 
negative impact), body mass index, triglyceride, cleaved CK-18 and CK-18 minus cleaved CK-18. In set of 
79 NAFLD patients, the authors found AUROC of 0.81, which was superior to the NashTest AUROC of 
0.70. The discrepancy in results along with small sample sizes calls for external validation. 
The Nice Model is a scoring system incorporating 3 independent variables which predict non-alcoholic 
fatty liver disease activity score (NAS) ≥5: alanine aminotransferase (ALT), CK-18, and the presence of 
metabolic syndrome (186). Using ALT, CK-18, and the presence of metabolic syndrome alone, an AUROC 
of 0.78, 0.74, and 0.74 was obtained respectively for detection of definitive NASH. Combining these 3 
variables increased AUROC to 0.88 in the training group and 0.83 in the validation group. The reported 
sensitivity of logarithmic transformation of this scoring system was 84%, with a specificity of 86% and 
negative predictive value (NPV) of 98%. Yet, the positive predictive value (PPV) of this model is quite 
low.  
OxNASH is a risk score model which incorporates 13-hydroxyl-oactadecadienoic acid (13-HODE)/linoleic 
acid (LA) ratio, age, body mass index (BMI), and aspartate aminotransferase (AST) (187). In addition to 
the variables which were included in other models such as age, BMI, and AST, the rationale for oxNASH 
in clinical diagnosis of NASH is based on the finding that oxidative stress is an important mechanism of 
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pathogenesis in NAFLD (188). Although this model showed an acceptable AUROC, it has not been 
externally validated and blood markers for oxidation products are not easy to perform in most centers. 
HAIR (hypertension, increased ALT, and insulin resistance) had been introduced in 2001 and its 
performance characteristics for NASH was relatively high (189). However, this scoring system included 
highly selective patients who were suffering from severe obesity (BMI > 35 kg/m²) and to date, no 
external validations have been carried out. 
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Table 10: Clinical models for predicting NASH 
Study Name Component/Formula Study 
Population 
Results Comment 
Poynard et 
al, 2006 (183) 
NashTest 1. Age 
2. Sex 
3. Height 
4. Weight 
5. Triglyceride 
6. Cholesterol 
7. α2-MG 
8. Apolipoprotein A1 
9. Haptoglobin 
10. GGT 
11. ALT 
12. AST 
13. Total bilirubin 
- undisclosed formula 
160 - training 
group 
97 - 
validation 
group 
383 - controls 
AUROC 0.79 
Se 33%, Sp 94% 
PPV 66%, NPV 
81% 
Validated in 274 
patients with 
morbid obesity - Se 
21%, Sp 96%, PPV 
27%, NPV 94% 
(calculated) 
Younossi et 
al, 2008 (137) 
NASH 
Diagnostics 
1. Cleaved CK-18 
2. CK-18 minus 
cleaved CK-18 
3. Adiponectin 
4. Resistin 
- undisclosed formula 
69 - training 
group 
32 - 
validation 
group 
AUROC 0.85 
Se 72%, Sp 91% 
(threshold 
0.4320) 
 
Reevaluated in 79 
patients by same 
group - AUROC 
0.70, Se 61%, Sp 
69%, PPV 68%, 
NPV 63% 
(threshold 0.389) 
Younossi et 
al, 2011 (185) 
NASH Model 
of NAFLD 
Diagnostic 
Panel 
1. Type 2 diabetes 
mellitus 
2. Gender 
3. BMI 
4. Triglyceride 
5. Cleaved CK-18 
79 NAFLD 
patients 
AUROC 0.81 
Se 91%, Sp 47%, 
PPV 61%, NPV 
86% (threshold 
0.2210) 
Se 44%, Sp 92%, 
PPV 83%, NPV 
65%  (threshold 
0.6183) 
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6. CK-18 minus 
cleaved CK-18 
Anty et al, 
2010 (186) 
Nice Model 1. ALT 
2. CK-18 
3. Metabolic 
syndrome 
464 morbidly 
obese 
patients 
310 - training 
group 
154 - 
validation 
group 
AUROC 0.83-0.88  
Se 84%, Sp 86%, 
PPV 44%, NPV 
98% (logarithmic 
transformation, 
threshold 
0.1400) 
Model = -5.654 + 
3.780E-02 x ALT x 
2.215E-03 x CK-18 
= 1.825 x 
(presence of 
metabolic 
syndrome = 1) 
Logarithmic 
transformation = 
1/1(1+EXP(-Nice 
Model)) 
 
Feldstein et 
al, 2010 (187) 
oxNASH 1. 13-HODE/LA ratio 
2. Age 
3. BMI 
4. AST 
73 - training 
group 
49 - 
validation 
group 
AUROC 0.74-0.83 
Se 81-84% 
(threshold 55) 
Sp 63-97% 
(threshold 73) 
Model = 100 x 
exp(z)/{(1+exp(z)) 
z = -10.051 + 
0.0463 x age 
(years) + 0.147 x 
BMI + 0.0293 x AST 
+ 2.658 x 13-
HODE/LA ratio 
Dixon et al, 
2001(189) 
HAIR 1. Hypertension 
2. (increased) ALT 
3. IR 
105 morbidly 
obese 
patients 
AUROC 0.90 
Se 80%, Sp 89% 
(threshold 2) 
Hypertension = 1 
ALT > 40 IU/L = 1 
IR index > 5.0 = 1 
 
Legend: NASH, non-alcoholic steatohepatitis; α2-MG, alpha2 macroglobulin; GGT, gamma-glutamyl-
transpeptidase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; AUROC, area under 
the receiver-operating curve; Se, sensitivity; Sp, specificity; PPV, positive predictive value; NPV, negative 
predictive value; CK-18, cytokeratin-18; BMI, body mass index; NAFLD, non-alcoholic fatty liver disease; 
13-HODE, 13-hydroxyl-oactadecadienoic acid; LA, linoleic acid; IR, insulin resistance 
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3.4 NON-INVASIVE DIAGNOSIS OF FIBROSIS AND CIRRHOSIS 
 
Fibrosis and cirrhosis is the common pathway of chronic liver diseases. Fibrosis is a natural response to 
tissue injury. With ongoing liver injury, there is accumulation of fibrous tissue. Eventually, the liver 
architecture is disrupted, and multiple nodules are formed and separated by thick fibrous septa. This 
marks the development of cirrhosis. A number of serious complications can occur with the onset of 
cirrhosis. Although HCC has been reported in patients with non-cirrhotic NAFLD (190, 191) cirrhosis is 
still the most important risk factor of HCC (58, 59). Other complications include ascites, spontaneous 
bacterial peritonitis, variceal bleeding, hepatic encephalopathy and hepatorenal syndrome. Therefore, it 
is important to stage the degree of fibrosis and cirrhosis. Liver biopsy is the reference standard for 
determining the stage of fibrosis, but due to its limitations (as described in chapter 1), non-invasive 
assessment methods need to be developed.   
 
3.4.1 Biomarkers and prediction scores 
 
Biomarkers of fibrosis are divided into 2 types. Class I biomarkers measure fibrogenesis and fibrinolysis 
directly. Class II biomarkers do not measure fibrosis directly but are clinical parameters associated with 
fibrosis. For example, patients with higher aminotransferases are more likely to have active disease and 
therefore fibrosis, but aminotransferases are not a measurement of fibrosis and the association is not 
absolute (192). Moreover, it is important to note that fibrosis and cirrhosis are the results of years of 
disease activity. Thus, a single-time measurement of markers of disease activity would not have good 
correlation with the severity of fibrosis. In fact, when NAFLD reaches the stage of cirrhosis, steatosis and 
necroinflammation typically regress (193). NASH is currently believed to be the most important 
aetiology underlying cryptogenic cirrhosis (194, 195). 
As none of the available biomarkers has sufficient accuracy in diagnosing fibrosis as a standalone test, 
there have been a number of prediction scores (Table 11). In general, the scores were derived using 
liver histology as the reference standard. Clinical parameters and biomarkers associated with different 
fibrosis stages were identified, and a score was constructed based on the relative importance of each 
factor. Some of the scores were developed and validated in NAFLD patients only, while the majority 
were first developed for patients with other liver diseases such as chronic hepatitis C and later adopted 
for NAFLD. 
The NAFLD fibrosis score is one of the most extensively tested prediction scores (196). It comprises age, 
hyperglycemia, body mass index (BMI), platelet count, albumin, aspartate aminotransferase (AST) and 
alanine aminotransferase (ALT). The score was derived from 480 patients in the training cohort and 
further tested in 253 patients in the validation cohort. Using a pair of high and low cutoffs, the score had 
82% positive predictive value and 88% negative predictive value in diagnosing F3 disease. Around 30% of 
patients had score between the 2 cutoffs and thus indeterminate results. The latest AASLD guideline 
supports the use the NAFLD fibrosis score to risk stratify NAFLD patients (97). Since 90% of the original 
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cohort for the development of the NAFLD fibrosis score were Caucasians (196), the score has been 
independently validated in the Chinese population. NAFLD Fibrosis score was found to still have a high 
negative predictive value of 91% in Chinese, but few patients had high scores suggestive of advanced 
fibrosis. The phenomenon may be partly because Asian patients tend to develop metabolic 
complications at a lower BMI (197).  
Other scores have not been as extensively studied, but the FIB-4 index appears to have the highest 
accuracy in diagnosing fibrosis in NAFLD patients when compared to other prediction scores. The FIB-4 
index comprises age, platelet count, AST and ALT. In 3 separate validation studies in America, Europe 
and Asia, the FIB-4 index had an area under the receiver-operating characteristics curve of over 0.80 in 
diagnosing F3-4 disease (127, 198, 199). The components and performance of other prediction scores 
are shown in Table 11. 
It is important to note that the prediction scores were validated against liver histology. Since liver 
histology is an imperfect reference standard with sampling variability, intraobserver and interobserver 
bias, there is a ceiling for the perceived accuracy in such validation studies (200). In other words, even if 
a score has 100% accuracy, assuming the accuracy of liver biopsy is 90%, the score will still disagree with 
histology in 10% of cases and classified as inaccurate results. In reality, however, the prediction scores 
are modeled against histology and therefore would suffer from a similar degree of case misclassification. 
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Table 11: Biomarkers and prediction scores of liver fibrosis in NAFLD 
   F2 F3 
Score Components Class I or II 
biomarkers 
Sensitivity Specificity Sensitivity Specificity 
Specific for 
NAFLD 
      
NAFLD fibrosis 
score(196) 
Age, hyperglycemia, BMI, 
platelet, albumin, AST/ALT 
ratio (dual cutoffs) 
II - - 0.77 0.96 
BARD score (201)  BMI, AST/ALT ratio, 
diabetes 
II - - 0.62 0.66 
FibroMeter 
NAFLD (202) 
Glucose, AST, ferritin, 
platelet, ALT, body weight, 
age 
II 0.79 0.96 - - 
       
Not specific for 
NAFLD 
      
AST/ALT ratio 
(203) 
AST, ALT II - - 0.21 0.90 
APRI (204) AST, platelets (dual cutoffs) II - - 0.65 0.97 
ELF (205) Hyaluronic acid, TIMP1, 
PIIINP (dual cutoffs) 
I 0.80 0.67 0.80 0.90 
FIB-4 (206) Age, AST, platelet, ALT (dual 
cutoffs) 
II - - 0.74 0.98 
FibroTest (207) Total bilirubin, GGT, α2-
macroglobulin, ApoA1, 
haptoglobin (dual cutoffs) 
I and II 0.71 0.98 0.88 0.99 
Hepascore(208) Age, gender, bilirubin, GGT, 
hyaluronic acid, α-2 
macroglobulin 
I and II 0.51 0.88 0.76 0.84 
Legend: ALT, alanine aminotransferase; ApoA1, apolipoprotein A1; APRI, AST-to-platelet ratio index; 
AST, aspartate aminotransferase; BMI, body mass index; ELF, enhanced liver fibrosis panel; GGT, 
gamma-glutamyl transpeptidase; NAFLD, non-alcoholic fatty liver disease; PIIINP, procollagen III amino-
terminal peptide; TIMP1, tissue inhibitor of matrix metalloproteinase 1 
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3.4.2 Physical measurements 
 
3.4.2.1 Ultrasound, computed tomography and magnetic resonance imaging 
Ultrasound is the most commonly performed imaging test in patients with liver disease. A recent meta-
analysis found that ultrasound is able to diagnose NAFLD when hepatic steatosis exceeds 33% at a good 
accuracy (84.8% sensitivity and 93.4% specificity) (209). The drawbacks are that it is a qualitative 
measure and its lack of ability to detect minor steatosis. Also, it is affected by intraobserver and 
interobserver variability (kappa= 0.54-0.92, 0.44-1.00) and is unable to distinguish NASH from simple 
steatosis (209, 210). Cirrhosis can be diagnosed in advanced cases when the liver is small and shrunken, 
or when there are signs of portal hypertension such as ascites, splenomegaly, varices and recanalization 
of the umbilical vein. However, the diagnosis can be difficult in early cirrhosis when signs of portal 
hypertension are absent. It follows that fibrosis is certainly impossible to assess with ultrasound (210).  
Furthermore, hepatomegaly and increased liver echogenicity in patients with NAFLD would make 
ultrasonographic features of cirrhosis inconspicuous. As a result there have been various attempts to 
develop ultrasound quantitative measures based on the greater echogenicity of the liver in NAFLD 
compared to other organs. The Ultrasonographic Fatty Liver Indicator (US-FLI) and the Hepato-Renal 
index are two such methods (211, 212) but require further evaluation as only small studies have been 
performed.  
Computed tomography is superior to ultrasound in detecting focal steatosis, but otherwise has a similar 
diagnostic performance to ultrasound. CTs should be non-contrast because contrast affects the 
attenuation of the liver causing different thresholds. It is accurate in diagnosing hepatic steatosis that is 
at least moderate in severity (82% sensitivity, 100% specificity) (213). However, CT misdiagnoses fatty 
liver when there are other diffuse liver conditions such as haemachromatosis (214). Although CT can 
evaluate nodular liver and other features such as ascites and varices that may suggest cirrhosis, it cannot 
assess early cirrhosis or fibrosis, and it also cannot distinguish NASH from simple steatosis (215). There is 
also the additional drawback of radiation exposure. Thus it is not the modality of choice for routine 
diagnosis given the high prevalence of NAFLD.   
In prospective studies using liver biopsy as the gold standard, conventional MRI performed better than 
ultrasound in detecting minor steatosis (216), but is poor at diagnosing NASH and assessing fibrosis 
(210). Many varieties of MRI technique have been developed to improve its performance in the 
diagnostic spectrum of NAFLD.  Magnetic resonance spectroscopy (MRS) is emerging as a very promising 
modality. This directly measures the signal from hydrogen atoms and can distinguish between its 
different molecular bonds. The spectra pertaining to methyl groups in triglyceride molecules can be 
detected. Hence MRS is able to directly diagnose hepatic triglycerides, and can also quantify its content 
(HTC). MRS shows good diagnostic accuracy for all grades of steatosis (AUROC 0.87-0.89) (217). MRS 
also has the advantages of being able to assess the entire volume of liver. As more refined software and 
technique algorithms are being developed, it is challenging liver biopsy as a possible new gold standard 
in diagnosing steatosis (218). 
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Magnetic resonance elastography (MRE) is an MRI modality with promising results for diagnosing 
fibrosis. MRE is phase-contrast-based MRI technique that produces an image of a propagating shear 
wave. In the Mayo clinic protocol, a constant mechanical wave is produced from a disc shaped driver 
that is attached to the patient’s anterior right chest wall (219). The data acquired allows the MRI to 
generate an image map of the liver that depicts the quantitative tissue elasticity. Early studies of MRE 
suggest that it is superior to TE in diagnosing each stage of fibrosis (220) and has good accuracy for 
diagnosing NASH (221). The disadvantages of MRI techniques are that they are expensive and not widely 
available. Further external validation is also required. 
 
3.4.2.2 Transient elastography 
TE (Fibroscan, Echosens Paris France) enables non-invasive assessment of liver fibrosis using ultrasonic 
elastography principles. The Fibroscan probe consists of an ultrasound fitted on the axis of an 
electrodynamic transducer. The probe is placed on the skin overlying the liver, and generates a low-
amplitude 50Hz mechanical pulse which creates a shear wave. The velocity of the shear wave is directly 
related with the stiffness of the liver. Ultrasound signals at low energy 3.5MHz emitted from the probe 
measure the shear wave velocity and can directly calculate the elastic modulus. This is expressed in 
kilopascals and is known as liver stiffness measurement (LSM). TE has been validated as a measure of 
fibrosis across a wide spectrum of chronic liver disease and has overall a good accuracy. It has the 
advantage of being quick, easy to learn, well tolerated by patients, and assesses a volume of liver 
around 100-200 times the size of a liver biopsy. There have been many studies examining its use in 
NAFLD patients, and there is ongoing debate regarding its diagnostic accuracy and feasibility especially 
in obese patients.  
Meta-analysis on TE 
Nine studies including a total pool of 1047 NAFLD patients from different ethnic backgrounds were 
identified as suitable for meta-analysis (Table 15/Supplementary Table 4). Data on M probe included 
854 NAFLD patients. Data was grouped according to whether the M probe or the XL probe was used, 
and then further sub-grouped according to the fibrosis stage that it was being compared. Eight studies 
had suitable data for the M probe, whereas 1 study had suitable data only for the XL probe. There were 
7, 8 and 6 TE studies reported that its performance compared to liver biopsy for F≥2, 3 and 4 
respectively (Figure 16). For F≥2, the LSM cut-off ranged from 6.7-7.7 kPa, with 67-94% sensitivity, 61-
84% specificity and AUROC 0.79-0.87. For F≥3, the LSM cut-off was 8.0-10.4 kPa, with 65-100% 
sensitivity, 75-97% specificity and AUROC 0.76-0.98. For F4, the LSM cut-off was 10.3-17.5 kPa, with 78-
100% sensitivity, 82-98% specificity and AUROC 0.91-0.99. In the pooled estimates of diagnostic 
accuracy TE had overall for F≥2 79% sensitivity, 75% specificity; F≥3 85% sensitivity, 85% specificity and 
F4 92% sensitivity, 92% specificity (Table 14/Supplementary Table 3). Figure 20/Supplementary Figure 
4 showed the HSROC plots of TE. 
Discussion on TE 
 The overall results suggest that TE is excellent in diagnosing F ≥ 3 (85% sensitivity, 82% specificity) and 
F4 (92% sensitivity, 92% specificity) and has moderate accuracy for F ≥ 2 (79% sensitivity, 75% 
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specificity). Our analysis of 854 NAFLD patients in eight studies is the largest so far and most updated. 
The quality of data in the included studies was excellent, with all studies obtaining at least 12/13 on the 
modified QUADAS (Figure 17/Figure S1), and hence no subgroup analysis between high- and low-quality 
studies was performed. In addition, analysis of whether BMI and ALT was a factor in heterogeneity could 
not be performed because of wide range of these factors in each of the included studies. 
Obesity is the main reason for failed LSM, and the problem can be largely overcome using the XL probe 
(222, 223). The largest study of 193 patients reported the ability to obtain 10 measurements in 93% of 
patients with BMI > 30kg/m2 with AUROCS of 0.80, 0.85 and 0.91 for F≥2,3 and 4 respectively, although 
lower LSM cut-offs need to be used (129). Pooled statistical analysis could not be performed for the XL 
probe performance due to insufficient number of studies (224, 225). All TE studies had similar baseline 
characteristics, used similar cut-offs and there were no heterogeneity factors identified. TE studies had 
high quality data and subgroups and post-hoc sensitivity analysis did not show that this affected the 
overall summary estimates.  
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Figure 16: Forest plot from meta-analysis for Transient Elastography 
Forest plot from meta-analysis of sensitivities and specificities for TE to diagnose different fibrosis 
stages using a random-effect model. TP:True Positives, FP: False Positives, FN: False Negatives, TN: 
True Negatives.  
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3.4.2.3 Acoustic radiation force impulse (ARFI) 
Acoustic radiation force impulse imaging (ARFI) is a form of tissue elastography that is integrated into in 
a conventional high end ultrasound machine (Siemens S2000).  A region-of-interest (ROI) in the liver is 
targeted using short-duration acoustic pulses with a fixed frequency of 2.67 MHz Shear-waves are 
generated away from the region of excitation that are tracked using an ultrasonic, correlation-based 
method. The shear wave speed of the tissue within a ROI is measured and can be used to calculate the 
elasticity of the liver. Like TE, the result is expressed in kilopascals. ARFI has the advantage of being a 
feature existing on an ultrasonography machine. This allows for the convenience of assessing for 
structural abnormalities, steatosis as well as fibrosis in a single sitting. 
Summary estimates for ARFI were not possible in this review due to insufficient data being available. 
Only 2 studies fit our selection criteria (128, 145) , although a further 2 articles (226, 227) could have 
been included if attempts to contact study authors were successful. The AUROCS reported in our 
candidate studies (128, 145, 226, 227) ranged from 0.74-0.97 for the diagnosis of F≥3 in NAFLD. From a 
recent meta-analysis on the performance of ARFI across a heterogeneous range of liver disease, the 
mean AUROCS were 0.87, 0.91 and 0.93 for the diagnosis of F≥2, 3 and 4 respectively (228). ARFI appears 
to be is a promising modality for NAFLD, but availability of this feature on ultrasound devices is currently 
limited.  
 
3.4.2.4 Liver scintigraphy 
Technetium-99 m-2-methoxy-isobutyl-isonitrile (Tc 99-MIBI) is a lipophilic cationic agent that was 
initially designed for myocardial perfusion imaging utilizing the property of Tc99-MIBI uptake and 
retention being related to mitochondrial function. In NASH, the precise mechanism is unclear, but it has 
been observed that the liver: heart ratio and the liver: spleen ratio uptake of Tc99-MIBI is decreased in 
NASH compared to simple steatosis (229, 230). Further studies are needed.  
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3.5 CONCLUSION 
 
NAFLD is a disease that affects 15-40% of the general population. Accurate identification of patients 
with progressive or advanced disease is one of the most urgent clinical needs. At present, serum tests 
and physical measurements such as TE come close as highly accurate non-invasive tests to exclude 
advanced fibrosis and cirrhosis in NAFLD patients. CK18 has moderate accuracy in diagnosing NASH 
while other biomarkers have not been extensively studied. Further studies are needed to explore the 
optimal test combinations and the role of these tests in prognostication and treatment monitoring. 
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3.6 Supplementary Material 
 
Table 12: Modified QUADAS 
Supplementary Table 1. Modified Quality assessment of Diagnostic Accuracy Studies Checklist (Modified 
QUADAS) 
1. Was the spectrum of patients representative of the patients who will receive the test in 
practice? (Generalizability item) 
2. Were selection criteria clearly described? (Clarity item) 
3. Is the reference standard likely to correctly classify the target condition? (Validity item) 
4. Is the time between reference standard and index test short enough to be reasonably sure that 
the target condition did not change between the two tests? (Validity item) 
5. Did the whole sample or a random selection of the sample receive verification using a reference 
standard of diagnosis? (Validity item)  
6. Did patients receive the same reference standard regardless of the index test result? (Validity 
item) 
7. Was the reference standard independent of the index test (ie, the index test did not form part of 
the reference standard)? (Validity item) 
8. Was the execution of the index test described in sufficient detail to permit replication of the 
test? (Clarity item) 
9. Was the execution of the reference standard described in sufficient detail to permit its 
replication? (Clarity item) 
10. Were the reference standard results interpreted without knowledge of the results of the index 
test? (Validity item)  
11. Were the same clinical data available when test results were interpreted as would be available 
when the test is used in practice? (Validity item) 
12. Were uninterpretable/intermediate test results reported? (Clarity item) 
13. Were withdrawals from the study explained? (Clarity item) 
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Table 13: Characteristics of studies on cytokeratin-18 fragments 
Supplementary Table 2. Characteristics of studies on cytokeratin-18 fragments 
Study Location Patients (n) Age (yrs) Gender (%male) BMI (kg/m2) ALT (U/L) %NASH (n) 
Wieckowska 2006 Cleveland USA 39 50.8±11.1 46.1 31.5±4.0 73 53.8 (21) 
Yilmaz 2006 Bursa Turkey 83 48.9±9.1 54.2 30.3±4.8 42 54.2 (45) 
Diab 2008 Cleveland USA 86 51.0 20.9 48 21.5 25.6 (22) 
Younassi 2008a Inova Fairfax USA 69 37.4±8.3, 42.5±10.4, 
39.3±9.8 
6.7, 40.1, 9.4 45.7±4.8, 
48.2±8.7 
47.0±9.1 
22.1±12.2, 
47.9±32.1 
21.9±8.1 
31.9 (22) 
Feldstein 2009 Cleveland USA 139 48.0 26.7 34.2 66.0 49.6 (69) 
Papatheodoridis 2010c Athens Greece 58 47±16 
47±12 
59, 47 28±5 
30±4 
79, 76 51.7 (30) 
Musso 2011 Turin, Italy 41 37±2d 70d 25.4±0.5d 70±5d 39.0 (16) 
Grigorescu 2012b Cluj-Napoca Romania 79 39.1±10.7 
48.3±11.4 
70, 71.2 28.6±3.8 
30.5±3.8 
48.6±26.2 
86.3±49.0 
74.7 (59) 
Joka 2012b Hannover Germany 22 49.9±3.2 
45.6±3.3 
70, 66.7 26.0±0.9, 
27.8±1.1 
52.8±8.4 
94.4±10.4 
45.5 (10) 
Pirvelescue 2012b Bucharest, Romania 60 45.9±10.6 
44.9±9.4 
29.8, 30.8 39.6±11 
49.4±7.6 
21.3±11.8 
42.3±15.2 
21.7 (13) 
Shen 2012 Hong Kong China 146 48.1±9.7 66.6 27.4±3.9 71±42 56.2 (82) 
NA: Not Applicable 
Variables with ± represent mean±standard deviation. Variables without ± indicate that it is the median value for that variable 
a. Variables reported in subgroup order: SS, NASH, controls 
b. Variables reported in subgroup order:Non NASH, NASH 
c. Variables reported in subgroup order: M30<250, M30≥250 
d. Overall data for NAFLD patients not available. Data for the largest subgroup of (14/16) NASH patients with AA allele for LOX-1 IVS4-14 A→6 gene 
reported 
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Table 14: Overall and subgroup analyses transient elastography and cytokeratin-18 fragments 
Supplementary Table 3. Overall and subgroup analyses transient elastography and 
cytokeratin-18 fragments† 
 Number of 
studies 
Sensitivity (95% 
CI) 
Specificity (95% 
CI) 
Transient elastography (M probe)    
Overall    
     ≥ F2 7 0.79 (0.72 to 
0.84) 
0.75 (0.71 to 
0.79) 
≥ F3 8 0.85 (0.73 to 
0.92) 
0.85 (0.79 to 
0.90) 
= F4 6 0.92 (0.82 to 
0.97) 
0.92 (0.86 to 
0.96) 
Adequate index test description (Yes)    
     ≥ F2 6 0.79 (0.73 to 
0.85) 
0.74 (0.70 to 
0.78) 
≥ F3 7 0.82 (0.73 to 
0.88) 
0.83 (0.78 to 
0.87) 
Adequate reference test description (Yes)    
     ≥ F2 6 0.77 (0.72 to 
0.82) 
0.76 (0.72 to 
0.80) 
≥ F3 7 0.86 (0.74 to 
0.93) 
0.86 (0.80 to 
0.91) 
= F4 5 0.92 (0.80 to 
0.97) 
0.93 (0.88 to 
0.96) 
    
Cytokeratin-18 (M30)    
Overall    
     The best overall 7 0.66 (0.59 to 
0.72) 
0.82 (0.69 to 
0.90) 
High sensitivity 6 0.82 (0.75 to 
0.87) 
0.65 (0.43 to 
0.82) 
High specificity 6 0.58 (0.38 to 
0.76) 
0.98 (0.89 to 
0.97) 
Acceptable delay between tests (Yes)    
     The best overall 4 0.65 (0.57 to 0.74 (0.59 to 
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0.73) 0.85) 
High sensitivity 4 0.83 (0.74 to 
0.90) 
0.74 (0.48 to 
0.90) 
Adequate index test description (Yes)    
     The best overall 6 0.66 (0.59 to 
0.73) 
0.81 (0.65 to 
0.91) 
High sensitivity 5 0.81 (0.73 to 
0.87) 
0.71 (0.51 to 
0.85) 
High specificity 5 0.62 (0.40 to 
0.81) 
0.98 (0.83 to 
1.00) 
Adequate reference test description 
(Unclear) 
   
     The best overall 4 0.69 (0.60 to 
0.78) 
0.76 (0.64 to 
0.85) 
High sensitivity 4 0.85 (0.77 to 
0.90) 
0.58 (0.28 to 
0.84) 
High specificity 4 0.54 (0.28 to 
0.78) 
0.94 (0.89 to 
0.97) 
Blinding for index test results (Yes)    
     The best overall 4 0.63 (0.55 to 
0.71) 
0.85 (0.62 to 
0.95) 
† We were unable to provide pooled estimates of diagnostic accuracy for specific patient 
subgroups because no bivariate analyses could be fitted on less than four studies or 2 x 2 
data contained one or more zero values. 
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Table 15: Characteristics of 9 studies on transient elastography 
Supplementary Table 4. Characteristics of 9 studies on transient elastography 
Study Location NAFLD patients Age (yrs) Gender (%male) BMI (kg/m2) ALT (U/L) 
Yoneda 2008 Yokohama Japan 97 51.8±13.7 41.2 26.6±4.2 80±62.3 
Lupsor 2010 Cluj-Napoca, Romania 69 42a 70.8 28.71a 80a 
Wong 2010 Pessac, France and Hong Kong, China 246 51±11 54.9 28.0±4.5 75±54 
Yoneda 2010 Yokohama, Japan 54 M:48.3±13.5 
F:52.5±11.4 
46.3 M:28.2±5.0 
F:26.2±4.4 
M:66.4±29.1 
F:54.9±33.1 
Myers 2010 Multicentre, Canada 50 49ab 66.2 26ab 61ab 
Petta 2011 Palermo, Italy 146 44.1±13.2 71.2 29.1±4.1 80.9±57.8 
Gaia 2011 Turin, Italy 72 48a 72.2 27.5a 58a 
Kumar 2013 New Dehli, India 120 39.1±12.8 75.0 26.1±3.6 62.5 
Wong 2012c Pessac, France and Hong Kong, China 193 52±11 57.0 28.9±4.8 73±76 
Unless stated, variables with ± represent mean and standard deviation 
a. Median Value reported 
b. Values refer to entire cohort of chronic liver disease patients. Specific values for NAFLD patients not reported.  
c. Data for XL probe included only.  
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Figure 17: QUADAS assessment of 9 studies on transient elastography 
 
Supplementary Figure 1. QUADAS assessment of 9 studies on transient elastography 
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Figure 18: QUADAS assessment of 11 studies on cytokeratin-18 fragments 
 
Supplementary Figure 2. QUADAS assessment of 11 studies on cytokeratin-18 fragments 
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Figure 19: HSROC graphs for CK18 
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Figure 20: HSROC graphs for TE 
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4.0 Chapter Summary 
 
Objective: Type 2 diabetes is an important risk factor for non-alcoholic fatty liver disease (NAFLD), but 
current guidelines provide conflicting recommendations on whether diabetic patients should be 
screened for NAFLD. We therefore studied the strategy of screening diabetic patients by FibroScan. 
Design: Liver steatosis and fibrosis were assessed by controlled attenuation parameter (CAP) and liver 
stiffness measurements (LSM) respectively using Fibroscan, at a diabetic center for patients from 
primary care and hospital clinics. Probe-specific LSM cutoffs were used to detect advanced fibrosis. 
Results: Of 1918 patients examined, 1799 (93.8%) had valid CAP and 1884 (98.2%) had reliable LSM 
(1770 with the M probe and 114 with the XL probe). The proportion of patients with increased CAP and 
LSM was 72.8% (95% confidence interval 70.7-74.8%) and 17.7% (95% confidence interval 16.0-19.5%), 
respectively. By multivariable analysis, female gender, higher body mass index, triglycerides, fasting 
plasma glucose and alanine aminotransferase, and non-insulin use were associated with increased CAP. 
Longer duration of diabetes, higher body mass index, alanine aminotransferase, spot urine albumin-
creatinine ratio, and lower high-density lipoprotein-cholesterol were associated with increased LSM. 94 
patients with increased LSM underwent liver biopsy: 56% had steatohepatitis; 50% had F3-4 disease. 
Conclusion: Diabetic patients have a high prevalence of NAFLD and advanced fibrosis. Those with high 
BMI and dyslipidaemia are at particularly high risk and should be the target for liver assessment. Our 
data supports screening for NAFLD and/or advanced fibrosis in patients with type 2 diabetes.  
 
What is already known about this subject? 
- Non-alcoholic fatty liver disease (NAFLD) is common in patients with type 2 diabetes. 
- Diabetes is an important risk factor of steatohepatitis and cirrhosis in NAFLD patients. 
- Current major hepatology organisations (AASLD, EASL and APASL) provide little guidance on NAFLD 
screening in diabetic patients because of the paucity of data. 
- It is possible to measure liver fat and fibrosis quickly by Fibroscan. Its application as a screening tool 
in high-risk patients has not been systematically studied. 
What are the new findings? 
- Around 70% of diabetic patients from primary care and hospital clinics had increased controlled 
attenuation parameter suggestive of NAFLD. 
- Around 18% of diabetic patients had increased liver stiffness of ≥9.6 kPa. 
- Patients with high body mass index, dyslipidaemia and increased alanine aminotransferase were at 
highest risk of increased controlled attenuation parameter and liver stiffness. 
- Among patients with increased liver stiffness, 56% had steatohepatitis, 21% had advanced fibrosis 
and 29% had cirrhosis. 
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How might it impact on clinical practice in the foreseeable future? 
- There is a high prevalence of NAFLD and NAFLD with advanced fibrosis in patients with type 2 
diabetes.  
- Screening with Fibroscan is a convenient initial assessment for patients with type 2 diabetes. It may 
result in early detection of fibrosis and cirrhosis. However, its accuracy does not allow confident 
diagnosis of advanced disease. Further improvements in non-invasive assessment of liver fibrosis are 
needed. 
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4.1 INTRODUCTION 
 
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease, affecting 15–40% of 
the population worldwide (231). Of these NAFLD patients, 20-30% has non-alcoholic steatohepatitis 
(NASH), the progressive form of NAFLD which is associated with liver fibrosis. In 10-20% of NASH 
patients, this eventually progresses to cirrhosis and a high risk of hepatocellular carcinoma.(17, 58, 59) 
 
Type 2 diabetes is a major risk factor for NAFLD. Both feature insulin resistance as a core component of 
their pathophysiology. As such, up to 90% of diabetic patients in some populations also have 
NAFLD.(232) However, due to insufficient data, current guidelines offer conflicting recommendations on 
whether diabetic patients should be screened for NAFLD.(97, 233) The main arguments against 
screening include uncertainties surrounding diagnostic tests and treatment options and lack of 
knowledge related to the long-term benefits of screening. On the other hand, screening may identify 
patients with NAFLD-related cirrhosis who would benefit from hepatocellular carcinoma and varices 
surveillance.  
 
Knowledge on the epidemiology of NAFLD is incomplete because of the limitations of various diagnostic 
modalities. Liver biopsy is considered the reference standard, but is impractical to apply to a large study 
population. Conventional abdominal ultrasonography is easily accessible but is only qualitative. It is poor 
in detecting minor steatosis and suffers from intra/inter observer and variation.  
 
Transient Elastography is a non-invasive test of liver fibrosis that is quick, easy to perform, and has a 
high degree of patient acceptance.(234) It has high accuracy and reproducibility when used to detect 
advanced fibrosis and cirrhosis. In addition, the latest model measures a novel physical parameter called 
the controlled attenuation parameter (CAP). Since fat affects ultrasound propagation, CAP 
measurement has been shown to be accurate in estimating the amount of liver fat.(235-237) Using this 
non-invasive technique, it is now possible to measure liver fat and fibrosis in a large number of patients. 
 
In this study, we aim to test the strategy of NAFLD and fibrosis screening in patients with type 2 
diabetes. We also studied factors associated with increased CAP and liver stiffness to guide selection of 
patients for screening. 
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4.2 METHODS 
4.2.1 Subjects 
This is a prospective cohort study. From March 2013 to May 2014, we screened 2466 consecutive 
patients aged 18 years or above with type 2 diabetes who attended comprehensive diabetic 
complications screening at the Diabetes Mellitus and Endocrine Centre Prince of Wales Hospital Hong 
Kong. The sources of referrals include hospital and primary care clinics in the New Territories East 
Cluster, which serves a population of 1.2 million. Subjects with active malignancy, positive hepatitis B 
surface antigen or antibody against hepatitis C virus, secondary causes of fatty liver (e.g. consumption of 
amiodarone and tamoxifen), and congestive hepatopathy were excluded. Men who consumed more 
than 20 g and women who consumed more than 10 g of alcohol per day were also excluded. All patients 
provided informed written consent. The study protocol was approved by the Clinical Research Ethics 
Committee of The Chinese University of Hong Kong. The patients would be prospectively followed for 10 
years for hepatic, cardiovascular and metabolic complications. This paper reports the results of the 
baseline hepatic assessment. 
 
4.2.2 Clinical assessment 
The patients underwent a comprehensive 4-h assessment for diabetes-related complications and risk 
factors according to the European DIABCARE protocol.(238) The assessment included an interview by 
diabetes nurses, vitals, anthropometric measurements, fundus examination, and podiatry assessment. 
The medical history, current drugs, smoking and alcohol consumption were recorded using standard 
questionnaires. Body mass index was calculated as body weight (kg) divided by body height (m) squared. 
Waist circumference was measured at a level midway between the lower rib margin and iliac crest with 
the tape all around the body. Blood pressure was measured on both arms in the sitting position after 
resting for at least 15 minutes. After fasting for 8 h overnight, blood was sampled for assays of fasting 
lipids, glucose, glycated hemoglobin (HbA1c), and renal and liver function tests. The upper limit of normal 
for alanine aminotransferase (ALT) was 30 IU/l for men and 19 IU/l for women.(239) The abbreviated 
Modification of Diet in Renal Disease equation recalibrated for Chinese was used to calculate the 
estimated glomerular filtration rate (eGFR).(240) Spot urine for albumin-creatinine ratio was performed 
to detect albuminuria. 
 
4.2.3 Fibroscan examination 
During the diabetic complication assessment visit, liver stiffness measurement (LSM) and CAP were 
obtained using FibroScan®502 (Echosens, Paris, France) as described previously.(241) All patients were 
fasted for at least 8 h before the procedure. The LSM score was represented by the median of 10 
measurements and was considered reliable only if at least 10 successful acquisitions were obtained and 
the interquartile range (IQR)-to-median ratio of the 10 acquisitions was ≤0.3. The CAP score was 
represented by the median value. The significance of the IQR-to-median ratio for CAP is not well-defined 
compared to LSM. Thus, it was not used as criteria for reliability for CAP measurements. The CAP was 
considered reliable and included in the final analysis based upon whether 10 successful acquisitions 
were obtained as the sole requirement. The M probe was used in the first instance for all patients so 
that both LSM and CAP could be obtained. If the M probe failed, the XL probe catering for obese 
patients was used.(242) 
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Hepatic steatosis was graded by CAP using the M probe according to published cutoffs (S1=222-232; 
S2=233-289; S3≥290 dB/m).(236) Probe-specific LSM cutoffs used to define advanced fibrosis and 
cirrhosis (M probe F3 = 9.6-11.4, F4≥11.5; XL probe F3=9.3-10.9, F4≥11.0 kpa) were derived from 
previous studies.(241, 242) Two operators performed the procedures. Both had more than 5 years of 
experience with Fibroscan, and had performed more than 2000 procedures. 
 
4.2.4 Liver histology 
Patients with suspected advanced fibrosis or cirrhosis based on the Fibroscan examination were invited 
to undergo liver biopsy. Percutaneous liver biopsy was performed using the 16G Temno needle. Liver 
histology was assessed by a single experienced pathologist (A.W.C.) who was blinded to the clinical data. 
Histological scoring was performed according to the NASH Clinical Research Network system.(61) 
Fibrosis was staged from 0 to 4: F0 = absence of fibrosis; F1 = perisinusoidal or portal; F2 = perisinusoidal 
and portal/periportal; F3 = septal or bridging fibrosis; and F4 = cirrhosis. NASH was defined by the 
presence of hepatic steatosis and inflammation with hepatocyte injury (ballooning) with or without 
fibrosis.(97) 
 
4.2.5 Statistical analysis 
Data was summarized and presented using appropriate descriptive statistics. The normality of 
continuous variables was assessed by skewness statistic and graphically by normal probability plot. 
Triglycerides, fasting plasma glucose, HbA1c , plasma creatinine and alanine aminotransferase were all 
natural log-transformed before being entered into inferential statistical analysis. Patient characteristics 
between those with and without valid CAP measurements were compared using independent t-test, chi-
square or Fisher’s exact tests as appropriate. Multivariable logistic regression analyses were conducted 
to identify patient characteristics independently associated with each of the outcomes: (1) NAFLD and 
(2) advanced fibrosis. Univariate analysis was first performed on each of the considered independent 
variables to select candidate variables for the multivariable analyses. Those factors with a P value < 0.25 
in the univariate analyses were selected as candidate variables for backward stepwise multivariable 
logistic regressions to delineate factors independently associated with each of the outcomes.(243) 
Furthermore, in order to avoid collinearity, only the independent variable with the highest Wald statistic 
value (or equivalently the smallest p value) was selected as candidate variable among each set of highly 
inter-correlated (r >0.8) independent variables [including (1) body weight, BMI and waist circumference; 
(2) systolic and diastolic blood pressure; (3) total cholesterol and LDL- cholesterol]. Hosmer-Lemeshow 
test was used to assess the goodness-of-fit of the final multivariable logistic regression models 
obtained.(243) An insignificant result of Hosmer-Lemeshow test indicates a model that fits the data well.  
The results of significant factors identified were presented with their odds ratio (OR) and 95% 
confidence intervals (CI). All the statistical analyses were performed using SPSS 22.0 (SPSS Inc, Chicago, 
IL, USA). All statistical tests involved were two-tailed and statistical significant level was set at 0.05. 
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For a prevalence of NAFLD ranging from 30% to 90%, a sample size of 1800 subjects would estimate the 
prevalence of NAFLD with a margin of error ranging from 1.4 – 2.3% at 5% level of significance. For a 
prevalence of advanced fibrosis of 1-20%, the same sample size would estimate the prevalence with 
margin of error ranging from 0.5 – 1.9% at 5% level of significance. 
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4.3 RESULTS 
 
A total of 2119 patients fulfilled the inclusion criteria and underwent Fibroscan assessment, and 1918 
underwent complete diabetes complication screening.   Of these, 1884 (98.2%) had a reliable LSM by 
either the M probe or XL probe, while 1799 (93.8%) had reliable CAP scores using the M probe (Figure 
21).  
The mean age was 61 years, and 54% were males (Table 16). A total of 6.6% had platelet count below 
150 × 109/L (6.6% of the patients with valid CAP measurements and 6.7% of those without). Compared 
with patients who failed M probe examination, those with valid CAP data had shorter duration of 
diabetes, lower BMI, waist circumference, systolic blood pressure and HbA1c, were more likely to smoke, 
and were less likely to be male and use anti-hypertensive and insulin. Patients with valid CAP also had 
less albuminuria. 
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Figure 21: Study participant flowchart 
CAP, controlled attenuation parameter; LSM, liver stiffness measurement   
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Table 16: Characteristics of the study population 
    With valid CAP  
  All (n=1918)  No (n=119) Yes (n=1799) P value 
Clinical and biochemical profile       
Age (years)  60.6 (11.5)  59.7 (12.4) 60.6 (11.5) 0.379 
Years since diabetes diagnosed  10.9 (8.5)  13.5 (8.4) 10.7 (8.5) 0.001 
Sexa       
Male  1041 (54.3%)  38 (31.9%) 1003 (55.8%) <0.001 
Female  877 (45.7%)  81 (68.1%) 796 (44.2%)  
Educational levela       
Primary or below  767 (40.3%)  47 (39.8%) 720 (40.3%) 0.289 
Secondary  928 (48.7%)  53 (44.9%) 875 (49.0%)  
College or above  209 (11.0%)  18 (15.3%) 191 (10.7%)  
Full / part-time workinga  771 (40.6%)  42 (35.6%) 729 (41.0%) 0.251 
Current smokera  210 (11.0%)  6 (5.1%) 204 (11.4%) 0.034 
Regular alcohol drinkera  70 (3.7%)  2 (1.7%) 68 (3.8%) 0.317 
Body weight (kg)  69.1 (14.2)  82.9 (18.1) 68.2 (13.4) <0.001 
Body mass index (kg/m2)    26.6 (4.5)  32.8 (5.7) 26.2 (4.1) <0.001 
Waist circumference (cm)  92.9 (11.1)  106.8 (11.4) 92.0 (10.5) <0.001 
Systolic blood pressure (mmHg)  138.0 (19.2)  141.8 (20.4) 137.7 (19.1) 0.023 
Diastolic blood pressure (mmHg)  76.2 (11.2)  76.6 (13.3) 76.1 (11.0) 0.693 
Total cholesterol (mmol/L)  4.3 (0.9)  4.3 (0.9) 4.3 (0.9) 0.486 
HDL-cholesterol (mmol/L)  1.3 (0.4)  1.3 (0.4) 1.3 (0.4) 0.284 
LDL-cholesterol (mmol/L)  2.3 (0.7)  2.3 (0.7) 2.3 (0.7) 0.646 
Triglycerides (mmol/L)b  1.3 (0.9 – 1.9)  1.4 (1.1 – 2.0) 1.3 (0.9 – 1.9) 0.128 
Fasting plasma glucose (mmol/L)b  7.2 (6.1 – 8.9)  7.8 (6.2 – 10.0) 7.2 (6.1 – 8.9) 0.089 
Glycated hemoglobin (%)b  7.4 (6.7 – 8.6)  8.0 (6.8 – 9.3) 7.4 (6.7 – 8.5) 0.008 
Alanine transferase (IU/L)b 
 
23.0 (17.0 – 
32.0) 
 21.0 (17.0 – 
34.0) 
23.0 (17.0 – 
32.0) 
0.716 
Platelet count (× 109/L)b  227 (192 – 269)  234 (194 – 289) 226 (191 – 268) 0.218 
Estimated glomerular filtration rate 
(ml/min) 
 100.7 (34.6)  94.7 (39.6) 101.1 (34.2) 0.086 
Urine albumin-creatinine ratio 
(mg/mmol) 
 2.6 (0.7 – 13.9)  4.6 (1.6 – 23.6) 2.4 (0.7 – 12.8) <0.001 
Micro or macroalbuminuriaa  888 (46.9%)  76 (64.4%) 812 (45.8%) <0.001 
       
Medication use       
Oral anti-diabetic drugsa  1661 (86.6%)  105 (88.2%) 1556 (86.5%) 0.589 
Anti-hypertensivesa  1340 (69.9%)  102 (85.7%) 1238 (68.8%) <0.001 
Lipid lowering drugsa  1297 (67.6%)  90 (75.6%) 1207 (67.1%) 0.054 
Insulina  744 (38.8%)  72 (60.5%) 672 (37.4%) <0.001 
Variables marked with a are presented as frequency (%), b are presented as median (interquartile range), 
and the rest are presented as mean (standard deviation).  
CAP, controlled attenuation parameter; HDL-cholesterol, high density lipoprotein cholesterol; LDL-
cholesterol, low density lipoprotein cholesterol; LSM, liver stiffness measurement 
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4.3.1 Proportion of patients with increased CAP and LSM 
Among 1799 patients with valid CAP data, the median CAP score was 266 dB/m (IQR 216-313). 1309 
(72.8%; 95% confidence interval [CI] 70.7-74.8%) had increased CAP of 222 dB/m or more (Figure 
22/2A). The number of patients with grade 1, 2 and 3 steatosis as suggested by CAP values was 92 
(5.1%), 533 (29.6%) and 684 (38.0%), respectively. 
 
Among 1770 patients with reliable LSM by the M probe, the median LSM was 6.3 kPa (IQR 4.9-8.3). 303 
of them (17.1%) had LSM ≥9.6 kPa by M probe suggestive of advanced fibrosis or cirrhosis; 199 (11.2%) 
also had LSM ≥11.5 kPa suggestive of cirrhosis (Figure 22/2B). In addition, 114 patients failed M probe 
examination but had successful LSM by the XL probe. Their median LSM was 6.9 kPa (IQR 4.8-9.6). 31 of 
them (27.2%) had LSM ≥9.3 kPa by XL probe suggestive of advanced fibrosis or cirrhosis; 25 (21.9%) had 
LSM ≥11.0 kPa suggestive of cirrhosis (Figure 22/2C). Taken together, the proportion of patients with 
increased LSM by either the M probe or the XL probe was 17.7% (95% CI 16.0-19.5%). 
 
As expected, increased LSM was mainly observed in patients with increased CAP. 269 of 1309 (20.6%) 
patients with increased CAP had increased LSM, compared with 34 of 490 (6.9%) patients with normal 
CAP (P<0.001). The median LSM of patients with normal CAP but increased LSM was 14.2 kPa (IQR 11.1-
16.5). Some of these patients might have burnt out NASH. 
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Figure 22: Distribution of CAP, LSM (M probe) and LSM (XL probe) 
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4.3.2 Factors associated with increased CAP 
By univariate analysis, increased CAP ≥222 dB/m was associated with higher body weight, BMI, waist 
circumference, diastolic blood pressure, triglycerides, fasting plasma glucose and ALT (Table 17). It was 
also associated with lower high density lipoprotein (HDL)-cholesterol and the use of oral anti-diabetic 
drugs, anti-hypertensives and lipid lowering drugs. Fewer patients with increased CAP were on insulin 
treatment. By multivariable analysis, female gender, higher BMI, triglycerides, fasting plasma glucose 
and ALT level, and not using insulin remained as independent factors associated with increased CAP 
(Hosmer-Lemeshow test; P=0.564). Increased CAP was found in 410 of 751 (54.6%), 609 of 736 (82.7%), 
and 280 of 296 (94.6%) patients with BMI <25, 25-30 and ≥30 kg/m2, respectively (P<0.001) (Figure 23/ 
3). When the different classes of oral anti-diabetic drugs were analyzed separately, none of them were 
associated with an increased or decreased risk of increased CAP in the multivariable analysis (data not 
shown). 
 
276 of 335 (82.4%) men with ALT ≥30 IU/l had increased CAP, compared with 434 of 665 (65.3%) men 
with ALT <30 IU/l (P<0.001). Similarly, 409 of 502 (81.5%) women with ALT ≥19 IU/l had increased CAP, 
compared with 185 of 291 (63.6%) women with ALT <19 IU/l (P<0.001). The sensitivity, specificity, 
positive predictive value and negative predictive value of the combined ALT cutoffs to detect increased 
CAP were 52.5% (95% CI 49.8-55.3%), 68.9% (95% CI 64.6-73.0%), 81.8% (95% CI 79.1-84.4%) and 35.3% 
(95% CI 32.2-38.4%), respectively. 
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Table 17: Comparison of study population characteristics and increased controlled attenuation parameter 
  Increased CAP     
Characteristics 
 No (n=490) Yes (n=1309) ORU 
Univariate P 
value 
ORA (95% 
CI) 
Multivariate P 
value 
Clinical and biochemical 
profile 
       
Age (years)  61.1 (11.2) 60.5 (11.6) 0.96c 0.327 NE  
Years since diabetes 
diagnosed  
 10.8 (8.9) 10.7 (8.4) 0.99c 0.841 NE  
Sexa        
Male (ref)  291 (29.0%) 712 (71.0%) 1  1  
Female 
 199 (25.0%) 597 (75.0%) 1.23 0.058 
1.68 (1.31 – 
2.15) 
<0.001 
Educational levela        
Primary or below (ref)  216 (30.0%) 504 (70.0%) 1  NS  
Secondary  220 (25.1%) 655 (74.9%) 1.28 0.030   
College or above  51 (26.7%) 140 (73.3%) 1.18 0.374   
Full / part-time workinga        
      No (ref)  296 (28.2%) 755 (71.8%) 1  NE  
      Yes  188 (25.8%) 541 (74.2%) 1.13 0.268   
Current smokera        
      No (ref)  433 (27.3%) 1151 (72.7%) 1  NE  
      Yes  54 (26.5%) 150 (73.5%) 1.05 0.794   
Regular alcohol drinkera        
      No (ref)  463 (26.9%) 1255 (73.1%) 1  NE  
      Yes  22 (32.4%) 46 (67.6%) 0.77 0.327   
Body weight (kg)  61.1 (10.8) 70.8 (13.3) 1.99c <0.001 NE  
Body mass index (kg/m2) 
 23.7 (3.2) 27.2 (4.0) 1.33 <0.001 
1.30 (1.25 – 
1.35) 
<0.001 
Waist circumference 
(cm) 
 85.6 (9.0) 94.4 (10.0) 2.65c <0.001 NE  
Systolic blood pressure 
(mmHg) 
 136.6 (20.6) 138.1 (18.5) 1.04c 0.152 NE  
Diastolic blood pressure 
(mmHg) 
 74.9 (11.0) 76.6 (11.0) 1.16c 0.003 NS  
Total cholesterol 
(mmol/L) 
 4.2 (0.9) 4.3 (0.9) 1.10 0.128 NS  
HDL-cholesterol 
(mmol/L) 
 1.4 (0.4) 1.3 (0.4) 0.40 <0.001 NS  
LDL-cholesterol 
(mmol/L) 
 2.2 (0.7) 2.3 (0.7) 1.06 0.458 NE  
Triglyceride, TG 
(mmol/L)b 
 
1.0 (0.8 – 
1.4) 
1.4 (1.0 – 
2.0) 
3.45 <0.001 
2.03 (1.59 – 
2.58) 
<0.001 
Fasting plasma glucose 
(mmol/L)b 
 
6.8 (5.7 – 
8.4) 
7.4 (6.3 – 
9.0) 
2.34 <0.001 
1.74 (1.18 – 
2.58) 
0.005 
Glycated hemoglobin 
(%)b 
 
7.2 (6.5 – 
8.6) 
7.4 (6.8 – 
8.5) 
1.37 0.264 NE  
Alanine transferase 
(IU/L)b 
 
19.0 (15.0 – 
24.0) 
24.0 (18.0 – 
35.0) 
3.17 <0.001 
2.14 (1.63 – 
2.81) 
<0.001 
eGFR (ml/min)  98.8 (37.3) 101.9 (32.9) 1.03c 0.088 NS  
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Urine ACR (mg/mmol)b 
 
1.9 (0.6 – 
11.8) 
2.7 (0.8 – 
13.6) 
1.03 0.203 NS  
        
Medication use        
Oral anti- diabetic drugsa        
      No (ref)  84 (34.6%) 159 (65.4%) 1  NS  
      Yes  406 (26.1%) 1150 (73.9%) 1.50 0.006   
Anti-hypertensivesa        
      No (ref)  191 (34.0%) 370 (66.0%) 1  NS  
      Yes  299 (24.2%) 939 (75.8%) 1.62 <0.001   
Lipid lowering drugsa        
      No (ref)  189 (31.9%) 403 (68.1%) 1  NS  
      Yes  301 (24.9%) 906 (75.1%) 1.41 0.002   
Insulina        
      No (ref)  284 (25.2%) 843 (74.8%) 1  1  
      Yes 
 206 (30.7%) 466 (69.3%) 0.76 0.012 
0.64 (0.50 – 
0.82) 
<0.001 
Variables marked with a are presented as frequency (row %), b are presented as median (interquartile 
range) and log-transformed before being entered into association analysis; all others are presented as 
mean (standard deviation). 
c The odds ratio was estimated for every 10-unit increase of the underlying factor. 
eGFR, estimated glomerular filtration rate; ACR, albumin-creatinine ratio; ref,  reference group of the 
categorical variable; ORU, unadjusted odds ratio; ORA, odds ratio adjusted for other significant factors 
obtained from backward stepwise logistic regression analysis using variables with p-value <0.25 in 
univariate analysis as candidate variables; NS, not statistically significant in multivariable analysis; NE, 
not entered into multivariable analysis owing to p ≥ 0.25 or collinearity. 
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4.3.3 Factors associated with increased LSM 
By univariate analysis, increased LSM (≥9.6 kPa by M probe or ≥9.3 kPa by XL probe) was associated with 
higher body weight, BMI, waist circumference, blood pressure, triglycerides, fasting plasma glucose, 
HbA1c, ALT, and spot urine albumin-creatinine ratio (Table 18). It was also associated with lower total 
cholesterol, HDL-cholesterol, low density lipoprotein-cholesterol and eGFR, and the use of anti-
hypertensives and lipid lowering drugs. By multivariable analysis, longer duration of diabetes, higher 
BMI, ALT and spot urine albumin-creatinine ratio, and lower HDL-cholesterol remained as independent 
factors associated with increased LSM (Hosmer-Lemeshow test; P=0.672). Increased LSM was found in 
60 of 744 (8.1%), 141 of 754 (18.7%), and 131 of 370 (35.4%) patients with BMI <25, 25-30 and ≥30 
kg/m2, respectively (P<0.001) (Figure 23/3). When the different classes of oral anti-diabetic drugs were 
analyzed separately, none of them were associated with an increased or decreased risk of increased 
LSM in the multivariable analysis (data not shown). 
 
108 of 345 (31.3%) men with ALT ≥30 IU/l had increased LSM, compared with 85 of 673 (12.6%) men 
with ALT <30 IU/l (P<0.001). Similarly, 116 of 540 (21.5%) women with ALT ≥19 IU/l had advanced 
fibrosis, compared with 24 of 320 (7.5%) women with ALT <19 IU/l (P<0.001). The sensitivity, specificity, 
positive predictive value and negative predictive value of the combined ALT cutoffs to detect advanced 
fibrosis were 67.3% (95% CI 61.9-72.3%), 57.2% (95% CI 54.7-59.7%), 25.3% (95% CI 22.5-28.3%) and 
89.0% (95% CI 86.9-90.9%), respectively. The proportion of patients with increased CAP and LSM by ALT 
level is shown in Table 19. 
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Table 18: Comparison of study population characteristics and increased liver stiffness 
  Increased LSM     
Characteristics 
 No (n=1550) Yes (n=334) ORU 
Univariate P 
value 
ORA (95% 
CI) 
Multivariate P 
value 
Clinical and biochemical 
profile 
       
Age (years)  60.4 (11.3) 61.2 (12.5) 1.06c 0.255 NE  
Years since diabetes 
diagnosed  
 10.8 (8.6) 11.6 (8.3) 1.11c 0.149 
1.20 (1.01 
– 1.41) 
0.034 
Sexa        
Male (ref)  827 (81.0%) 194 (19.0%) 1  NS  
Female  723 (83.8%) 140 (16.2%) 0.83 0.116   
Educational levela        
Primary or below (ref)  625 (82.7%) 131 (17.3%) 1  NE  
Secondary  745 (81.6%) 168 (18.4%) 1.08 0.569   
College or above  168 (83.2%) 34 (16.8%) 0.97 0.868   
Full / part-time workinga        
      No (ref)  904 (81.5%) 205 (18.5%) 1  NE  
      Yes  628 (83.1%) 128 (16.9%) 0.90 0.390   
Current smokera        
      No (ref)  1366 (82.0%) 300 (18.0%) 1  NE  
      Yes  174 (84.1%) 33 (15.9%) 0.86 0.464   
Regular alcohol drinkera        
      No (ref)  1486 (82.4%) 318 (17.6%) 1  NE  
      Yes  53 (79.1%) 14 (20.9%) 1.23 0.492   
Body weight (kg)  67.5 (13.2) 76.7 (16.1) 1.55c <0.001 NE  
Body mass index (kg/m2) 
 26.1 (4.1) 29.3 (5.2) 1.17 <0.001 
1.14 (1.10 
– 1.17) 
<0.001 
Waist circumference 
(cm) 
 91.5 (10.5) 99.5 (11.5) 1.94c <0.001 NE  
Systolic blood pressure 
(mmHg) 
 137.3 (19.4) 141.4 (18.2) 
1.11 
c 
0.001 NS  
Diastolic blood pressure 
(mmHg) 
 75.8 (11.1) 77.8 (11.7) 
1.16 
c 
0.004 NE  
Total cholesterol 
(mmol/L) 
 4.3 (0.9) 4.2 (0.9) 0.86 0.033 NE  
HDL-cholesterol 
(mmol/L) 
 1.3 (0.4) 1.2 (0.4) 0.36 <0.001 
0.65 (0.44 
– 0.95) 
0.027 
LDL-cholesterol 
(mmol/L) 
 2.3 (0.7) 2.2 (0.7) 0.77 0.004 NS  
Triglyceride, TG 
(mmol/L)b 
 
1.3 (0.9 – 
1.8) 
1.5 (1.1 – 
2.2) 
1.83 <0.001 NS  
Fasting plasma glucose 
(mmol/L)b 
 
7.2 (6.0 – 
8.7) 
7.7 (6.3 – 
9.6) 
1.91 0.001 NS  
Glycated hemoglobin 
(%)b 
 
7.4 (6.7 – 
8.5) 
7.5 (6.8 – 
9.1) 
1.98 0.027 NS  
Alanine transferase 
(IU/L)b 
 
22.0 (16.0 – 
29.0) 
32.0 (22.0 – 
48.0) 
4.48 <0.001 
4.08 (3.12 
– 5.34) 
<0.001 
eGFR (ml/min)  101.7 (34.2) 96.1 (36.3) 0.95c 0.007 NS  
Urine ACR (mg/mmol)b 
 
2.1 (0.7 – 
11.3) 
6.2 (1.6 – 
30.2) 
1.22 <0.001 
1.17 (1.10 
– 1.25) 
<0.001 
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Medication use        
Oral anti-diabetic drugsa        
      No (ref)  210 (84.3%) 39 (15.7%) 1  NE  
      Yes  1340 (82.0%) 295 (18.0%) 1.19 0.360   
Anti-hypertensivesa        
      No (ref)  501 (88.7%) 64 (11.3%) 1  NS  
      Yes  1049 (79.5%) 270 (20.5%) 2.02 <0.001   
Lipid lowering drugsa        
      No (ref)  518 (85.1%) 91 (14.9%) 1  NS  
      Yes  1032 (80.9%) 243 (19.1%) 1.34 0.029   
Insulina        
      No (ref)  963 (83.4%) 192 (16.6%) 1  NS  
      Yes  587 (80.5%) 142 (19.5%) 1.21 0.114   
Variables marked with a are presented as frequency (row %), b are presented as median (interquartile 
range) and log-transformed before being entered into association analysis; all others are presented as 
mean (standard deviation). 
c The odds ratio was estimated for every 10-unit increase of the underlying factor. 
eGFR, estimated glomerular filtration rate; ACR, albumin-creatinine ratio; ref, reference group of the 
categorical variable; ORU, unadjusted odds ratio; ORA, odds ratio adjusted for other significant factors 
obtained from backward stepwise logistic regression analysis using variables with p-value <0.25 in 
univariate analysis as candidate variables; NS, not statistically significant in multivariable analysis; NE, 
not entered into multivariable analysis owing to p ≥ 0.25 or collinearity. 
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Figure 23: Prevalence of CAP and LSM by BMI 
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Table 19: Proportion of patients with increased CAP and LSM by ALT levels 
 CAP <222 dB/m CAP ≥222 dB/m P 
All patients (n=1799)    
Normal LSM 456 (93.1%) 1040 (79.4%) <0.001 
Increased LSMa 34 (6.9%) 269 (20.6%)  
Normal ALTb (n=956)    
Normal LSM 317 (94.1%) 539 (87.1%) <0.001 
Increased LSMa 20 (5.9%) 80 (12.9%)  
High ALTb,c (n=837)    
Normal LSM 138 (90.8%) 497 (72.6%) <0.001 
Increased LSMa 14 (9.2%) 188 (27.4%)  
aIncreased LSM was defined as LSM ≥9.6 kPa by the M probe or ≥9.3 kPa by the XL probe. 
bThere were 6 patients with missing ALT values. 
cHigh ALT was defined as ALT ≥30 IU/L in men and ≥19 IU/L in women. 
ALT, alanine aminotransferase; CAP, controlled attenuation parameter; LSM, liver stiffness 
measurement 
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4.3.4 Liver histology 
94 patients underwent liver biopsy (Table 20). The mean liver biopsy length was 20 (SD 7) mm and mean 
number of portal tracts was 8 (SD 3). Eighty seven patients had M probe examination with a median CAP 
of 320 dB/m (IQR 286-350 dB/m) and LSM 14.1 kPa (IQR 11.8-20.6 kPa). Seven patients only had XL 
probe examination, and the median LSM was 17.6 kPa (IQR 8.6-29.2 kPa). Seventy five of these 94 (80%) 
patients had increased LSM (≥9.6 kPa by M probe or ≥9.3 kPa by XL probe). The sensitivity, specificity, 
positive predictive value and negative predictive value of increased LSM to detect F3-4 disease were 
94%, 34%, 59% and 84%, respectively. Eighty two of the 87 patients who had a median CAP had an 
increased CAP (≥222 dB/m). The sensitivity, specificity, positive predictive value and negative predictive 
value of increased CAP to detect steatosis (S≥1) was 95%, 14%, 93% and 20% respectively.  Lobular 
inflammation was found in 89 (95%) patients, hepatocyte ballooning in 54 (57%), and fibrosis in 89 (95%) 
(Table 5). In particular, 60 (50%) patients had F3-4 disease. 78 (83%) patients had NAFLD activity score 
≥3.  53 (56%) subjects had NASH.  
 
Seven subjects had steatosis found in <5% of hepatocytes (liver specimen length 14-26 mm). Three had 
normal liver histology, 1 had mild lobular inflammation but no fibrosis, 2 had bridging fibrosis (F3) and 1 
had cirrhosis (F4). All 3 patients with F3-4 disease had grade 1-2 lobular inflammation and no other 
etiologies of chronic liver disease. The picture was suggestive of burnt out NASH. 
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Table 5. Histological severity of 94 patients with liver biopsy 
 
Table 20: Histological severity of 94 patients with liver biopsy 
Histological features Grade/Stage n % CAP (dB/m) LSM (kPa)a 
Steatosis 0 7 7 238 (234-263) 17.3 (14.5-28.8) 
 1 38 40 310 (284-349) 14.4 (11.6-26.7) 
 2 38 40 324 (303-348) 13.8 (11.8-17.1) 
 3 11 12 351 (310-393) 12.8 (7.3-15.3) 
Lobular inflammation 0 5 5 263 (249-306) 14.9 (14.2-20.1) 
 1 57 61 318 (283-351) 14.2 (11.8-22.2) 
 2 32 34 326 (295-351) 13.7 (9.0-17.1) 
 3 0 0 - - 
Ballooning 0 40 43 324 (274-358) 13.1 (9.3-16.8) 
 1 47 50 317 (279-347) 14.3 (11.9-21.3) 
 2 7 7 310 (299-364) 26.6 (15.3-36.8) 
Fibrosis 0 5 5 235 (204-263) 8.8 (14.9-18.4) 
 1 29 31 341 (310-359) 11.8 (7.8-12.9) 
 2 13 14 306 (272-341) 12.6 (7.7-14.4) 
 3 20 21 321 (296-350) 14.0 (12.7-16.3) 
 4 27 29 323 (292-338) 23.8 (14.8-35.3) 
NAFLD activity scoreb 0-2 16 17 269 (238-331) 14.5 (13.1-21.3) 
 3-4 62 66 319 (288-349) 14.0 (11.7-21.8) 
 ≥5 16 17 333 (321-356) 14.1 (8.8-16.8) 
Non-NASH  41 44 322 (270-357) 13.2 (9.9-17.0) 
NASH  53 56 317 (288-347) 14.5 (11.9-23.8) 
CAP and LSM were expressed in median (interquartile range). 
aThe LSM based on M probe examination is shown because only 7 patients in this cohort required XL 
probe measurements. 
bThe NAFLD activity score: 0-2 Non NASH, 3-4 Possible NASH, ≥5 Probable NASH 
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CAP, controlled attenuation parameter; LSM, liver stiffness measurement; NAFLD, nonalcoholic fatty 
liver disease; NASH, nonalcoholic steatohepatitis 
  
 138 
 
4.4 DISCUSSION 
 
In this large prospective hospital cohort, NAFLD was found in the large majority of diabetic patients. A 
significant proportion also had increased LSM. Patients with high BMI and additional metabolic factors 
were most likely to have increased CAP and LSM. 
In previous community-based studies using abdominal ultrasonography, around 32-62% of diabetic 
patients were found to have NAFLD.(244-247) The prevalence of NAFLD is higher in our cohort for 
several reasons. First, abdominal ultrasonography is operator-dependent and is insensitive to mild 
steatosis.(210) Therefore, NAFLD may be underreported and missed in some cases. In comparison, CAP 
measurement by FibroScan can detect liver fat involving as little as 10% of the hepatocytes.(235-237) 
Our study confirmed the discriminating ability of CAP for detecting steatosis was confirmed in the 87 
subjects who had a liver biopsy. The sensitivity and positive predictive value of CAP to detect S≥1 were 
95% and 93% respectively.       
Our study was conducted at the hospital setting. Although we had an open referral system for both 
hospital and primary care clinics, the metabolic burden of our patients was higher than that of patients 
in the community setting.  
 
Since we could measure CAP and liver stiffness simultaneously with FibroScan, it was possible to assess 
not only the prevalence of NAFLD but also disease severity. According to past histological studies, 
diabetes is one of the most important risk factors of cirrhosis in patients with NAFLD (189, 248). At the 
population level, diabetes also doubles the risk of hepatocellular carcinoma in men.(249) A retrospective 
study of 1131 diabetes patients using FibroTest also reported a prevalence of between 2.8–5.6% for 
advanced fibrosis.(250) Similarly, studies from Europe and Australia found that 5-35% of diabetic 
patients had increased LSM by different cutoffs.(251-253) In our study, 18% of the patients were found 
to have increased LSM. We further performed liver biopsy in 94 patients and confirmed the presence of 
advanced fibrosis or cirrhosis in half of the patients. If we adjust for the positive predictive value of LSM, 
around 10% of our diabetic patients would still have advanced liver disease. This argues strongly in favor 
of liver assessment in diabetic patients. 
 
 
Previous studies report an LSM failure rate of around 3% and unreliable measurements in 12-16%.(222, 
223) In the current study, however, 98.2% of the subjects could have successful and reliable LSM. 
Differences in study design can explain the apparent discrepancies. First, the use of XL probe allowed 
successful LSM even in obese patients.(242) Second, recent data suggest that the success rate of LSM 
(number of valid acquisitions divided by the total number of acquisitions) does not affect the reliability 
of LSM as compared to liver histology.(55) Therefore, we did not include success rate as one of the 
reliability criteria in this study. Finally, all examinations were performed by experienced operators who 
had performed more than 2000 measurements before. Operator experience is pivotal in achieving 
successful and reliable LSM.(222) 
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Although FibroScan is easy to perform, it is unlikely that clinicians can apply it to all diabetic patients 
because of the large number of patients and the availability of assessment. Therefore, it is important to 
identify patients at risk of NAFLD and advanced liver disease. Traditional metabolic risk factors such as 
high BMI and dyslipidaemia were independent factors associated with NAFLD and increased LSM. In 
other words, patients with diabetes and additional metabolic diseases are at higher risk of having 
advanced liver disease and may benefit from liver assessment. That said, it is important to note that 
among diabetic patients with BMI less than 25 kg/m2, 55% still had increased CAP and 8% had increased 
LSM. In previous population studies, NAFLD and advanced fibrosis are observed in a small but significant 
proportion of non-obese subjects. Such patients usually have other components of metabolic syndrome 
and despite relatively normal BMI often have recent weight gain.(231, 254) In contrast, ALT correlates 
poorly with histological severity.(192, 255) Metabolic factors are more important than ALT in guiding 
liver assessment in diabetic patients. 
 
Thiazolidinediones improve liver histology in NASH patients, and use of metformin has been shown to 
be associated with a lower mortality rate in cirrhotic patients.(256, 257) Nevertheless, neither class of 
drugs was independently associated with NAFLD or advanced fibrosis in our study. It should however be 
noted that the current study is not a randomized controlled trial. The selection of different drugs was 
influenced by the underlying disease status. Unexpectedly, insulin use was associated with a lower risk 
of NAFLD. This is counterintuitive as patients requiring insulin treatment usually have failed treatment 
with oral anti-diabetic drugs and thus have poorer diabetic control. One possible explanation is that 
patients with cirrhosis are more insulin resistant and therefore more likely require insulin treatment. As 
a NAFLD patient progresses to cirrhosis, liver fat tends to disappear and the patient would thus be 
classified as having no fatty liver.(193) In fact, there was a trend that insulin use was associated with 
advanced fibrosis in our entire cohort (Table 18). Three of our patients who underwent liver biopsy also 
had features of burnt out NASH. 
 
Our study has the strength of a large sample size and the use of one of the best and widely available 
non-invasive tests of liver steatosis and fibrosis. Compared to previous studies, ours also had 
comprehensive diabetic assessment. Nevertheless, there were several limitations. First, at the time of 
the study, CAP could only be measured by the M probe. More obese patients who required XL probe 
examination only had LSM but not CAP data. The true prevalence of NAFLD would therefore be even 
higher. This would be particularly relevant to Western countries where the prevalence of obesity is 
higher. In the Caucasian cohorts described above, 8-15% of the diabetic patients had failed M probe 
examination.(251-253) Nonetheless, the FibroScan programme has been updated to allow CAP 
measurement by XL probe. If validated, CAP measurement can also be done in obese patients. Second, 
liver biopsy was only performed in a subset of patients. However, it is unethical to biopsy patients with 
no apparent liver disease. A low LSM also has excellent negative predictive value in excluding advanced 
fibrosis.(241) Along the same line, the diagnostic performance of LSM in the histology subgroup of this 
study should be interpreted with caution because patients undergoing liver biopsy were selected based 
on increased likelihood of advanced disease. Third, our study was conducted on the local Hong Kong 
Chinese patients, which may limit the generalizability of the findings to other ethnicities. Finally, we only 
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reported the baseline assessment. The patients are currently under prospective follow-up for 10 years. 
The prognostic implications of the baseline liver assessment will be further unraveled. 
 
In conclusion, diabetic patients at hospital and primary care clinics have a high prevalence of NAFLD and 
advanced liver fibrosis. Diabetic patients with high BMI and dyslipidaemia are at particularly high risk 
and may be the target for liver assessment. Our data support screening for NAFLD and/or advanced 
fibrosis in patients with type 2 diabetes. However, while LSM is good at ruling out advanced fibrosis, its 
accuracy in ruling in the disease remains limited. 
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CHAPTER 5: Assessment of liver fibrosis in chronic 
hepatitis B patients with transient elastography, 
and other non-invasive measures. 
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5.0 CHAPTER SUMMARY 
 
Introduction: Staging liver fibrosis is useful in determining which chronic hepatitis B patients will benefit 
from antiviral therapy. Liver biopsy is the reference standard, but has several limitations. Non-invasive 
methods to stage liver disease are needed. Transient Elastography (TE) has been developed and has 
shown good correlation to date. The diagnostic accuracy and usefulness of TE is evaluated against liver 
histology. The performance of TE is compared with other easily performed non-invasive methods: FIB 4 
index, Aspartate Platelet Ratio Index (APRI), Aspartate Alanine aminotransferase Ratio (AAR), Age 
Platelet Index (API), Fibrosis Index (FI).  TE was also compared with Caffeine Breath Test (CBT) in a small 
cohort. 
The accuracy of liver histology assessment is potentially affected by interobserver variability. Significant 
variability in histological assessment is therefore a factor which affects the validation of non-invasive 
methods. We sought to determine the degree of interobserver variability in the histological assessment 
of liver biopsy.   
Methods: Chronic hepatitis B patients who had a liver biopsy within the past 6 months were identified 
and invited to have TE. Clinical history, laboratory data and histopathology were collected. Transient 
elastography was performed. At least 10 successful measurements of LSM was required for a valid 
reading, with an interquartile range to median ratio of < 30% when LSM≥7.1 kPa. On liver biopsy 
specimens available, a second blinded assessment was performed. The fibrosis stage from the second 
assessment was compared to the original assessment.  
Results: Seventy one patients were recruited. Liver Stiffness Measurement (LSM) Area Under Receiver 
Operator Characteristic (AUROC) curves for F≥1, 2, 3 and 4 were 0.825 (95% CI 0.728-0.922, p<0.001), 
0.792 (95% CI 0.689-0.895, p< 0.001), 0.874 (95% CI 0.775-0.973, p<0.001) and 0.945 (95% CI 0.867-
1.000, p=0.001) respectively. Using ALT level specific LSM Cut-offs, F≥2 and F≥3 can be diagnosed or 
excluded with a very high degree of certainty (>90%)  in 49.3% and 57.7% respectively. TE compared 
favourably against FIB 4, APRI, AAR, API and FI for every stage of fibrosis. In 7 patients, caffeine breath 
tests had the best performance for diagnosing fibrosis stage. Liver biopsies were classified differently in 
the second histological assessment in 44% of cases, with the intraclass correlation coefficient showing 
moderate agreement (K =0.457, p<0.001).  
Conclusions: TE is a reliable and accurate non-invasive tool for diagnosing fibrosis stage. It has 
particularly high accuracy for F≥3 and F4, and is superior to FIB-4, APRI, API, AAR and FI. It can reduce 
the need for liver biopsies in the majority of chronic hepatitis B patients. However the inherent 
variability of liver biopsy can impede the true accuracy of non-invasive modalities.  
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5.1 BACKGROUND 
5.1.1 Introduction to chronic hepatitis B – burden of disease worldwide and in Australia 
 
Approximately 240 million people are chronically infected with hepatitis B virus (HBV) (93, 94). More 
than 75 % reside in the Asia and the Western Pacific (258). 
Chronic Hepatitis B infection has a wide spectrum of disease and dynamic natural history. There are 4 
recognized phases of infection. These are known as immune tolerance, immune clearance, inactive and 
immune reactivation.  Different patients transition through these phases with a great deal of variability 
and irregularity.   
Progression toward liver cirrhosis and development of hepatocellular carcinoma (HCC) complicate CHB 
infection. The annual incidence of cirrhosis is about 2% and HCC 3-6% (highest risk in cirrhotic patients) 
(259). The main risk factors (of HCC or cirrhosis) are  male gender, hepatitis B e antigen (HBeAg) status, 
serum HBV viral load, alanine aminotransferase (ALT) level, HBV genotype, family history of 
hepatocellular carcinoma (HCC), and alcohol consumption (260). The cumulative lifetime risk of cirrhosis 
and HCC can range 15.9 - 76.2% and 4.4 - 61.8% respectively (260).  
Chronic hepatitis B is the major cause of HCC accounting for 60-80% of the world’s total cases. HBV 
results in over 780 000 deaths per year from end stage liver disease and HCC (93, 94). HBV comprise 5–
10% of cases for liver transplantation (261-263) 
In Australia, vaccination programs have significantly reduced the incidence of new HBV infection, 
resulting in a low prevalence of HBV. However, there are at risk communities where there is a much 
higher prevalence due to population movements. The latest estimate of CHB prevalence in Australia is 
approximately 1% (204,000 persons) (113).  People who are born overseas account for 56.1% of the 
total cases of CHB, with 95% of new cases are due to immigrants from endemic countries.  The migrants 
with the highest rates of CHB are those from the Asia/Pacific (3.55%) and Africa/Middle East (2.69%). 
The increasing incidence of CHB related HCC appears to be largely occurring in Asia-Pacific born 
Australians, and is projected to increase from 140 cases in 2005 to 250 cases per year by 2025 (264). At 
risk groups for people born in Australia are those who inject drugs (4%), Aboriginal and Torres Strait 
islanders (3.7%), and men who have sex with men (3%) (113). 
 
5.1.2 Limitations of current chronic hepatitis B antiviral therapy 
 
The goal of therapy is to prevent progression of CHB infection to cirrhosis, decompensation, HCC and 
death. Active HBV replication is the key driver of liver injury and disease progression. Current antivirals 
suppress viral replications, but are unable to eradicate the virus. In patients receiving antiviral therapy, 
rates of complete virological response, as defined as hepatitis B surface antigen (HBsAg) loss, remain low 
(265). 
The 2 main forms for antiviral therapy for CHB infection are pegylated interferon and 
nucleotide/nucleoside analogues (NAs). Pegylated interferon offers finite treatment duration, but can be 
 145 
 
associated with significant side effects. HBeAg seroconversion occurs in 32% (in those who are HBeAg 
positive at baseline), undetectable viral load in 14-19%, and ALT normalization in 41-59% (266).   
The current first line NAs, entecavir monohydrate and tenofovir disoproxil fumerate, are potent 
antivirals with high genetic barrier to drug resistance and few side effects.  Entecavir achieves viral 
suppression with undetectable DNA in 96% of patients, and a 0.4% rate of resistance over 4 years (267). 
Tenofovir  therapy is associated with undetectable viral DNA in 99% of patients, with no resistance after 
5 years (15).  
The disadvantage of NAs is that viral suppression relies on sustained therapy, with relapse upon drug 
cessation. In HBeAg positive patients who achieve HBeAg seroconversion during treatment, more than 
90% have detectable viral levels within 4 years of stopping treatment (268, 269). In HBeAg negative 
patients, , viral relapse (defined as HBV DNA>2000 IU/ml after 3 or more consecutive undetectable 
levels taken 6 months apart) occurs in 91.4% within 1 year of NAs cessation (270).  Hepatitis B surface 
antigen loss is recommended as the end point of therapy by local and international guidelines (259, 267, 
271, 272). Rates of surface antigen loss are only up to 2% per year (273-275) and hence most patients 
require long term therapy. This can be associated with high costs, and since the highest rates of CHB 
infection occur in low income countries, long term antiviral therapy may be out of reach for majority of 
the population (276).This means it is crucial to accurately select patients who will derive the most 
benefit from antivirals. 
 
5.1.3 The importance of assessing liver fibrosis in chronic hepatitis B 
 
Regional and international guidelines universally recommend liver fibrosis staging to be considered as 
part of the assessment of CHB patients (259, 267, 271, 272, 277). Diagnosing the stage of liver fibrosis is 
important because it allows for the identification of CHB patients with advanced disease, which aids in 
determining which patients will benefit from antiviral therapy, and from surveillance of cirrhosis 
complications. Therapy should be considered in those with moderate (Metavir stage F2) or advanced 
fibrosis (Metavir stage F3) (259, 267, 271, 272, 277) so as to prevent progression to cirrhosis (Metavir 
stage F4). Early cirrhosis can have no clinical, biochemical or radiological features. Diagnosis with more 
accurate measures will allow for the optimal commencement of surveillance programs to detect HCC 
and treat gastro-oesophageal varices.    
 
 
5.1.4 Transient Elastography in chronic hepatitis B 
 
Liver biopsy is the reference standard test that is recommended by all guidelines in the assessment of 
fibrosis (259, 267, 271, 272). However, liver biopsy is not an ideal method of assessment for liver fibrosis 
due to reasons discussed earlier in this thesis (see section 1.5). In brief, liver biopsy is poorly accepted by 
patients due to pain and risk of complications. It is resource intensive which makes it impractical to 
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apply routinely in large volumes. There can also be variability in sampling and interobserver 
interpretation.  
In 2009 when this study was initiated, Transient elastography (TE) was still only an emerging method of 
liver fibrosis assessment. Most of the TE data at the time were from Europe on Caucasian hepatitis C 
patients with little literature on hepatitis B patients.   
Marcellin et al in 2008 (87) was first to perform a dedicated study in CHB patients that compared Liver 
stiffness measurement (LSM) and liver biopsy. In 173 patients, the diagnostic performance for TE was:  
AUROC= 0.81 (95% confidence intervals (CI) 0.73-0.86) for F≥2; 0.93 (95% CI 0.88-0.96) for F≥3; and 0.93 
(95% CI 0.82-0.98) for F=4. Optimal LSM cutoff values were determined to be LSM≥7.2 kPa for F≥2, and 
LSM≥11.0 kPa for F=4. These LSM cutoffs were lower than those observed for hepatitis C patients (77, 
78, 84). This was thought to be due to hepatitis C having relatively more micronodular cirrhosis (278, 
279), where nodules are smaller and denser implying denser fibrosis. 
The only other literature at the time was by Wong et al in 2008 (280), who examined the relationship of 
LSM and the distribution of the fibrosis in CHB patients via image and morphometric analysis. Liver 
Stiffness Measurement had a higher correlation with pericellular fibrosis (r=0.43), compared to 
periportal (r=0.21) or perivenular fibrosis (r=0.25). Pericellular fibrosis occurs in the latter stages of 
fibrosis progression. Hence the investigators concluded that LSM correlates better with advanced 
fibrosis and cirrhosis.  The serum ALT was also noted to have an effect on the LSM. Elevated ALT was 
associated with higher LSM scores and higher cutoffs were required to diagnose the same stage of 
fibrosis compared to normal ALT subjects (280). 
Since there had been only 2 validation studies for chronic hepatitis b, our goal was to provide further 
validation of the diagnostic performance of TE in CHB fibrosis staging. The performance of TE was 
compared to other non-invasive markers of fibrosis, and the effect of ALT on determining optimal LSM 
cut-offs was also examined. At the time the study’s conception, these aims would have led to results 
that would have been amongst the first reported.  As of the time of writing however, many studies have 
since reported the use of TE and other non-invasive measures of liver fibrosis in CHB patients. Although 
no longer as novel, our findings are still important to report for comparison and independent validation, 
particular for our local population. More recent studies are discussed in the context of our study’s 
findings later in discussion sections 5.4.7 and 5.4.8 of this chapter.  
 
 
5.1.5 Caffeine Breath Test, FIB-4 index, APRI, API, FI, AAR and other non-invasive measures 
of liver fibrosis 
 
Other non-invasive measures of liver fibrosis for CHB include Caffeine breath test (CBT) (281, 282), Hui 
index (283), Zeng Index (284), age-spleen ratio index (285)and compensated cirrhosis index (286).  
Measures that were specifically for CHC include the following: FIB-4 index (287), aspartate platelet ratio 
index (APRI) (288), age platelet index (API)(289), fibrosis index (FI) (290),  aspartate aminotransferase-
alanine aminotransferase ratio (AAR) (291), cirrhosis discriminant score (292), Fibrotest (293), Forns 
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Index (294), European Liver Fibrosis score (295), Hepascore (296), Fibrometer (297), Go¨teborg 
University Cirrhosis Index (298), Fibroindex (299), and S index (300). 
Amongst the measures mentioned, the FIB-4 index, APRI, API, FI and AAR are the panels with the 
greatest simplicity. These only require liver function and/or platelet count levels while other panels 
require more elaborate parameters such as specific imaging results (eg. spleen length) or fibrosis 
markers (eg. hyaluronic acid). Elaborate parameters are not routinely performed and so could not be 
obtained in this cross sectional study. Hence the FIB-4 index, APRI, API, FI and AAR were chosen to be 
comparators with TE.  
Caffeine breath test measures the plasma caffeine clearance using 13C- caffeine which is a reflection of 
hepatic dysfunction (281). A local study of 48 CHB patients found that fibrosis correlated with the 13C-
caffeine breath test (r=-0.62, P < 0.001) and independently predicted significant (F≥ 2) and advanced (F≥ 
3) fibrosis. Improvement in the13C-caffeine clearance level by 61% (P<0.001) was seen in those 
responsive to lamivudine. By comparison, values remained stable or deteriorated in those with 
persistent viraemia and elevated alanine aminotransferase (282).  The performance of TE and other non-
invasive measures has never been assessed against CBT, and thus we made this comparison in a small 
number of patients in this study.  
 
 
5.1.6 Inter-observer variability in histological staging of liver fibrosis may limit the accuracy 
of non-invasive tests 
 
Inter-observer variability in liver biopsy assessment is well described. In academic centres with 
pathologists who specialise in hepatic histopathology, reproducibility in scoring fibrosis is good. A high 
level of concordance was found amongst 10 specialist liver pathologist who were part of the METAVIR 
study group (K=0.80-0.91) (32). This variability is higher outside of these specialist centres with 
discordance of up to 49.9%. In this study, we sought to determine the degree of inter-observer 
variability in the assessment of liver fibrosis stage by re-evaluating liver biopsy slides and comparing the 
results with the original assessment.  This was performed with the aim of clarifying the sensitivity and 
specificity against which the noninvasive tests are being measured against.  
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5.1.7 Hypothesis and specific objectives 
 
The main hypothesis is that the LSM will show similar AUROCs to Marcellin’s study of between 0.81 – 
0.93 (87) for predicting  the fibrosis stage in chronic hepatitis B patients.  We believe the LSM will 
compare favourably to other non-invasive tests and will provide further validation for the use of TE to 
diagnose fibrosis stage in our local population of chronic hepatitis B. In detail, the following are the 
objectives: 
• Objective 1: To assess the rate of scan failure and the reliability of TE scans 
• Objective 2: To determine the diagnostic performance of TE and suggest LSM cut-offs for each 
stage of Fibrosis in CHB patients 
• Objective 3: To examine the effect of ALT on LSM and to devise specific cut-offs for elevated and 
normal ALT  
• Objective 4: To apply the cut-offs on the study population and evaluate the utility of using TE to 
diagnose moderate and advanced fibrosis 
• Objective 5: To evaluate the effectiveness of TE for diagnosing clinically silent cirrhosis 
• Objective 6: To compare the performance of TE against other non-invasive measures of APRI, 
AAR, FIB4, FI and API. 
• Objective 7: To compare the performance of caffeine breath testing with Fibroscan and other 
non-invasive measures of fibrosis in a small cohort of patients.  
• Objective 8: To determine the interobserver variability by comparing the initial histological 
assessment for liver biopsy compared to a second histological evaluation.    
 
 
 
 
 
 
 
 
 
  
 149 
 
5.2 METHODS 
 
5.2.1 Patient Selection and recruitment 
 
From June 2008 to September 2009, chronic hepatitis B patients (as defined by presence of Hepatitis B 
surface antigen positive > 6 months) who had a valid liver biopsy (at least 6 portal tracts and 15mm in 
length) at 2 tertiary centres were prospectively recruited. TE was performed within 6 months of the liver 
biopsy. Some patients already had TE and liver biopsy within a 6 month time frame as part of clinical 
management and were included retrospectively. Seventy three patients were recruited. All subjects 
were over 18yrs of age and gave written informed consent.  
 
5.2.2 Transient Elastography Assessment    
 
The performance of the Fibroscan has been described in detail earlier in this thesis (refer to section 1.7). 
In brief, scans were taken on the right lobe of the liver. The probe is placed in the intercostal space along 
the axillary line with the subject lying supine and the right arm at maximum abduction. A minimum of 
ten successful measurements was required, with the median score taken as the LSM. The success rate is 
the percentage of successful scans out of total number of attempts. The LSM is expressed in kilopascals 
(kPa). The LSM was considered reliable if the interquartile range/median ratio (IQR/M ratio) was less 
than 30% when the result is ≥ 7.1 kPa (55). Two trained operators including this author performed all the 
TE scans.    
Two patients of the total 73 had unsuccessful readings, so that 71 cases were included in the final 
analysis.   
 
5.2.3 Data Collection 
 
Clinical data were collated from medical records from the public hospital or private specialists’ rooms. 
Proforma included the following information: age, gender, alcohol intake, any other documented 
chronic liver disease,  details of any antiviral therapy, INR, liver function tests, platelet count, hepatitis B 
sAg status, hepatitis B c antigen status, hepatitis B DNA viral load, alpha fetoprotein and any imaging 
results. Lab results closest to the Fibroscan date and not exceeding 1 month were recorded.  
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5.2.4 Original histological assessment of fibrosis stage and a second reference histological 
assessment    
 
Baseline liver biopsy was record including Metavir Fibrosis score, biopsy length and number.  
Where slides were still available, the biopsies were reviewed and Metavir score assessed by two 
experienced histopathologists (B.P.C.L and J.T), who were blinded to the results of the original 
assessment. Discrepancies between the two assessors were resolved with further discussions to reach a 
consensus assessment. The Metavir Fibrosis score obtained from the second evaluation was used as the 
final reference score for comparisons with all the non-invasive tests in the study. 
5.2.5 Non-invasive markers 
 
Formulas for the non-invasive measures analysed in the study are:  
• FIB-4 = [age (yrs) x AST (U/L)] / [platelet count (x109/L) x square root(ALT(U/L))] (287)   
• APRI = 100x(AST (U/L) / upper level of normal) / platelet count (x109/L).(204) 
• API score = The sum of age score and platelet count score [age (years):<30 = 0, 30–39 = 1, 40–49 
= 2, 50–59 = 3, 60–69 = 4, >70 = 5; platelet count (109/l): >225 = 0, 200–224 = 1, 175–199 = 2, 
150–174 = 3, 125–149 = 4,<125 = 5] (289) 
• AAR = AST (U/L) / ALT (U/L). (291) 
• FI score (fibrosis index) = 8 - 0.01 × number of platelets (10⁹/L) - albumin (g/dl)(290) 
 
5.2.6 Caffeine Breath Test 
 
Seven subjects were recruited to undergo caffeine breath testing within 6 months of their liver biopsy. 
Subjects abstained from caffeine-containing products and limited alcohol consumption to 10 g for 24 h 
prior to testing. All nonessential medications were withheld for 48 h prior to testing. After an overnight 
fast, subjects ingested 2 mg/kg of [3-methyl-13C] caffeine (99% 13C), obtained as powder from 
Cambridge Isotope Laboratories (Cambridge, MA, USA) and dissolved in 30 mL of water, followed by a 
40 mL water wash of the container. The quantity of caffeine consumed was equivalent to two cups of 
coffee. Subjects sat quietly for 15 min before and throughout the CBT as physical activity influences 
endogenous CO2 production. Sixteen Paired breath samples were obtained simultaneously during 
prolonged expiration into 10 mL glass vials via straws. Samples were collected immediately prior to, and 
60 min after, caffeine ingestion. The 13C-enrichment of expired CO2 was determined by continuous flow 
isotope ratio mass spectrometry17 using an Automated 13-Carbon Breath Analyzer (PDZ Europa, 
Cheshire, UK). 13C enrichment was expressed as D, by subtracting the average pre-dose enrichment from 
the average post-dose measurement, with respect to the international (13C/12C) PDB standard, 
originating from the Pee-Dee-Belemnite, a fossil limestone of the Pee-Dee-Formation in South Carolina, 
with a 13C/12C isotope ratio of 0.0112372.18. This was then expressed per 100 mg of the original 
caffeine dose. The reference range was determined in previous studies (281, 301).  
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5.2.7 Data analysis 
 
All statistical analyses were performed using SPSS version 21.0 (IBM Inc). Continuous variables were 
analysed using linear regression and independent samples T-test.  Paired-related continuous variables 
were analysed using the paired T-test. Chi-squared test was used for categorical variables and Fisher’s 
exact test when appropriate. Multivariate analysis was performed using multiple stepwise logistic 
regression on variables found to be significant on univariate analysis. The overall accuracy of LSM in 
diagnosing histological bridging fibrosis and cirrhosis was calculated using the receiver operating 
characteristics (ROC) curve and its 95% CI. The accuracy of APRI, AAR and FIB-4, FI AND API were also 
calculated using the receiver operating characteristics curve. All statistical tests involved were two-tailed 
and statistical significant level was set at 0.05. 
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5.3 RESULTS 
 
5.3.1 Clinical data and characteristics of  the study patients 
 
The mean age of the study population was 46.1 yrs (SD 11.9) and were predmoninantly male (69%). The 
mean of the log10HBVDNA  viral load was 5.0 IU/ml (SD 2.5), ALT 121 IU/L (SD 284) and AST 79 IU/L (SD 
161). HBeAg positive patients consisted of 33/71 (46.5%) subjects.  
 
The mean bilirubin, albumin and platelet count were not elevated. The mean ETOH consumed per week 
was 4.8g (SD 10). Data for INR, alphafetoprotein, imaging, height and weight were incomplete and was 
not included in the analysis. 
 
Metavir fibrosis stage used was based on the second assessment of the liver biopsy (as described in 
5.2.4). A total of 54/71 biopsies were able to be re-assessed.. For the remainder 17 liver biopsies, the 
Metavir stage from the original biopsy assessment was used. The frequency of each fibrosis stage were 
as follows: F0=14/71 (19.7%), F1=12/71 (16.9%), F2=26/71 (36.6%), F3=14/71 (19.7%) and F4=5/71 
(7.0%). Details of the liver biopsy length and portal tracts were not routinely reported and could not be 
analysed. 
 
The number of subjects who were already being treated with antivirals was 27/71 (38.0%), while 18/71 
(25.4%) were to start treatment post Fibroscan. The remainder 25/71 (35.2%) continued to be 
monitored without antivirals. The various characteristics of the study population are summarised in 
Table 21.  
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Table 21: Clinical data of the study patients 
Clinical characteristic   
 Male  49/71 (69%) 
 Age (yrs)a 46.1 (11.9) 
 Log10HBVDNA (IU)a 5.0 (2.5) 
HBe antigen positivea 33/71 (46.5%) 
BR (µmol/L)a 13 (8) 
ALT (IU/L)a 121 (287) 
ALB (g/L)a 44 (5) 
AST (IU/L)a 79 (161) 
Platelets (x109)a 217 (50) 
ETOH (g/week)a 4.8 (10) 
  
Metavir Stage (after 2nd assessment histology assessment)   
F0 14/71 (19.7%) 
F1 12/71 (16.9%) 
F2 26/71 (36.6%)  
F3 14/71 (19.7%) 
F4 5/71 (7.0%)  
  
Treatment  Status  
Treatment current 27/71 (38.0%) 
Treatment planned, yet to be initiated 18/71 (25.4%) 
Treatment previous, since ceased 1/71 (1.4%)  
No antivirals – monitoring only 25/71 (35.2%) 
 
a. Represents the mean value (standard deviation). All other variables report the frequency 
with percentages in parentheses. 
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5.3.2 Liver Stiffness Measurement of the study population (objective 1) 
 
There were 71/73 subjects who had a valid TE. The median LSM was 6.9 kPa (IQR 5.3-10.7 kPa). The 
mean IQR/M ratio was 0.20 (SD 0.24). Sixty six out of 71 (93.0%) scans were reliable, as defined as 
having an IQR/M ratio of greater of equal to 0.30, when the LSM ≥ 7.1 kPa (55). The findings are shown 
in  
 
 
Table 22. 
 
 
 
 
Table 22: Liver Stiffness Measurement characteristics of the study population 
Fibroscan parameter  
LSM (kPa)a 6.9 (5.3-10.7) 
IQR/M ratiob 0.20 (0.24) 
Valid Scansc 71/73 (97.3%) 
Reliable scansc 66/71 (93.0%) 
Success rateb 90.4 (14.7) 
 
a. Median LSM is reported with interquartile range 
b. Mean (standard deviation) 
c. Frequency (percentage) 
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5.3.3 Diagnostic performance of Liver Stiffness Measurement for Fibrosis Stage for all 
subjects (objective 2) 
 
The Metavir stage of fibrosis and corresponding LSMs for each subject are shown as a boxplot in Figure 
24. 
 
The area under the receiver operator characteristic (AUROC) curves for LSM diagnosing F0 vs F≥1, F01 vs 
F≥2, F012 vs F≥3 and F0-3 vs F4 was calculated (Figure 25). All patients (normal and elevated ALT) in the 
study were included in this analysis.  
 
The AUROCS for diagnosing F≥1, 2, 3 and 4 were: 0.825 (95% CI 0.728-0.922, p<0.001); 0.792 (95% CI 
0.689-0.895, p< 0.001); 0.874 (95% CI 0.775-0.973, p<0.001) and 0.945 (95% CI 0.867-1.000, p=0.001) 
respectively. 
For F≥1, 2, 3 and 4, the cut-off with best diagnostic accuracy overall was determined by choosing the 
value which corresponded to the greatest sum of the sensitivity and specificity. The optimal cut-offs for 
sensitivity was chosen by selecting the coordinate on the AUROC curve that was at least 90% and with 
best corresponding specificity. The optimal cut-offs for specificity were chosen similarly.  
The LSM cut-offs with the best overall diagnostic accuracy for F≥1,2,3 and 4 were: ≥ 6.5 kPa (68.4% 
sensitivity, 92.9% specificity); ≥7.5 kPa (71.4% sensitivity, 77.8% specificity); ≥ 9.7 kPa (84.2% sensitivity, 
92.3% specificity);  ≥ 11.9 kPa (100% sensitivity, 84.8% specificity) respectively.  
The optimal sensitivity and specificity cut-offs in assessing each fibrosis stage were: F1 ≥ 4.7 kPa (93% 
sensitivity, 33.6% specificity) and F1 ≥ 6.5 kPa (68.4% sensitivity, 92.9% specificity); F2 ≥ 5.2 kPa (91.4% 
sensitivity, 36.1% specificity) and F2 ≥ 9.7 kPa (sensitivity 51.4%, specificity 94.4%); F3 ≥ 6.0 kPa 
(sensitivity 94.7%, specificity 44.2%) and F3 ≥ 9.7 kPa ( sensitivity 84.2% and specificity of 92.3%); F4  
≥11.9 kPa (sensitivity 100%, specificity 84.8%) and F4 ≥15.9 kPa (sensitivity 80.0%, specificity 97.0%). 
Table 23 below summarises the findings.   
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Figure 24: Boxplot of LSM and Fibrosis stage 
For each liver biopsy, the fibrosis stage is plotted against the LSM as a boxplot. The box represents the 
set of LSM scores between the 25-75th percentile, while the horizontal line within the box represents the 
median. The whiskers extending from the box represent the highest and lowest LSM score.    
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Figure 25: ROC curves of LSMs for F≥1, 2, 3 and 4 for patients with any ALT 
 158 
 
 
Table 23: LSM AUROCs for diagnosing F≥1, 2, 3, 4 and Optimal LSM cut-offs in all subjects 
 
  
F≥ AUROC 95% 
Confidence 
Interval 
P value (vs 
AUROC = 
0.5) 
Best Overall 
LSM kPa  
(Sn,Sp%) 
Best LSM kPa for > 
90% sensitivity, 
(Sn,Sp%) 
Best LSM kPa for > 
90% specificity: 
(Sn,Sp%) 
1 0.825 0.728-0.922 <0.001 6.5 (68.4, 
92.9) 
4.7 (93.0, 33.6) 6.5 (68.4, 92.9) 
 
2 0.792 0.689-0.895 <0.001 7.5 (71.4, 
77.8) 
5.2 (91.4, 36.1) 9.7 (51.4, 94.4) 
3 0.874 0.775-0.973 <0.001 9.7 (84.2, 
92.3) 
6.0 (94.7, 44.2%) 9.7 (84.2, 92.3) 
4 0.945 0.867-1.000 0.001 11.9 (100, 
84.8) 
11.9 (100, 84.8) 15.9 (80.0, 97.0) 
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5.3.4 Diagnostic performance of Liver Stiffness Measurement for Fibrosis Stage for normal 
ALT patients (objective 3) 
 
The AUROC curves for LSM diagnosing F0 vs F≥1, F01 vs F≥2, F012 vs F≥3 and F0123 vs F4 was calculated 
in those with normal ALT and summarised in (Figure 26).  
 
The AUROCS for diagnosing F≥ 1, 2, 3 and 4 were: 0.792 (95% CI 0.632-0.952, p=0.027); 0.762 (95% CI 
0.603-0.921, p=0.009); 0.956 (95% CI 0.868-1.000, p<0.001); and 0.909, but was not significant (95% CI 
0.801-1.000 95%, p=0.169) 
 
The LSM cut-offs with the best overall diagnostic accuracy for F≥1,2 and 3 were: ≥ 6.6 kPa (57.1% 
sensitivity, 100% specificity); ≥ 9.7 kPa (44.4% sensitivity, 100% specificity); ≥ 9.7 kPa (88.9% sensitivity, 
100% specificity).  
 
The optimal cut-offs for sensitivity and specificity respectively are as follows - F1: ≥ 4.5 kPa (9.6.4% 
sensitivity, 33.3% specificity) and ≥ 6.6 kPa (57.1% sensitivity, 100% specificity); F2: ≥ 4.7 kPa (100% 
sensitivity, 25% specificity) and ≥ 9.7 kPa (100% sensitivity 44.4% specificity); and F3: ≥ 6.0 kPa (100% 
sensitivity, 60% specificity ) and ≥ 9.7 kPa ( 88.9% sensitivity 100% specificity). Table 24 summarizes the 
findings. 
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Figure 26: ROC curves of LSM for F≥1, 2, 3 and 4 in patients with normal ALT  
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Table 24: LSM AUROCs for diagnosing F≥1, 2, 3, 4 and Optimal LSM cut-offs in Normal ALT 
subjects 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
F≥ AUROC 95% 
Confidence 
Interval 
P value (vs 
AUROC = 
0.5) 
Best Overall 
LSM kPa  
(Sn,Sp%) 
Best LSM kPa for > 
90% sensitivity, 
(Sn,Sp%) 
Best LSM kPa for > 
90% specificity: 
(Sn,Sp%) 
1 0.792 0.632-0.952 0.027 6.6 (57.1, 
100) 
4.5 (96.4, 33.3) 6.6 (57.1,100) 
2 0.762 0.603-0.921 0.009 9.7 (44.4, 
100) 
4.7 (100, 25) 9.7 (44.4, 100) 
3 0.956 0.868-1.000 <0.001 9.7 (88.9, 
100) 
6.0 (100, 60) 9.7 (88.9, 100) 
4 0.909 0.811-1.000 0.169 n/a n/a n/a 
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5.3.5 Diagnostic performance of Liver Stiffness Measurement for Fibrosis Stage for high ALT 
patients (objective 3) 
 
The AUROC curves for LSM diagnosing F0 vs F≥1, F01 vs F≥2, F012 vs F≥3 and F0123 vs F4 was calculated 
in those with elevated ALT and summarised in (Figure 27).  
The AUROCS for diagnosing F≥ 1, 2, 3 and 4 were: 0.886 (95% CI 0.751-0.982, p=0.002); 0.847 (95% CI 
0.723-0.971, p<0.001); 0.817 (95% CI 0.639-0.994, p=0.003); and 0.939 (95% CI 0.858-1.000, p=0.005). 
The LSM cut-offs with the best overall diagnostic accuracy for F≥ 1,2,3 and 4 were: ≥ 6.5 kPa (79.3% 
sensitivity, 87.5 % specificity); ≥ 7.6 kPa (88.2% sensitivity, 75% specificity); ≥ 10.5 kPa (80% sensitivity, 
85.2% specificity);  and ≥15.9 kPa (100% sensitivity, 93.9% specificity). 
The optimal sensitivity and specificity cut-offs respectively were as follows. F1: ≥ 5.8 kPa (90% 
sensitivity, 62.5% specificity) and ≥ 7.6 kPa (69% sensitivity, 100% specificity); F2: ≥ 5.8 kPa (100% 
sensitivity, 40% specificity) and ≥ 12.3 kPa (52.9% sensitivity, 95% specificity); F3: ≥ 6.0 kPa (90% 
sensitivity, 29.6% specificity ) and ≥ 12.5 kPa ( 70% sensitivity 92.6% specificity); and F4: ≥15.9 kpa 
(sensitivity 100.0%, specificity 93.9%).  
Table 25 summarizes the findings. 
 
 
 
 
 
 
 
 
 
 
 
 
  
 163 
 
 
 
 
 
 
        
                                                                                                                                                                                                                
Figure 27: ROC curves of LSMs for F≥1, 2, 3 and 4 in patients with high ALT 
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Table 25: LSM AUROCs for diagnosing F≥1, 2, 3, 4 and Optimal LSM cut-offs in high ALT 
subjects 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
F≥ AUROC 95% 
Confidence 
Interval 
P value (vs 
AUROC = 
0.5) 
Best Overall 
LSM kPa  
(Sn,Sp%) 
Best LSM kPa for 
> 90% sensitivity, 
(Sn,Sp%) 
Best LSM kPa for 
> 90% specificity: 
(Sn,Sp%) 
1 0.886 0.751-0.982 0.002 6.5 (79.3, 
87.5) 
5.8 (90.0, 62.5) 7.6 (69.0, 100) 
2 0.847 0.723-0.971 <0.001 7.6 (88.2, 75) 5.8 (100, 40.0) 12.3 (52.9, 95.0) 
3 0.817 0.639-0.994 0.003 10.5 (80.0, 
85.2) 
5.8 (100, 29.6) 12.5 (70.0, 92.6) 
4 0.939 0.858-1.000 0.005 15.9 (100, 
93.9) 
15.9 (100, 93.9) 15.9 (100, 93.9) 
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5.3.6 Optimal LSM cut offs for moderate and advanced fibrosis (objective 4) 
 
Optimal cut offs were chosen to “rule in” and “rule out” F≥2 and F≥3 were derived from the analyses 
made from the previous section. The cut off corresponding to at least 90% sensitivity with the best 
possible specificity was used to “rule out” disease. While the cut off that corresponded to at least 90% 
specificity with the best possible sensitivity was used to “rule in” disease.  The positive and negative 
predictive values were then calculated. The group of cut-offs selected was also specific to whether the 
ALT was normal or abnormal. This is summarised in Table 26 
 
Table 26: Optimal LSM cut-offs for F≥2 and F≥3 according to normal or elevated ALT 
 LSM (kPa) for F≥2 a LSM (kPa)for F≥3 a 
 Rule out  Rule in Rule out Rule in 
Normal ALT 
subjects 
4.7 (100, 25.0, 
60.0, 100)  
9.7 (44.4, 100, 100, 
61.5) 
6.0 (100, 60, 47.4, 
100) 
9.7 (88.9, 100, 
90.0, 70.3) 
High ALT subjects 5.8 (100, 40.0, 
58.6, 100) 
12.3 (52.9, 95.0, 
90.0, 70.4) 
5.8 (100, 29.6, 
34.5, 100) 
12.5 (70.0, 92.6, 
77.8, 89.3) 
a. corresponding sensitivity, specificity, positive predictive value and negative predictive value in 
parentheses 
 
Normal ALT subjects have F2 and F3 ruled out if the LSM ≤ 4.7 kPa (100% NPV) and ≤ 6.0 kPa (100% NPV) 
respectively. If LSM ≥ 9.7 kPa, then F2 or F3 (100% PPV for both) was ruled in. For subjects whose LSM 
fell in between these cut-offs (ie. 4.8 – 9.6 kPa for F2 and 6.1 – 9.6 kPa for F3), the PPV ranges between 
60-100% (F2) and 47.4-90% (F3), and the NPV ranges 61.5-100% (F2) and 70.3-100% (F3) respectively. 
Hence these LSM values are within a “grey zone” for F2 and F3, where there is not a high degree of 
certainty for an accurate diagnosis.  
Likewise, the “grey zone” for high ALT subjects was 5.9 – 12.2 kPa for F2 (PPV 58.6-90.0%, NPV 70.4-
100%) and 5.9 – 12.4 kPa for F3 (PPV 34.5-77.8%, NPV 89.3-100%) respectively.  
In summary:  
For F≥2:  
• In normal ALT subjects, it is ruled out for 8/34 and ruled in for 8/34 subjects 
• In high ALT subjects, it is ruled out for 9/37 and ruled in for 11/37 subjects 
• Overall 36/71 subjects (50.7%) were ruled out or ruled in for F≥2 
• 35/71 subjects (49.3%) could not be determined with a high degree of accuracy and are 
considered in the “grey zone” 
For F≥3 
• Normal ALT subjects, ruled out for 15/34 and ruled in for 8/34 subjects 
• High ALT subjects, ruled out for 9/37 and ruled in for 9/37 subjects. 
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• Overall 41/71 (57.7%) of subjects were ruled out or ruled in for F≥3 
• 30/71 subjects (42.3%) could not be determined with a high degree of accuracy and are in 
the “grey zone”.  
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5.3.7 Clinical, biochemical, imaging features of cirrhotic subjects compared with LSM 
(objective 5) 
 
There were 5 patients with histologically proven cirrhosis. The results of their LSM ranged from 12.0 kPa 
to 32.4 kPa. All 5/5 subjects had a derived F stage of F4 using the LSM. Childs Pugh score was 5 out of 15, 
and thus a classification of Childs A cirrhosis applied for all 5 subjects. None had any abnormalities of the 
bilirubin, albumin, INR, or platelet count.  Two subjects had recent ultrasound imaging available that 
showed no features of associated with cirrhosis, such as nodularity, portal vein dilatation, hypersplenism 
and hepatofugal flow. The results are shown in Table 27.  
 
Table 27: Comparison of clinical, biochemical, ultrasound imaging and LSM scores in histologically 
proven cirrhosis patients 
Subject Clinical 
features 
of 
cirrhosis 
Br 
(µmol/L) 
ALB 
(g/L) 
INR Childs 
Pugh 
score 
(302) 
Platelets 
(x109) 
US  LSM 
(kPa) 
LSM 
derived 
F score 
1 None 12 42 1.1 5 173 No 
cirrhotic 
features 
12.0 4 
2 None 12 43 1.1 5 196 n/a 32.4 4 
3 None 16 40 1.0 5 164 n/a 17.6 4 
4 None 4 44 1.0 5 250 n/a 29.9 4 
5 None 13 40 1.0 5 178 No 
cirrhotic 
features 
17.3 4 
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5.3.8 Summary of the comparison of the diagnostic performance of non-invasive measures 
for liver fibrosis (objective 6) 
 
The diagnostic performance of FIB-4, APRI, API, AAR and FI was evaluated by calculating each measure’s 
AUROC for detecting F≥1, 2, 3 and 4. For each non-invasive measure, the cut-offs that corresponded 
with the best diagnostic accuracy, minimum 90% sensitivity and minimum 90% specificity were 
calculated for each fibrosis stage.  
The full details of these results are presented in sections 5.3.10 – 5.3.14. A summary of the results are 
described here in this section 5.3.9. The next section of new results is 5.3.15 – Caffeine breath test.  
Overall, Fibroscan had the highest numeric AUROC for diagnosing each stage of fibrosis: F1, 2, 3, 4 
AUROC=0.825, 0.792, 0.874 and 0.945 respectively. Statistically, the AUROCs for LSM are either superior 
or equal with the other non-invasive markers across all the F stages. Compared with FIB-4, the AUROC 
for LSM was significantly higher for F≥1 (p=0.043) and F≥3 (AUROC model for FIB-4 not valid), while 
there was no statistical difference for F≥2 (p=0.733) and F=4 (p=0.432). Compared to APRI, the LSM 
AUROC was superior for F≥1 (p=0.027), F≥3 (p=0.023), and F=4 (p=0.016), while there was no difference 
for F≥2 (p=0.134). For API, FI and AAR, the AUROC comparison was either statistically inferior, inferior by 
default due to the AUROC being invalid (not significant compared to a random classification model 
AUROC=0.5) except for API in the diagnosis of F=4 (0.945 vs 0.900) in which the AUROC was numerically 
lower, but not statistically significant (p=0.492). The next best performing test was the FIB4-I: F1, 2, 4 
AUROC= 0.677, 0.711 and 0.912 respectively; followed by the APRI score: F1, 2, 3, 4 AUROC=0.672, 
0.698, 0.720 and 0.821 respectively. API only demonstrated accuracy for diagnosing F=4, AUROC=0.900. 
AAR and FI only had a valid AUROC model for F2: 0.642 and 0.684 respectively and were poor tests 
overall.   
Table 28 summarises the comparison of AUROCS for each stage of liver fibrosis for the non-invasive 
measures that have been analysed. 
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Table 28: Comparison of AUROCS of each non-invasive test for fibrosis stage 
 LSM  FIB-4  APRI  API  FI  AAR  
F ≥1 AUROC 0.825 0.677 0.672 NS NS NS 
P value Vs LSM - 0.043 0.027 n/a n/a n/a 
Vs FIB-4 0.043 - 0.989 n/a n/a n/a 
Vs APRI 0.027 0.989 - n/a n/a n/a 
Vs API n/a n/a n/a - n/a n/a 
Vs FI n/a n/a n/a n/a - n/a 
Vs AAR n/a n/a n/a n/a n/a - 
F ≥2 AUROC 0.792 0.711 0.698 NS 0.642 0.684 
P value vs LSM - 0.733 0.134 n/a 0.034 0.224 
Vs FIB-4 0.733 - 0.278 n/a 0.051 0.260 
Vs APRI 0.134 0.278 - n/a 0.420 0.894 
Vs API n/a n/a n/a - n/a n/a 
Vs FI 0.034 0.051 0.420 n/a - 0.471 
Vs AAR 0.224 0.260 0.894 n/a 0.471 - 
F ≥3 AUROC 0.874 NS 0.720 NS NS NS 
P value Vs LSM - n/a 0.023 n/a n/a n/a 
Vs FIB-4 n/a - n/a n/a n/a n/a 
Vs APRI 0.023 n/a - n/a n/a n/a 
Vs API n/a n/a n/a - n/a n/a 
Vs FI n/a n/a n/a n/a - n/a 
Vs AAR n/a n/a n/a n/a n/a - 
F =4 AUROC 0.945 0.912 0.821 0.900 NS NS 
P value Vs LSM - 0.432 0.016 0.492 n/a n/a 
Vs FIB-4 0.432 - 0.040 0.929 n/a n/a 
Vs APRI 0.016 0.040 - 0.137 n/a n/a 
Vs API 0.492 0.929 0.137 - n/a n/a 
Vs FI n/a n/a n/a n/a - n/a 
Vs AAR n/a n/a n/a n/a n/a - 
NS: AUROC model not significant, compared to a random classification model 
n/a: not applicable. No statistical comparison made as model was not significant 
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5.3.9 Diagnostic performance of FIB-4 index for Fibrosis Stage (objective 6) 
 
The FIB-4 AUROC for Fibrosis was calculated for F≥1, 2 3 and F=4 
The AUROCS for diagnosing F≥ 1, 2 and 4 were: 0.677 (95% CI 0.536-0.817, p=0.042); 0.711 (95% CI 
0.660-0.883, p<0.001); and 0.912 (95% CI 0.843-0.981, p=0.002). The AUROC for diagnosing F≥3 was not 
significant.  
The FIB4-I cut-offs with the best overall diagnostic accuracy for F≥ 1, 2 and 4 were: ≥ 1.4733 (43.9% 
sensitivity, 92.9 % specificity); ≥ 1.3427 (71.4% sensitivity, 77.8% specificity); and ≥ 1.8342 (100% 
sensitivity, 86.6% specificity). 
The optimal sensitivity and specificity cut-offs respectively were as follows. F1: ≥ 0.7298 (90% 
sensitivity, 28.8% specificity) and ≥ 1.4733 (43.9% sensitivity, 92.9% specificity); F2: ≥ 0.7761 (91.4% 
sensitivity, 25% specificity) and ≥ 1.6128 (48.6% sensitivity, 91.7% specificity); and F4: ≥ 1.8342 (100% 
sensitivity, 86.6% specificity) and ≥ 2.174 (60% sensitivity, 91.9% specificity). The summary of the AUROC 
results and cut-offs are shown in Table 29 and the corresponding AUROC curves are shown in Figure 28.  
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Figure 28: ROC curves of FIB4-Index for F≥1, 2, 3 and 4  
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Table 29: FIB4-Index AUROCs for diagnosing F≥1, 2, 3, 4 and Optimal cut-offs  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
F≥ AUROC 95% 
Confidence 
Interval 
P value (vs 
AUROC = 
0.5) 
Best Overall 
FIB 4 
(Sn,Sp%) 
Best FIB 4 for > 
90% sensitivity, 
(Sn,Sp%) 
Best FIB 4 for > 
90% specificity: 
(Sn,Sp%) 
1 0.677 0.536-0.817 0.042 1.4733 (43.9, 
92.9) 
0.7298 (90.0, 
28.6) 
1.4733 (43.9, 
92.9) 
2 0.711 0.660-0.883 <0.001 1.3427 (71.4, 
77.8) & 
1.3786 (68.6, 
80.6) 
0.7761 (91.4, 25) 1.6128 (48.6, 
91.7) 
3 0.635 0.475-0.795 0.084 n/a n/a n/a 
4 0.912 0.843-0.981 0.02 1.8342 (100, 
86.6) 
1.8342 (100, 86.6) 2.174 (60, 91.9) 
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5.3.10 Diagnostic performance of Aspartate Platelet ratio index (APRI) for Fibrosis Stage 
(objective 6) 
 
The APRI AUROC for Fibrosis was calculated for F≥1,2 3 and F=4 
The AUROCS for diagnosing F≥ 1, 2, 3 and 4 were: 0.672 (95% CI 0.534-0.809, p=0.048); 0.698 (95% CI 
0.576-0.821, p=0.004); 0.720 (95% CI 0.596-0.844, p=0.005); and 0.821 (95% CI 0.712-0.930, p=0.017). T  
The APRI cut-offs with the best overall diagnostic accuracy for F≥ 1, 2, 3 and 4 were: ≥ 0.5185 (49.1% 
sensitivity, 85.7% specificity); ≥ 0.559 (51.7% sensitivity, 83.3% specificity); ≥ 0.559 (68.4% sensitivity, 
75.0% specificity); and ≥ 0.6106 (100% sensitivity, 74.2% specificity). 
The optimal sensitivity and specificity cut-offs respectively were as follows. F1: ≥ 0.2329 (90% 
sensitivity, 14.3% specificity) and ≥ 0.559 (43.9% sensitivity, 92.9% specificity); F2: ≥ 0.286 (91.4% 
sensitivity, 33.3% specificity) and ≥ 1.174 (17.1% sensitivity, 91.7% specificity); F3: ≥0.3493 (90% 
sensitivity, 42.3% specificity) and ≥ 1.2929 (15.8% sensitivity, 90.4% specificity); and F4: ≥ .6106 (100% 
sensitivity, 74.2% specificity) and ≥ 1.3429 (20% sensitivity, 90.9% specificity). The ROC curves for APRI 
for each stage of fibrosis is shown in Figure 28. The summary of the AUROC results and cut-offs are 
shown in  
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Table 30.   
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Figure 29: ROC curves of APRI for F≥1, 2, 3 and 4  
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Table 30: APRI AUROCs for diagnosing F≥1, 2, 3, 4 and Optimal cut-offs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
F≥ AUROC 95% 
Confidence 
Interval 
P value (vs 
AUROC = 
0.5) 
Best Overall 
APRI 
(Sn,Sp%) 
Best APRI for > 
90% sensitivity, 
(Sn,Sp%) 
Best APRI for > 
90% specificity: 
(Sn,Sp%) 
1 0.672 0.534-0.809 0.048 0.5185 (49.1, 
85.7) 
0.2329 (90.0, 
14.3) 
0.559 (43.9, 92.9) 
2 0.698 0.576-0.821 0.004 0.559 (57.1, 
83.3) 
0.286 (91.4, 33.3) 1.174 (17.1, 91.7) 
3 0.720 0.596-0.844 0.005 0.559 (68.4, 
75.0) 
0.3493 (90.0, 
42.3) 
1.2929 (15.8, 
90.4) 
4 0.821 0.712-0.930 0.017 0.6106 (100, 
74.2) 
0.6106 (100, 74.2) 1.3429 (20.0, 
90.9) 
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5.3.11 Diagnostic performance of Age Platelet Index (API) for Fibrosis Stage (objective 6) 
 
The API AUROC for Fibrosis was calculated for F≥1, 2, 3 and F=4  
API was only able to reliably diagnose F4, with AUROCs for F1, 2 and 3 not being statistically significant. 
The AUROC for F4 was 0.900 (95% CI 0.821-0.979, p=0.003). The cut-off with best diagnostic accuracy 
was API≥5 (100% sensitivity, 77.3% specificity). The optimal cut-offs for sensitivity and specificity 
respectively were API≥5 (sensitivity 100.0%, specificity 77.3%) and API≥ 6 (sensitivity 60.0%, specificity 
90.9%). The ROC curves for API for each stage of fibrosis is shown in Figure 30. The summary of the 
AUROC results and cut-offs are shown in Table 31.   
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Figure 30: ROC curves of API for F≥1, 2, 3 and 4  
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Table 31: API AUROCs for diagnosing F≥1, 2, 3, 4 and Optimal cut-offs  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
F≥ AUROC 95% 
Confidence 
Interval 
P value (vs 
AUROC = 
0.5) 
Best Overall 
API (Sn,Sp%) 
Best API for > 90% 
sensitivity, 
(Sn,Sp%) 
Best API for > 90% 
specificity: 
(Sn,Sp%) 
1 0.489 0.315-0.662 0.897 n/a n/a n/a 
2 0.613 0.480-0.745 0.102 n/a n/a n/a 
3 0.517 0.343-0.691 0.825 n/a n/a n/a 
4 0.900 0.821-0.979 0.003 5 (100, 77.3)  5 (100, 77.3) 6 (60.0, 90.9) 
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5.3.12 Diagnostic performance of Fibrosis Index (FI) for Fibrosis Stage (objective 6) 
 
The FI AUROC for Fibrosis was calculated for F≥1, 2 3 and F=4 
The FI AUROC for Fibrosis was calculated for F≥1, 2 3 and F=4 
Only F≥2 had a significant AUROC, which was 0.642 (95% CI 0.511-0.774, p=0.039). The best overall cut-
off was ≥ 1.08 (91.4% sensitivity, 47.2% specificity). The optimal cut-offs for sensitivity and specificity 
respectively was ≥ 1.08 (91.4% sensitivity, 47.2% specificity) and ≥ 2.105 (22.9% sensitivity, 91.7% 
specificity). The ROC curves for FI for each stage of fibrosis is shown in Figure 31. The summary of the 
AUROC results and cut-offs are shown in Table 32.   
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Figure 31: ROC curves of FI for F≥1, 2, 3 and 4   
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Table 32: FI AUROCs for diagnosing F≥1, 2, 3, 4 and Optimal cut-offs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
F≥ AUROC 95% 
Confidence 
Interval 
P value (vs 
AUROC = 
0.5) 
Best Overall 
FI (Sn,Sp%) 
Best FI for > 90% 
sensitivity, 
(Sn,Sp%) 
Best FI for > 90% 
specificity: 
(Sn,Sp%) 
1 0.618 0.428-0.809 0.172 n/a n/a n/a 
2 0.642 0.511-0.774 0.039 1.08 (91.4, 
47.2) 
1.08 (91.4, 47.2) 2.105 (22.9, 91.7) 
3 0.608 0.464-0.753 0.165 n/a n/a n/a 
4 0.735 0.523-0.947 0.082 n/a n/a n/a 
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5.3.13 Diagnostic performance of Aspartate aminotransferase and alanine aminotransferase 
ratio (AAR) for Fibrosis Stage (objective 6) 
  
The AAR AUROC for Fibrosis was calculated for F≥1, 2 3 and F=4 
Only F≥2 had a significant AUROC, which was 0.684 (95% CI 0.559-0.808, p=0.008). The best overall cut-
off was ≥ 0.6954 (77.1% sensitivity, 63.9% specificity). The optimal cut-offs for sensitivity and specificity 
respectively were ≥ 0.5353 (91.4% sensitivity, 30.6% specificity) and ≥ 1.0571 (71.4% sensitivity, 91.7% 
specificity). The AUROCS for AAR diagnosing F≥1, 3 and F=4 were not significant. Table 33 summarises 
the findings and Figure 32 show the ROC curves.  
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Figure 32: ROC curves of AAR for F≥1, 2, 3 and 4   
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Table 33: AAR AUROCs for diagnosing F≥1, 2, 3, 4 and Optimal cut-offs  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
F≥ AUROC 95% 
Confidence 
Interval 
P value (vs 
AUROC = 
0.5) 
Best Overall 
AAR (Sn,Sp%) 
Best AAR for > 
90% sensitivity, 
(Sn,Sp%) 
Best AAR for > 
90% specificity: 
(Sn,Sp%) 
1 0.632 0.455-0.808 0.129 n/a n/a n/a 
2 0.684 0.559-0.808 0.008 0.6954 (77.1, 
63.9) 
0.5353 (91.4, 
30.6) 
1.0571 (71.4, 
91.7) 
3 0.505 0.356-0.655 0.948 n/a n/a n/a 
4 0.488 0.296-0.680 0.928 n/a n/a n/a 
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5.3.14 Diagnostic Performance of Caffeine breath test (objective 7) 
 
Each of the 7 subjects whom received a caffeine breath test had their histological fibrosis stage 
compared along with the derived fibrosis stage for each non-invasive test. Analysis in section 5.3.13 and 
5.3.14 showed AAR and FI to be failed tests due to poor AUROCs and so these were omitted. The 
derived fibrosis stage for TE, APRI, FIB4-I and API, would be determined using optimal specificity (>90%) 
cut-offs that were reported earlier in the previous sections of this chapter. For CBT, this was derived 
from previous studies (281, 301). Only F4 could only be determined with the API. Table 34 summarises 
the comparisons.  
The small sample size prevented statistically evaluation. A descriptive analysis of how well each non-
invasive measure classifies F stage was performed.  
Caffeine breath test correctly classified 4/7 cases, with 1 case misclassified by 1 stage and 2 cases 
misclassified by 2 stages. Transient Elastography correctly classified 3/7 cases misclassifying 1 case by 1 
stage, and 3 cases misclassified by 2 stages. FIB-4 had 2/7 correct classifications, misclassifying 2 cases 
by 1 stage, and 3 cases by 2 stages.  No cases were correctly classified by APRI but 2, 3 and 2 cases were 
misclassified by 1, 2 and 3 stages respectively.  
 
Table 35 outlines the correct and incorrect classifications. 
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Table 34: Comparison of fibrosis stage assessment in subjects with caffeine breath test  
 
 
 
Table 35: Misclassification of fibrosis stage by non-invasive markers compared with histology 
 CBT LSM APRI FIB-4 API 
Correctly 
classified 
4 3 0 2 1 out 2 cases 
F4 correct 
Misclassified by 
1 stage 
 
1 1 2 2  
Misclassified by 
2 stages 
2 3 3 3  
Misclassified by 
3 stages 
  2   
 
 
 
 
Subject # Histological F 
stage 
(Metavir) 
TE CBT APRI FIB-4 API 
LSM 
(kpa) 
Fa  
 
Caffeine 
Clr 
Fa  Ratio Fa index Fa Index F4 
1 1 9.0 1 1.88 1 0.308 0 1.17 0 4 N 
2 2 5.9 0 1.06 4 0.467 0 1.64 1 4 N 
3 2 5.0 0 1.69 2 0.646 1 2.39 4 7 Y 
4 2 6.7 1 0.75 4 0.342 0 1.07 0 3 N 
5 2 5.3 0 1.76 2 0.493 0 0.81 0 5 Y 
6 4 12.0 4 0.71 4 0.617 1 2.40 4 5 Y 
7 4 32.4 4 1.32 3 0.612 1 1.88 4 2 N 
a. The Fibrosis stage was derived based on the value of the corresponding non-invasive test. For TE, 
APRI, FIB4-I and API, these were derived from results in this study. For CBT, this was derived from 
previous studies (283, 303). Only F4 could be determined with the API. 
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5.3.15 Comparison of liver fibrosis staging between the initial histological assessment with a 
second assessment (objective 8) 
 
In the initial histology assessment of fibrosis of 71 cases, the number of F0, F1, F2, F3 and F4 were 12, 
18, 24, 12 and 5 respectively.  
The second assessment on 54 of these, the F0 increased from 12 to 14; F1 decreased from 18 to 12; F2 
increased from 24 to 26; F3 increased from 12 to 14; F4 remained the same at 5 cases. This is shown in 
Table 36. In the remainder 17 cases, where slides were not available for review, the result of the initial 
assessment was retained. 
Table 36: Frequency of fibrosis stage as assessed by Initial and second histological examination 
Metavir Score Number of cases on Initial 
Examination 
Number of cases after second 
examination  
0 12 14 
1 18 12 
2 24 26 
3 12 14 
4 5 5 
 
A total of 24 of 54 (44.4%) cases were restaged a different fibrosis stage. A difference of one stage was 
found in 19/54 (35.2%), two stages in 2 (3.7%) cases and three stages was 1 case (1.9%). Two cases 
(3.9%) cases were considered inadequate samples on re-evaluation.   
The intraclass correlation coefficient was calculated using the Cohen’s K to determine the level of 
agreement between original and reference histological assessment of the Metavir Fibrosis score. There 
was only moderate agreement: K =0.457, p<0.001.  
Construction of 2x2 tables for the initial and review histological assessment was done. The number of 
true positives, true negatives, false positives and false negatives was entered into the 2x2 table. The 
initial histological assessment was compared against the second assessment being used as the reference 
standard as discussed in section 5.2.4. The sensitivity, specificity, positive predictive value and negative 
predictive value of the first histological assessment for each stage of fibrosis were then derived.  
The original histological assessment had high specificity (95%, 91.7% and 98%), for F0 (38/40: true 
negatives out of total negatives), F3 (44/48: true negatives out of total negatives) and F4 (49/50: true 
negatives out of total negatives) respectively. Specificity for F1 was good (84.4%: 27/32 true negatives 
out of total negatives), but only fair for F2 (77.8%: 35/45 true negatives out of total negatives).  
Sensitivity for F2 was good at 88.9% (8/9 true positives over total positives). However, sensitivity for F0, 
F1, and F4 were poor at 64.3% (9/14 true positives over total positives), 54.5% (12/22 true positive over 
total positives) and 66.7% (2/3 true positives over total positives) respectively.  The sensitivity for F3 was 
extremely poor at 16.7% (1/6 true positives over total positives. Table 37 summarises the diagnostic 
performance of the original assessment against the reference histological assessment.  
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Table 37: Diagnostic performance of initial histological assessment using the 2nd assessment 
as reference 
 F0 F1 F2 F3 F4 
Sensitivity (%) 64.3 54.5 88.9 16.7 66.7 
Specificity (%) 95.0 84.4 77.8 91.7 98.0 
Positive Predictive value (%) 81.8 70.6 44.4 20.0 66.7 
Negative Predictive value (%) 88.4 73.0 97.2 89.8 98.0 
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5.3.16 Summary of the Main Findings 
 
• Successful Fibroscan can be performed to measure liver stiffness in hepatitis B patients with 
97% having valid scans, and of those 93.7% having reliable scans.   
• LSM had excellent diagnostic performance for F≥3 and F=4. AUROC curves for F≥1, 2, 3 and 4 
were 0.825 (95% CI 0.728-0.922, p<0.001), 0.792 (95% CI 0.689-0.895, p< 0.001), 0.874 (95% CI 
0.775-0.973, p<0.001) and 0.945 (95% CI 0.867-1.000, p=0.001) respectively. 
• Using ALT level specific LSM Cut-offs, F≥2 and F≥3 can be diagnosed or excluded with a very high 
degree of certainty (>90%)  in 49.3% and 57.7% respectively.  
• LSM was able to diagnose 5/5 cases of biopsy proven F4 cirrhosis, in which these patients had 
no clinical or imaging features.  
• Fibroscan was the best non-invasive measure for every stage of fibrosis when compared with 
FIB-4I, APRI, API, AAR and FI.  
• In a small sample of 7 patients, caffeine breath tests performed well compared with other non-
invasive tests.  
• There was only moderate agreement between the first and second histological assessments of 
Metavir fibrosis stage (K =0.457, p<0.001) There was a disagreement in 44.4% of liver biopsy 
assessments, with a difference of classification by 1 stage being the most common.   
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5.4 DISCUSSION 
 
5.4.1 Transient Elastography in Chronic hepatitis B patients was performed reliably in 
93.7% of cases 
 
A valid LSM was obtained using TE in 97.3% of cases, with reliable LSM was obtained in 93.7% of cases. 
Overall this demonstrates that TE can be feasibly performed with a high degree of success and accuracy 
in chronic hepatitis B patients. The operators of the Fibroscan for this study were also the dedicated 
operators performing Fibroscan for the clinical service, having performed more than a combined 900 
scans, further supporting other studies where operator experience is important in obtaining a high rate 
of valid, reproducible and reliable LSM’s (53).  
 
5.4.2 Transient Elastography has good to excellent diagnostic performance for fibrosis stage 
in chronic hepatitis B  
 
In our study, F≥2 was fair AUROC = 0.792 (95% CI 0.689-0.895, p< 0.001). F≥3 was good: AUROC = 0.874 
(95% CI 0.775-0.973, p<0.001). F=4 was excellent: AUROC = 0.945 (95% CI 0.867-1.000, p=0.001).  
Marcellin found the diagnostic performance of TE to be good for F≥2 (AUROC = 0.81), and excellent for 
F≥3 and F4 (both AUROC = 0.93) (87).  
Many other studies have since assessed the diagnostic performance of TE in hepatitis B patients. A 2013 
systematic review reported the range of AUROCS for F≥2 was 0.78-0.87; F≥3 0.87-0.92 and F4 0.80-0.96 
(303). A separate meta-analysis in 2012 identified 18 studies with 2772 patients. The pooled AUROCS for 
F≥2, F≥3 and F=4 were 0.859 (95% CI 0.857–0.860), 0.887 (95% CI 0.886–0.887), and 0.929 (95% CI 
0.928–0.929) respectively (304). Our results are consistent with those observed in these reviews and 
meta-analysis.  
The performance of TE is better for detecting advanced fibrosis and cirrhosis compared to mild and 
moderate fibrosis. The AUROCs are higher as the degree of fibrosis increases, suggesting that TE is more 
accurate for latter stages of fibrosis. This was seen in the results of our study, as well as the systematic 
review and meta-analysis (303, 304). One explanation may be that LSM has stronger correlation with 
pericellular fibrosis (280) compared with periportal and perivenular fibrosis. Pericellular fibrosis occurs 
more in latter stages of fibrosis when there is formation of septa.  
 Another explanation perhaps is that LSM is a better reflection of the volume of fibrosis, rather than the 
stage of fibrosis. This, along with its implications, is discussed in 5.4.11.  
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5.4.3 Patients with elevated ALT have higher LSM cut-offs by factor of 1.3  
Patients who have elevated ALT have higher optimal LSM cut-offs to diagnose the same stage of fibrosis. 
The optimal cut-offs for F≥3 and F4 for all patients (normal and high ALT included) were 9.7 kPa and 11.9 
kPa respectively.  For high ALT patients, the optimal LSM cut-offs for F≥3 was 10.5 kPa and F4 15.9 kPa. 
Therefore, the value of the cut-offs in high ALT patients need to be increased by approximately a factor 
of 1.3x, which is identical to reports by Wong et al (280).  
Wong’s study had reported a reduction in the diagnostic performance of TE in patients with high ALT 
compared to patients with normal ALT (280). In our study, we did not observe any consistent difference.  
The AUROC was superior for F≥1, F≥2 and F4 but inferior for F≥3 in patients with high ALT. Our study 
only had 37 subjects with high ALT and 34 subjects with normal ALT.  The lack of conclusive findings may 
be due to the small study population.   
 
5.4.4 Variation in optimal LSM cutoffs  
 
Defining the cut-offs for fibrosis stages has remained an area of ongoing debate. The lack of universally 
accepted cut-offs has significant implications when interpreting TE results (305). In our study the optimal 
LSM cut-off values for F≥2, 3 and 4 were 7.5 kPa, 9.7 kPa and 11.9 kPa respectively. Other studies have 
reported cut-offs for F≥2, 3 and 4 that range: 5.2 -8.5 kPa, 8.1 - 10.5 kPa and 10.3 – 12.9 kPa respectively 
(306-311).  
The variation in LSM cut-offs is likely due to differences in study factors. There are differences in the 
population studied, quality of the liver biopsies obtained, histology assessment and TE operator 
expertise.  
This issue is not unique to TE and exists for many clinical investigations. For instance, it is common for 
the ALT level, to have slightly different reference ranges when reported by different laboratories.  Over 
time, it is common practice for laboratories to revise reference values as updated data becomes 
available. The situation is analogous for LSM cutoffs diagnosing fibrosis stage and so the approach 
should be no different.   LSM cut-offs that are locally derived are most likely to accurately represent the 
fibrosis stage for that particular population and should be applied where available. However, since liver 
biopsy studies are not easily performed, local experts should determine which cut-offs to adopt from 
available studies, taking into account factors such as the demographic and data quality.  
There is no published data for Australian patients for LSM cut-offs in CHB fibrosis. Although there has 
been several studies already that compare TE with liver biopsy in CHB patients, there is still value in 
determining cut-offs in our local population. These are likely to be the most accurate for our local clinical 
practice.  
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5.4.5 Dual liver stiffness measurement cut-offs for diagnosing moderate and advanced 
fibrosis and the grey zones between cut-offs. 
 
The most rational way to use noninvasive methods for diagnosing liver fibrosis is to determine the range 
of values where there is high accuracy, and to reserve the use of liver biopsy only when the accuracy is 
not at an acceptable level. To maximize the use of TE, a high sensitivity cut-off (which has a high NPV 
and effectively rules out the stage of fibrosis in question), and a high specificity cut-off (which has a high 
PPV and effectively rules in the stage of fibrosis in question), should be applied. Only LSM scores that fall 
in between low and high cutoffs, the so called “grey zone” cannot be classified with a high enough level 
of accuracy, and thus a liver biopsy should be considered.   
Due to the fact that ALT affects LSM cut-offs, we devised separate sets of dual cut-offs and 
corresponding grey zones for patients with normal ALT and high ALT. For normal ALT, the grey zones for 
F≥2 were 4.8 - 9.6 kPa and F≥3 was 6.0 - 9.7 kPa. For high ALT patients, the grey zone for F≥2 was 5.8 - 
12.3 kPa and F≥3 was 5.8 - 12.5 kPa. Patients with LSM scores that fall within these grey zones means it 
is not possible to rule in or rule out F≥2 or F≥3 with a high degree of certainty. In the study cohort, 
50.7% and 42.3% of patients fell within the grey zone range for F2 and F3 respectively. Thus TE was able 
to rule in or rule out F2 and F3 accurately in 49.3% and 57.7% of patients respectively in the study, 
avoiding the need for a liver biopsy.    
Other studies have also recognized the need for dual cut-offs. Chan et al (88) proposed grey zone cutoffs 
for F3 in normal ALT and high ALT patients to be 6.0 - 9.0 kPa and 7.5 - 12.0 kPa respectively. TE was able 
to rule in or rule out F3 in 62% and 58% of normal and abnormal ALT subjects respectively (88).  
In our study, we used LSM cut-offs with slightly higher sensitivity and specificity, leading to the grey 
zones being wider. Hence we had a slightly greater proportion of subjects whose LSM scores were 
classified in the grey zone. If the grey zones in Chan’s paper were applied, the proportion of those who 
can be accurately ruled in/out for F3 increases from 57.7% to 67.6%, but at the cost of lower sensitivity 
and specificity.   
TE was able to diagnose F3 accurately in 57.7%, which meant 42.3% of subjects did not require a liver 
biopsy. In clinical practice, the proportion of CHB patients avoiding a liver biopsy may actually be even 
greater.  Guidelines from AASLD, EASL and APASL recommend antiviral therapy when there is 
persistently high ALT (259, 267, 271, 272) which is irrespective of the fibrosis stage.  A grey zone LSM 
would cause some uncertainty regarding whether these patients truly have F3, but performing a liver 
biopsy for clarification would not change the indication for antiviral therapy. Since liver biopsy is unlikely 
to change management, many clinicians may feel it is unnecessary in these circumstances.   
The instances where a liver biopsy is still needed to determine need for antiviral therapy after TE has 
been performed was investigated by this author with other local researchers. After determining the 
number of patients with LSMs within Chan’s grey zones and excluding those with persistently elevated 
ALT, only 9/47 (19.1%) patients would still require a liver biopsy to clarify whether antiviral treatment 
was indicated. TE assessment allows for the majority of CHB patients to avoid having a liver biopsy 
which means a reduction in associated costs estimated to be $AUD 74 214 per annum for the local 
institution (312).   
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5.4.6 Diagnosing compensated cirrhosis with transient elastography 
 
All cases (5 out of 5) were diagnosed with cirrhosis by TE while having no overt clinical, biochemical or 
imaging abnormalities. These findings confirm the excellent diagnostic capability for F4 that has been 
reported by  this study (AUROC = 0.945) and others (303). Identifying those with cirrhosis using TE will 
allow for the monitoring of the severe complications of HCC and varices and reduce mortality. 
 
5.4.7 Transient Elastography compared with FIB4-I, APRI, API, AAR and FI 
 
APRI, API, AAR and FI were originally developed for chronic hepatitis C patients (204, 288, 290, 313), 
while FIB4-I was first developed for a HCV-HIV co-infected cohort (287) . The diagnostic accuracy of TE 
was overall equal or superior compared to these other noninvasive measures for fibrosis stages 1 
through to 4.  This was followed by FIB-4 and APRI. The API was only able to diagnose F4, while AAR and 
FI were poor tests for fibrosis or cirrhosis in CHB- see Table 28. 
An early validation study for FIB4-I in 668 CHB patients demonstrated good results, with the reported 
following AUROCS: F≥2 = 0.865, F≥3 = 0.910 and F4 = 0.926 (314). However, these superior results have 
not been replicated. A meta-analysis of 34 studies and 8855 patients assessed the performance of FIB4-I 
to have AUROCS up to 0.18 lower - F2: AUROC =0.82 (95% CI 0.77-0.86), F3: 0.73 (95% CI 0.66 - 0.80) and 
F4: 0.84 (95% CI: 0.77-0.92)(315). Our study results for the diagnostic performance of FIB4-I are similar 
with the meta-analysis results – see Table 29. 
The aforementioned meta-analysis also examined the diagnostic performance of APRI for fibrosis stage 
in CHB patients. The reported AUROCs for F2, 3 and 4 were: 0.74 (95% CI 0.70-0.78); 0.78 (95% CI 0.75-
0.82) and 0.73 (95% CI 0.68-0.80) respectively (315). Our study findings for the performance of APRI are 
also similar with the meta-analysis - see Table 30. 
The use of API in CHB patients has a reported diagnostic performance for F4: AUROCs= 0.77-0.93 (285, 
314, 316). Only 2 other studies have reported that API has diagnostic validity to assess other fibrosis 
stages: AUROC= 0.77 for F2 (317) and AUROC = 0.90 for F3 (314). Our results which show API is only 
valid to diagnose F4 is consistent with the literature – see Table 31. 
AAR is an attractive marker because of its simplicity. However, a study of 1543 CHB patients reported 
AAR to have poor performance in diagnosing fibrosis. The AUROCs for F2, 3 and 4 were 0.57, 0.62 and 
0.64 respectively (318). Another study of 406 CHB patients reported slightly better performance: AUROC 
= 0.772 for F4 (319). But another study of 380 CHB patients reported that AAR to has no significant 
relationship with the degree of fibrosis and was concluded to be not useful in estimating fibrosis stage 
(320). AAR was also found to be a poor test in our study – see Table 33. 
At the time of writing, no other studies have described the use of FI for diagnosing fibrosis in chronic 
hepatitis B. Our findings suggest that it is not a useful test for fibrosis –see Table 32. 
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5.4.8 Caffeine breath test shows promising results 
 
CBT performed well when compared to TE and the other non-invasive measures in our small cohort. 
However, the utility of CBT is restricted by being relatively more labour intensive, time consuming and 
requiring a supply of radioactive 13C. CBT can have false positives due to recent smoking and intake of 
caffeine containing products.  TE is a more practical tool, and so CBT may need to demonstrate a 
significantly superior performance either alone or in combination with TE in order to gain widespread 
acceptance.   
 
 
5.4.9 Transient Elastography compared with other prominent non-invasive assessment of 
fibrosis in chronic hepatitis B patients – an updated overview 
 
There have been several recent developments for non-invasive markers of fibrosis in CHB. Of all these, 
the Fibrotest (FT) has been the second most widely studied behind TE. A meta-analysis by Poynard in 
2011 (321) analysed 1842 CHB patients with liver biopsies across 8 studies and compared FT with LSM (5 
studies, 618 patients). For the diagnosis of advanced fibrosis F3, AUROC was 0.84 (0.79–0.86) for FT and 
0.89 (0.83–0.96) for LSM. Although TE had a numerically superior AUROC, there was no statistical 
difference. A later head to head comparison in 179 Australian and French CHB patients of FT with 
hepascore and other serum based markers found that FT was inferior and only had an AUROC of 0.72 
compared with hepascore AUROC 0.83 (322). On the other hand, a more recent head to head 
comparison of 194 Korean CHB patients between FT and LSM found AUROCs of FT were 0.903, 0.907, 
and 0.866, comparable to those of LSM: 0.873, 0.897, and 0.910 for F≥2, 3 and 4 respectively. This study 
reported combining the 2 markers by multiplying the FT and LSM produced the best AUROCs: 0.941, 
0.931, and 0.929 for F≥2, 3, and 4, respectively (308).  
Of the remaining potential non-invasive measures, a review by Chen (303) attempted to identify quality 
markers  by setting criteria that it must have independent  validation, and have a diagnostic accuracy of 
AUROC > 0.85. Tests that fulfilled these criteria include the Forns index, Hepascore, Fibrometer, Zeng 
Index, Hui Index, API and FIB4-I. The latter 2 are inferior to TE which was also demonstrated in our study 
(see 5.4.9). For the other markers, the range of their reported diagnostic performance for each stage of 
fibrosis are as follows: F≥2 (AUROC: 0.72-0.81), F≥3 (AUROC: 0.75-0.89) and F4 (0.89-0.93). Results are 
promising, but more studies are required for these markers. None are close to the level of repeated 
validation that TE has received. Further research into combining the best non-invasive markers for 
fibrosis in CHB patients may reveal potentially even more accurate combinations.  
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5.4.10 Variability in histological assessment of fibrosis staging   
 
Our study highlights interobserver variability that can occur in liver histology assessment. Using a second 
histological assessment as the reference, the first assessment classified almost half (44.4%) differently. 
The intra-class correlation coefficient was found to only be at a moderate level (k=0.457, P< 0.001).  
Inter-observer variability has been reported widely in the literature and is estimated to account for 15-
33% of the variation (41, 42, 45). Higher levels of variability (49.9%) have been demonstrated when 
comparing fibrosis stage assessment between non specialist community pathologist and academic 
hepatopathologists  in chronic hepatitis C patients (46). We report similar findings in this hepatitis B 
cohort.  
The primary issue of misclassification in our study was under-staging disease especially at the advanced 
stages F3 and F4. There were 6 true cases of F3, but 5 assessments made an underestimation. There 
were 3 true cases of F4, with 1 assessment making an underestimation. Despite our overall small 
number of cases, and the lack of data on biopsy quality, it does highlight the limitation in using liver 
biopsy as a gold standard.        
 
5.4.11 Problems with comparing the LSM against liver biopsy   
 
The diagnostic performances of non-invasive markers are compared against the reference standard of 
liver biopsy. However, its inaccuracy subsequently limits the accuracy of any non-invasive markers that 
is being compared against biopsy for the staging of fibrosis. Our study has only highlighted the degree of 
inter-observer variability that may occur. There can also be inaccuracy stemming  from inadequate 
biopsy length (43)  and patchy disease (41). Because of these limitations, some experts feel that an 
AUROC >0.90 cannot be truly achieved (200), and that  that non-invasive fibrosis tests with an AUROC of 
0.85-0.90 may be as good as liver biopsy for staging liver fibrosis (323).  
Another issue is that the LSM, which is a scale variable, awkwardly compares with fibrosis stage, which is 
a categorical variable. While this comparison is commonly performed, some claim this to be flawed 
(324). Fibrosis staging is a qualitative morphological assessment of the distribution of fibrosis. The mix of 
features in the qualitative description does not include any component that assesses the quantitative 
amount of fibrosis in each stage. Although the quantity of fibrosis increases, the criteria for the diagnosis 
of increasing stages depend primarily on where fibrosis is located and distributed within the hepatic 
lobules. The fibrosis quantity for progressive fibrosis stages do not increase linearly or in a proportionate 
manner. For instance, stage 4 fibrosis does not imply twice the fibrosis quantity of stage 2 fibrosis.  
This can be well illustrated by the relationship between Ishak fibrosis stage and the collagen 
proportionate area (CPA) which is a measure of the quantity of fibrosis. The CPA and Ishak score clearly 
do not have a linear relationship (see Figure 33). They are related, but in the end are different 
evaluations.  
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Figure 33: Collagen Proportionate Area and Ishak stage  
From Standish 2006 (324) 
 
As mentioned in 5.4.2, LSM correlates better with latter stages of fibrosis rather than earlier stages of 
fibrosis. Wong et al’s (280) study that shows LSM correlates better with pericellular fibrosis is only partly 
the answer. The over-arching reason for the poor correlation is that the relationship is not linear or 
proportional between each stage. In the figure, fibrosis quantity is observed to increase minimally in the 
early stages (Ishak 0 to 2), before the steepness of the slope increases between Ishak 2 and 3. The slope 
becomes increasingly steeper from Ishak 3 to 4 and again from Ishak 4 to 5. This explains why the LSM 
interval for the early stages of fibrosis are close together, but then become much wider in the latter 
stages.  This observation is found consistently in all TE studies that aim to define cut-offs for each 
fibrosis stage. Our study also illustrates this observation very well. The cut-offs for F1, 2, 3 and 4 are 6.5 
kPa, 7.5 kPa, 9.6 kPa and 11.9 kPa respectively. The corresponding interval between each cut-off is 1 
kPa, 2.1 kPa and 2.3 kPa. As the gap between cut-offs are much smaller for earlier stages of fibrosis, the 
margin in which the LSM must fall within to reflect the fibrosis stage also becomes much smaller. Thus, 
small differences in the LSM at these intervals become more significant. Hence the LSM is not as 
accurate for diagnosing earlier stages compared to latter stages of fibrosis.   
It follows that a much better comparison of LSM can be made with a quantitative measure of fibrosis 
rather than the fibrosis stage. Methods for histologically quantifying liver fibrosis are still in 
development. The most appropriate and practicable method appears to be using computer assisted 
imaging analysis (IA) of histologically stained sections. IA uses segmentation of digital images to measure 
the area of collagen and the area of tissue, producing a ‘‘fibrosis ratio’’ or collagen proportionate area 
(CPA).  
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Early studies show that LSM correlates better with CPA rather than fibrosis stage. Isgro et al. has 
demonstrated that LSM is better correlated with CPA in CHB patients (r2=0.61) than to Ishak staging 
(r2=0.52) (325).  
Despite being an awkward comparison, prominent journals still publish studies that compare TE and 
other non-invasive markers with the histological fibrosis stage. CPA and similar measures of fibrosis 
volume are not commonly performed. At its core, fibrosis stage is still the most established and 
validated method of assessing fibrosis severity. Comparing non-invasive measures against the fibrosis 
stage is entrenched because the fibrosis stage has prognostic significance. While quantitative fibrosis 
measures such as CPA are a more scientifically sound method of comparison; it is largely an unknown 
quantity to most clinicians. Few data exists that allow us to make prognostic assumptions based on the 
CPA. Thus LSM being compared with fibrosis stage is still the most pragmatic way to determine its 
clinical significance.   
This begs the question upon whether LSM is better being considered as stand-alone marker.  Rather 
than being used as a marker for fibrosis stage, can certain LSM cut-off values be applied to imply 
clinically important outcomes? Longitudinal studies analyzing the relationship between LSM and clinical 
end points over long term follow up are required to determine the usefulness of the LSM being 
considered a stand-alone marker. The utility of TE being used in a longitudinal fashion in chronic 
hepatitis B patients is explored in the next chapter.  
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5.5 CONCLUSION 
 
Fibroscan is a reliable and accurate non-invasive tool for diagnosing fibrosis stage. It has a superior or 
equal diagnostic accuracy compared to FIB-4, APRI, API, AAR and FI for each stage of fibrosis. It has a 
particularly high diagnostic accuracy for F≥3 and F4 and reduced the need for liver biopsies in the 
majority of chronic hepatitis B patients. Liver histology was observed to have significant inter-observer 
variability.   The comparison of non-invasive markers against the imperfect “gold standard” of liver 
biopsy may underestimate the true accuracy of Fibroscan and other non-invasive markers. Correlation 
with clinically important are needed to determine the utility of the LSM beyond a marker of liver 
fibrosis.   
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CHAPTER 6:   A LONGITUDINAL STUDY OF 
TRANSIENT ELASTOGRAPHY IN CHRONIC 
HEPATITIS B PATIENTS 
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6.0 CHAPTER SUMMARY 
 
Introduction: Monitoring of liver fibrosis in chronic hepatitis B (CHB) allows for optimal timing for 
initiating antiviral therapy, assessing the response to treatment and for surveillance for cirrhotic 
complications.   There is little longitudinal data on the utility of Fibroscan LSM measurements in the long 
term follow up of CHB patients. We sought to identify which patients experienced a LSM decline, and 
determine clinical parameters associated with this change. 
Methods: Chronic hepatitis B patients who had a Fibroscan in the last 4 years were invited to have a 
follow up scan. Fibroscan was performed as previously described in chapter 1.7. Relevant clinical data 
were collected from medical records.  
Results: One hundred and twenty four patients were recruited and included in the analysis. The mean 
follow up period was 31.2 months (SD 13.1). LSM decline compared to baseline was observed in the 
following: patients who had antiviral therapy initiated 7.4 kPa (SD 3.0) vs 5.9 kPa (SD 2.5), p=0.009; 
patients who, with or without antiviral therapy, experienced HBeAg seroconversion: 8.6 (SD 3.7) kPa vs 
5.4 (SD 2.8) kPa and or experienced viral suppression: 6.2 (SD 2.5) kPa vs 4.8 (SD 2.2) kPa, p<0.001. A 
mild LSM decline occurred in patients who did not receive antiviral therapy: 5.2 (SD 2.0) kPa vs 4.6 (SD 
1.4) kPa, p=0.006. In those with persistent normal ALT (PNALT), a numerical fall in the mean LSM 
occurred, which was not statistically significant: 5.3 kPa (SD 1.8) vs 5.1 kPa (SD 1.7), p=0.353. However, 
in more than 1/3rd of patients the decline was > 1 kPa. Parameters that correlated with the change in 
LSM in those who began antiviral therapy were HBeAg seroconversion (r=0.668, p<0.001) and change in 
level of ALT (r=0.489, p<0.001). On the other hand, duration of monitoring was the parameter most 
correlated with LSM change in those who had PNALT (r=0.381, p=0.008) or were monitored and not 
given antivirals (r=0.321, p=0.007).  
Conclusions: CHB patients, who have active disease and subsequently treated with antivirals, have the 
greatest decline in LSM. This is associated with ALT normalization, HBeAg seroconversion and viral 
suppression. CHB patients who had quiescent disease and did not require antiviral treatment had a mild 
decline in LSM, while those with persistently normal ALT irrespective of treatment had a numeric but 
not significant decline in the mean LSM. The LSM change is correlated with the duration of monitoring in 
these patients. The LSM may not be an ideal tool to monitor fibrosis regression. Future studies on the 
use of the LSM should focus on its potential in being a prognostic tool for liver related morbidity and 
mortality. 
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6.1 Background 
6.1.1 Assessing liver fibrosis in chronic hepatitis B  
 
Chronic hepatitis B (CHB) affects 240 million people worldwide and causes over 780 000 deaths per year 
from cirrhosis and hepatocellular carcinoma (HCC) (93, 94). The development of liver fibrosis in CHB 
patients is an adverse prognostic factor (326).  
Treatment with antivirals results in fibrosis regression (15, 327-329) and reduces the incidence of long 
term complications of chronic hepatitis B such as HCC (330, 331). However, not all patients universally 
benefit with treatment. In up to 44%, fibrosis can remain static or may worsen (329), and in some 
patients already with advanced disease, treatment may not reduce the risk of HCC (330). Thus regular 
monitoring of fibrosis in those on treatment conveys important information about response to therapy, 
prognosis, and may be useful in guiding continued treatment and surveillance for liver related 
complications (259, 332). 
In patients who are not treated, regular fibrosis monitoring will help accurately identify patients who 
develop worsening fibrosis which may prompt antiviral therapy and surveillance for liver related 
complications (259, 332).  
Liver biopsy is the reference standard for the assessment of liver fibrosis. However, it has several 
disadvantages that have been highlighted in detail earlier (see Section 1.5 and 5.4.10). Liver biopsy is not 
an ideal method for the assessment of liver fibrosis, especially if repeated monitoring is desired. 
Transient Elastography (TE) performed with Fibroscan ® is a rapid, safe and pain free noninvasive 
method for assessing liver fibrosis and has become well-accepted by patients. In chapter 5, we 
demonstrated that Fibroscan is accurate and reliable for diagnosing fibrosis stage. It has a high 
diagnostic accuracy for F≥3 (AUROC 0.874 95% CI 0.775-0.973, p<0.001) and F4 (AUROC 0.945, 95% CI 
0.867-1.000, p=0.001), and is superior to FIB-4, APRI, API, AAR and FI. Fibroscan has one of the highest 
accuracies amongst non-invasive measures, while also being the most widely validated (303).    
 
6.1.2 The interpretation of liver stiffness decline in chronic hepatitis B patients is 
contentious  
 
There is limited data on the role of Fibroscan in long term follow up of patients with CHB. The focus has 
been primarily on the changes in LSM in response to antiviral therapy (333-336), and the role of LSM in 
prognostication of liver related mortality and morbidity (326, 337) referred to as liver related events 
(LREs).   
Reduction in LSM on treatment could be presumed to be due to fibrosis regression. But studies 
examining the changes in LSM in response to antiviral treatment have so far reported conflicting results. 
In a paired biopsy study, the reduction in LSM was found to correlate with ALT normalization and was 
unreliable in reflecting fibrosis regression (336). In contrast, 2 other studies (which excluded patients 
with elevated ALT levels) reported a reduction in LSM with antiviral therapy, concluding that it was due 
 204 
 
to fibrosis regression. The latter 2 studies confirmed fibrosis regression by performing liver biopsies in a 
limited sample of patients in their study population (334, 335). 
Further conflicting data was reported in a study of 426 CHB patients over 3 years (333). LSM decline was 
observed in patients treated with antivirals who had an elevated baseline ALT with subsequent 
normalization. However, LSM decline was not seen in those with persistently normal ALT (PNALT) who 
were treated.  On the other hand, untreated patients with raised baseline ALT with subsequent 
normalization did not experience an LSM decline, but an LSM decline was seen in untreated patients 
with PNALT. The data is inconsistent and further studies to evaluate the role of Fibroscan are needed. 
We seek to clarify these issues by analyzing the change in LSM over time in our local cohort of CHB 
patients, specifically attempting to address the effect of ALT and antiviral therapy on the LSM.  
Lastly, the few studies have also examined the prognostic value of LSM only included a total of 64 cases 
of HCC and 40 other LREs (variceal bleeding, ascites, hepatic encephalopathy) (326, 337). Thus we 
sought to describe any LREs in relation to the LSM at baseline and follow up.  
 
6.1.3 Hypothesis and specific objectives 
 
The main hypothesis is that LSM decline occurs in patients who have been treated with antivirals and 
who achieve PNALT. We also predict the LSM to decline in CHB patients who experience a decline in ALT, 
a decrease in HBV viral load and HBeAg seroconversion.  
Objective 1: To evaluate the LSM change between follow up and baseline, and to correlate this change 
with clinical parameters - in patients according to the status of their antiviral treatment  
Objective 2:  To evaluate the LSM change between follow up and baseline, and to correlate this change 
with clinical parameters - in patients with persistently normal ALT (PNALT) 
Objective3: To evaluate the LSM change between follow up and baseline according to  
• Type of antiviral therapy (for those who were treated) 
• HBeAg status and  
• HBV viral load.   
Objective 4: To describe liver related events in relation to the LSM at baseline and follow up. 
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6.2 METHODS 
 
6.2.1 Patient selection, recruitment, Fibroscan assessment and data collection 
 
All Fibroscans that were performed from August 2008 to January 2012 at Concord Repatriation General 
Hospital, Concord Sydney NSW Australia were reviewed. There were 2157 scans, of which 304 were 
performed for chronic hepatitis B patients (as defined by surface antigen positivity > 6 months). From 
January 2012 to December 2013, 166/304 patients returned for follow-up during this period of time and 
had a repeat Fibroscan. All patients were older than 18yrs and gave written informed consent. 
The performance of the Fibroscan has been described in detail earlier in this thesis (refer to section 1.7).  
Clinical data for these patients were obtained from existing medical records that were available from 
public hospital and private specialists’ rooms. Where available, data recorded include age, gender, 
alcohol intake, and any other documented chronic liver disease, imaging results, INR, liver function tests 
[bilirubin (BR), alkaline phosphatase (ALP), gamma glutamyl-transferase (GGT), alanine aminotransferase 
(ALT), aspartate aminotransferase (AST) and albumin (ALB). hepatitis B surface antigen status, hepatitis 
B E antigen status, hepatitis B DNA viral load, details of antiviral therapy, platelet count, and any liver 
disease related morbidity.  
For variable data (eg. hepatitis B DNA viral load), the value recorded was closest to the date of Fibroscan 
and not exceeding 3 months. If the parameter of interest was not evaluated within 3 months of the date 
of the Fibroscan, it was not recorded and data was considered incomplete for that subject. Clinical 
parameters corresponding to both the baseline and follow-up Fibroscan were recorded. Patients with 
complete data totaled 124/166 and were included in final analysis.  
 
6.2.3 Patient groups 
 
To determine the effect of antiviral treatment on LSM change over time, patients were categorized into 
four mutually exclusive groups. Group 1 was patients who were on no antiviral treatment. These 
patients were clinically assessed to not require antiviral treatment and were monitored without 
antivirals throughout the follow-up duration. Group 2 were patients who started treatment at the time 
of monitoring (defined as within 6 months of the baseline TE). Group 3 had prior antiviral therapy (last 
dose was greater than 6 months before the baseline TE). Lastly, group 4 was patients who were already 
on long-term antivirals (defined as being on at least 6 months of therapy prior to baseline TE) which 
were continued during the monitoring period. These groups are described in Figure 34.  
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6.2.3 Data analysis 
 
All statistical analyses were performed using SPSS version 21.0 (IBM Inc). Continuous variables were 
analysed using linear regression and independent samples T-test.  Paired-related continuous variables 
were analysed using the paired T-test. Chi-squared test and Fisher’s exact test were used for categorical 
variables when appropriate. Multivariate analysis was performed with stepwise multiple linear 
regression. Categorical variables were assigned dummy continuous variables for the purposes of 
statistically analysis. A p-value of <0.05 was considered statistically significant. 
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Figure 34: Patient Groups according to 
antiviral treatment status  
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6.3 RESULTS 
 
6.3.1 Liver Stiffness and clinical characteristics at baseline and follow up for the entire study 
cohort 
The study population had 68/124 (54.8%) patients who were male. The mean age was 47.6 (SD 10.6) yrs. 
At baseline, the mean level of liver biochemistry and platelet count were within reference limits. The 
mean baseline LSM was 5.8 kPa (SD 2.4) and the mean IQR/M ratio 19.0% (SD 11.9). Reliable LSM 
measurements were taken in 118/124 (91.2%) patients. The mean success rate was 91% (SD 15.6). 
HBeAg was positive in 36 patients (29%). The total number of patients on antiviral treatment was 42 
(33.9%) and the mean log10 HBV viral load was 3.6 IU/ml (SD 2.0).  The patient characteristics at baseline 
for the entire study cohort and for groups 1,2,3 and 4 are shown in Table 38: Clinical Characteristics of 
the entire study cohort, and subdivided into groups 1,2,3 and 4.. 
The mean time interval between the baseline and follow-up fibroscan was 31.2 months (SD 13.1, range 
6-55). There was a significant LSM decline at follow up: 5.8 (SD 2.5) kPa vs 5.1 (SD 1.9) kPa, p<0.001. The 
IQR/M ratio was higher at baseline compared to follow up, but was below the accepted reliability 
criteria threshold of ≤ 30%: 19.0 (SD 11.9) vs 15.5 (10.0), p=0.017. Furthermore, the number of reliable 
scans was not significantly different: 118/124 (95.2%) vs 122/124 (98.4%), p=0.281; nor was the success 
rate of scans 91.0% (SD 15.6%) vs 88.8% (SD19.0%), p=0.386. 
Other clinical parameters that changed at follow-up compared to baseline include the following:  
number of HBeAg positive patients decreased from 36/124 (29%) to 27/124 (21.8%), p<0.001; number 
of patients on antiviral treatment had increased from 42/124 (33.9%) to 67/124 (54%), p=0.0021; and 
log10HBV viral load decreased from 3.6 (SD 2.0) IU/ml to 2.6 (SD 1.7) IU/ml, p<0.001. There were also 
small differences that were statistically significant, but not clinically significant in the following: bilirubin 
13 (SD 6) umol/L vs 11 (SD 5) umol/L; albumin 45.4 (SD 3) g/L vs 44.6 (SD 3) g/L; and AST 35(SD 32) U/L 
vs 30 (SD 22) U/L. There was no difference between baseline and follow up levels of ALP, GGT, and ALT. 
The patient characteristics at baseline and follow up are summarised in Table 39.  
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Table 38: Clinical Characteristics of the entire study cohort, and subdivided into groups 1,2,3 and 4.  
Patient Characteristic Entire Cohort Group 1 Group 2  Group 3 Group 4 
Maleb 68/124 (54.8) 26/57 
(46.0%) 
13/25 
(52.0%) 
3/5 26/37 
(70.3) 
Agea (years) 47.6 (10.8) 50.3 (9.9) 41.6 (12.3) 37.8 (5.8) 49.2 (9.5) 
LSM (kPa)a 5.8 (2.5) 5.2 (2.0) 7.4 (3.0) 5.6 (2.3) 5.8 (2.1) 
IQR/M ratioa 19.0 (11.9) 0.20 (0.11) 0.17 (0.08) 0.26 
(0.17) 
0.17 (0.14) 
Reliable scansb 118/124 
(95.2)  
54/57 (94.7) 25/25 (100) 5/5 (100) 36/37 
(97.2) 
Success rate (%)a 91.0 (15.6) 90.1 (13.4) 94.5 (14.6) 76.1 (22) 90.6 (17.5) 
HBeAg +b 36/124 (29.0) 4/57 (7.0%)  11/25 (44%) 0/5 (0%) 20/37 
(54%) 
Antiviral treatmentb (%) 42/124 (33.9) 0/57 25/25 0/5 37/37 
BR (umol/L)a 13 (6) 12 (6) 10 (5) 16 (11) 14 (7) 
ALB (g/L)a 45 (3) 45 (2) 46 (6) 46 (4) 45 (2) 
ALP (IU/L)a 70 (19) 67 (17) 72 (23) 66 (18) 74 (20) 
GGT (IU/L)a 26 (16) 22 (15) 32 (17) 19 (14) 27 (14) 
ALT (IU/L)a 49 (73) 31 (19) 114 (142) 43 (37) 35 (21) 
AST (IU/L)a 35 (32) 27 (9) 64 (62) 27 (7) 28 (9) 
Log10HBV viral load 
(IU/ml)a 
3.6 (2.0) 3.7 (1.6) 5.2 (2.5) 3.5 (1.4) 2.5 (1.5) 
a. Continuous variables: The mean and (standard deviation) are shown.  
b. Categorical variables: The numbers and (proportions of total patients) are shown.  
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Table 39: Clinical characteristics of the entire study cohort at baseline and follow up 
Patient characteristic Baseline Follow up  P value 
Maleb 68/124 (54.8%) n/a n/a 
Agea 47.6 (10.8) n/a n/a 
LSM (kPa)a 5.8 (2.5) 5.1 (1.9) < 0.001 
IQR/M ratioa 19.0 (11.9) 15.5 (10.0) 0.017 
Reliable scansa (%) 118/124 (95.2%)  122/124 (98.4%) 0.281 
Success rate (%)a 91.0 (15.6) 88.8 (19.0) 0.386 
HBeAg +b (%) 36/124 (29.0%) 27/124 (21.8%) <0.001 
Antiviral treatment b 
(%) 
42/124 (33.9%) 67/124 (54.0%) 0.0021 
BR (umol/L)a 13 (6) 11 (5) 0.005 
ALB (g/L)a 45 (3) 45 (3) 0.012 
ALP (IU/L)a 70 (19) 70 (19) 0.952 
GGT  (IU/L)a 26 (16) 23 (14) 0.057 
ALT (IU/L)a 49 (73) 37 (40) 0.068 
AST (IU/L)a 35 (32) 30 (22) 0.028 
Log10HBV viral load 
(IU/ml)a 
3.6 (2.0) 2.6 (1.7) < 0.001 
a. Continuous variables: The mean and (standard deviation) are shown. Paired samples T-test 
was performed where applicable 
b. Categorical variables: The proportions and percentages of total patients are shown. Fisher’s 
exact test and Chi-square test was performed where applicable 
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6.3.2 Change in liver stiffness measurement from baseline compared with the change in 
other clinical parameters for the entire study cohort 
 
The change in LSM at follow up was found to have a significant association with the change in several 
biochemical and serological variables in univariate analysis. These include: ALB, ALP, GGT, ALT, AST, 
log10HBV DNA viral load; HBe antigen seroconversion; and the duration of follow-up. But in the 
multivariate analysis, the only significant correlation were the change in ALT: -12 IU/L (SD 74), r=0.489, 
p<0.001; and the HBeAg seroconversion: 9 cases (27 HBeAg positive cases at follow up compared to 36 
at baseline) r=-0.377, p<0.001. No other correlations were found. The analysis is summarised in Table 
40. 
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Table 40: Correlation of the change in clinical parameters with the change in liver stiffness for the entire study cohort 
Patient characteristic Change at follow up Correlation to change in LSM (r) P value 
Malec n/a -0.105 0.105 
Duration between LSMa (months) 31.2 (13.1) -0.153 0.045 
LSM (kPa)a 0.7 (1.8)   
HBeAg +b (# cases) -9 -0.377 <0.001d 
LogHBV viral load (IU/ml)a 1.0 (2.0) 0.350 <0.001 
Antiviral treatment b (# cases) +25 0.035 0.355 
BR (umol/L)a -1 (5) -0.055 0.274 
ALB (g/L)a -1 (4) -0.208 0.010 
ALP (IU/L)a 0 (13) 0.179 0.023 
GGT  (IU/L)a -2 (14) 0.318 <0.001 
ALT (IU/L)a -12 (74) 0.489 <0.001d 
AST (IU/L)a -5 (25) 0.430 <0.001 
a. Continuous variables: The mean (standard deviation) is shown.  
b.    Categorical variables: A dummy continuous variable was assigned for multiple regression 
c.    Baseline was compared to LSM change   
d.   Significant in multivariate analysis 
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6.3.3 Patients not treated with antivirals (Group 1) 
 
Fifty seven out of 124 patients were treatment naïve through the study period (group 1 - see 6.2.3). 
These patients were predominantly HBeAg negative 53/57 (92.9%), and had persistently normal ALT 
(PNALT) in 36/57 (61.2%) of cases. Males comprised 26/57 (46.0%) of total subjects. The mean age was 
50.3 yrs (SD 9.9), and the mean duration between baseline and follow up Fibroscans was 26.4 months 
(SD 11.3). The mean baseline ALT, AST and log10HBV viral load were: 31 IU/L (SD 19), 27 IU/L (SD 9) and 
3.7 IU/ml (SD 1.6) respectively. The rest of the liver biochemistry at baseline was within normal limits.  
At follow up, there was a significant decline in LSM: 5.2 kPa (SD 2.0) vs 4.6 kPa (SD 1.4), p=0.006. The 
LSM declined in 38/57 (67%) of subjects, and by > 1 kPa in 22/57 (39%) of subjects. There were small 
statistically significant, but clinically unimportant changes in the following parameters: : BR 12 umol/L 
(SD 6) vs 11 umol/L (SD 5), p<0.001; ALB 45 g/L (SD 2) vs 44 g/L (SD 3), p<0.001; ALP 67 IU/L (SD 17) vs 66 
IU/L (SD 16), p<0.001; GGT 22 IU/L (SD 15) vs 23 IU/L (SD 14), p<0.001; and log10HBV viral load 3.7 IU/ml 
(SD 1.6) vs 3.5 IU/ml (SD 1.7), p<0.001. The ALT and AST were not statistically different at follow up: 31 
IU/L (SD 19) vs 35 IU/L (SD 27), p=0.070 and 27 IU/L (SD 9) vs 30 IU/L (SD 10), p=0.197 respectively. The 
difference between the mean baseline and follow-up LSM and other clinical variables for group 1 is 
summarised in Table 41 
The change in LSM at follow up was found to have a significant association with male gender, duration 
between scans, and the change in ALT. But in multivariate analysis, the only associations were the 
duration between scans (r=-0.321, p=0.007) and the change in ALT (r=0.256, p=0.027). These 
relationships are shown in scatterplots below (see Figure 35 and Figure 36). A summary of the analysis 
is also shown in Table 42.  
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Table 41: Clinical characteristics of group 1 patients at baseline and follow up  
Patient Characteristic Baseline Follow up  P value 
Maleb 26/57 (46.0%) n/a n/a 
Agea (years) 50.3 (9.9) n/a n/a 
LSM (kPa)a 5.2 (2.0) 4.6 (1.4) <0.001 
IQR/M ratioa 0.20 (0.11) 0.15 (0.08) 0.231 
Reliable scansb 54/57 (94.7) 57/57 (100) 0.243 
Success rate (%)a 90.1 (13.4) 92.1 (17.3) 0.861 
HBeAg +b 4/57 (7.0%)  4/57 (7.0%) 1.000 
BR (umol/L)a 12 (6) 11 (5) <0.001 
ALB (g/L)a 45 (2) 44 (3) <0.001 
ALP (IU/L)a 67 (17) 66 (16) <0.001 
GGT  (IU/L)a 22 (15) 23 (14) <0.001 
ALT (IU/L)a 31 (19) 35 (27) 0.070 
AST (IU/L)a 27 (9) 30 (10) 0.197 
Log10HBV viral load 
(IU/ml)a 
3.7 (1.6) 3.5 (1.7) <0.001 
a. Continuous variables: The mean and (standard deviation) are shown. Paired samples T-test 
was performed where applicable 
b. Categorical variables: The proportions of total patients are shown. Fisher’s exact test and Chi-
square test was performed where applicable 
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Y-axis is the LSM change (kPa), while x-axis is the change in ALT between TE assessments. A line of best 
fit is drawn. 
  
Figure 35: Scatterplot of LSM change and ALT change in group 1 patients 
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Y-axis is the LSM change (kPa), while x-axis is the duration (months) between TE assessments. A line of 
best fit is drawn. 
 
  
Figure 36: Scatterplot of LSM change and duration between scans in group 1 patients 
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Table 42: Correlation of the change clinical parameters with the change in baseline liver stiffness in group 1 patients 
Patient Characteristic Change at follow up Correlation to change 
in LSM (r)  
P value 
Maleb n/a -0.293 0.013 
Duration between LSMa 
(months) 
26.4 (11.3) -0.321 0.007c 
HBeAg +b (cases) 0 -0.085 0.265 
Log10HBV viral load 
(IU/ml)a 
0.2 (1.4) 0.067 0.309 
BR (umol/L)a -1 (4) 0.028 0.419 
ALB (g/L)a -1 (3) -0.046 0.367 
ALP (IU/L)a -1 (12) 0.133 0.163 
GGT  (IU/L)a 1 (13) 0.032 0.407 
ALT (IU/L)a 3 (29) 0.256 0.027c 
AST (IU/L)a 3 (12) 0.212 0.057 
a. Continuous variables: The mean (standard deviation) is shown.  
b. Categorical variables: A dummy continuous variable was assigned for the multiple regression  
c. Significant in multivariate analysis 
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6.3.4 Patients started on antiviral therapy (Group 2) 
 
There were 25 out of 124 patients who were newly treated with antivirals (group 2 – see 6.2.3). There 
were 5/25 subjects treated with 48 weeks of pegylated interferon, 16/25 subjects were treated with 
entecavir and 4/25 subjects who were treated with tenofovir. Most of these patients had elevated ALT 
(23/25 subjects - 92.0%) and almost half were HBeAg positive (11/25 - 44.0%). There were 13/25 
subjects who were male (41.6%), with a mean age of 41.6 yrs (SD 12.3). The mean duration between 
baseline and follow up was 31.4 months (SD 14.0). The mean baseline ALT, AST and log10HBV viral load 
were: 114 IU/L (SD 142); 64 IU/L (SD 62) and 5.2 IU/ml (SD 2.5) respectively. The other parameters were 
within normal limits.  
There was a significant decline at follow up in the LSM: 7.4 kPa (SD 3.0) vs 5.9 kPa (SD 2.5), p=0.009. 
There was also a significant reduction in: GGT 32 IU/L (SD 17) vs 21 IU/L (SD 9), p=0.006; ALT 114 IU/L 
(SD 142) vs 50 IU/L (SD 74), p=0.005; AST 64 IU/L (SD 62) vs 37 IU/L (SD 45), p=0.005; and log10HBV viral 
load 5.2 IU/ml (SD 2.5) vs 2.2 IU/ml (SD 1.8), p<0.001. No other differences were found at follow-up in 
the other parameters. This is summarised in Table 43    
The change in LSM at follow up was found to be associated with HBeAg seroconversion, and with the 
change at follow up in ALB, GGT, ALT and AST on univariate analysis. But in multivariate analysis, the 
only association was HBeAg seroconversion (r=-0.668, p<0.001). An analysis of the clinical variables that 
were associated with the change in LSM from baseline compared follow-up for group 2 is shown in 
Table 44.  
  
 219 
 
 
Table 43: Clinical characteristics of patients of group 2 patients at baseline and follow up 
Patient Characteristic Baseline Follow up  P value 
Maleb 13/25 (52.0%) n/a n/a 
Agea (years) 41.6 (12.3) n/a n/a 
LSM (kPa)a 7.4 (3.0) 5.9 (2.5) 0.009 
IQR/M ratioa 0.17 (0.08) 0.14 (0.09) 0.751 
Reliable scansb 25/25 (100) 24/25 (96) 1.000 
Success rate (%)a 94.5 (14.6) 85.3 (20.0) 0.198 
HBeAg +b 11/25 (44%) 7/25 (28%) 0.377 
BR (umol/L)a 10 (5) 10 (4) 0.501 
ALB (g/L)a 46 (6) 44 (3) 0.306 
ALP (IU/L)a 72 (23) 68 (20) 0.301 
GGT  (IU/L)a 32 (17) 21 (9) 0.006 
ALT (IU/L)a 114 (142) 50 (74) 0.005 
AST (IU/L)a 64 (62) 37 (45) 0.005 
LogHBV viral load 
(IU/ml)a 
5.2 (2.5) 2.2 (1.8) <0.001 
a. Continuous variables: The mean and (standard deviation) are shown. Paired samples T-test 
was performed where applicable 
b. Categorical variables: The proportions of total patients are shown. Fisher’s exact test and Chi-
square test was performed where applicable 
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Table 44: Correlation of the change in clinical parameters with the change in liver stiffness for group 2 patients 
Patient Characteristic Change at follow up Correlation to change in LSM (r) P value 
Maleb n/a 0.130 0.268 
Duration between LSMa (months) 31.4 (14.0) 0.027 0.450 
HBeAg +b (# cases) -4 0.668 <0.001c 
LogHBV viral load (IU/ml)a -3.0 (2.7) 0.565 0.002 
BR (umol/L)a -1 (4) 0.145 0.245 
ALB (g/L)a -1 (6) 0.457 0.011 
ALP (IU/L)a -4 (15) 0.272 0.094 
GGT  (IU/L)a -11 (17) 0.532 0.003 
ALT (IU/L)a -63 (147) 0.605 0.001 
AST (IU/L)a -28 (45) 0.498 0.006 
a. Continuous variables: The mean (standard deviation) is shown.  
b. Categorical variables: A dummy continuous variable was assigned for the multiple regression  
c. Significant in multivariate analysis 
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6.3.5 Patients with previous antiviral therapy for a finite duration (group 3) 
 
There was only a small group of (5/124) of subjects who previously received antiviral therapy for a finite 
duration (group 3 – see 6.2.3).  There were 3 patients who were treated with 48 weeks of pegylated 
interferon, 1 patient treated with both lamivudine and pegylated interferon and 1 patient treated with 
lamivudine only. Treatment had ceased for at least 6 months prior to the baseline Fibroscan. There were 
3 males (60%), and the mean age was 37.8 yrs (SD 5.8). The mean duration between baseline and follow 
up Fibroscans was 29.4 months (SD 7.2). The mean baseline ALT, AST and log10HBV viral load was 43 IU/L 
(SD 37), 27 IU/L (SD 7) and 3.5 IU/ml (SD 1.4) respectively. The rest of the liver biochemistry was within 
normal limits.  
Group 3 patients showed a decline in LSM at follow up that approached significance: 5.6 kPa (SD 2.3) vs 
4.4 kPa (SD 1.5), p=0.055. None of the other parameters were showed a significant decline. An analysis 
of the clinical variables that were correlated with the change in LSM was not performed due to small 
numbers.  The analysis for group 3 is summarised in Table 45. 
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Table 45: Clinical characteristics of patients at baseline and follow up of Group 3 patients 
Patient Characteristic Baseline Follow up  P value 
Maleb 3/5 n/a n/a 
Agea (years) 37.8 (5.8) n/a n/a 
LSM (kPa)a 5.6 (2.3) 4.4 (1.5) 0.055 
IQR/M ratioa 0.26 (0.17) 0.14 (0.06) 0.205 
Reliable scansb 5/5 (100) 5/5 (100) 1.000 
Success rate (%)a 76.1 (22) 97 (6.4) 0.052 
HBeAg +b (# cases) 0/5 (0%) 0/5 (0%) 1.000 
BR (umol/L)a 16 (11) 10 (4) 0.160 
ALB (g/L)a 46 (4) 46 (4) 0.573 
ALP (IU/L)a 66 (18) 71 (14) 0.191 
GGT  (IU/L)a 19 (14) 20 (11) 0.849 
ALT (IU/L)a 43 (37) 28 (16) 0.341 
AST (IU/L)a 27 (7) 22 (6) 0.310 
Log10HBV viral load (IU/ml)a 3.5 (1.4) 3.3 (1.3) 0.570 
a. Continuous variables: The mean and (standard deviation) are shown. Paired samples T-test 
was performed where applicable 
b. Categorical variables: The proportions of total patients are shown. Fisher’s exact test and Chi-
square test was performed where applicable 
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6.3.6 Patients on long term antiviral therapy started prior to baseline (group 4):  
 
There were 37/124 subjects on long term with antivirals, started before the baseline scan (group 4-see 
6.2.3).  Twelve patients were maintained with entecavir monotherapy and 11 patients with tenofovir 
monotherapy. Five patients were treated with combination of entecavir and tenofovir. Lamivudine 
monotherapy was given in 4 patients and adefovir monotherapy given in 2 patients. Three patients were 
treated with combination of lamivudine and adefovir.  
There were 26 males (70.3%), a mean age of 49.2 yrs (SD 9.5), and a mean duration between baseline 
and follow up of 38.6 months (SD 13.3). Elevated ALT was present in 18/37 (48.6%) and the number of 
HBeAg positive was 20/37 (54.1%). The mean baseline ALT, AST and log10HBV viral load was 35 IU/L (SD 
21); 28 IU/L (SD 9) and 2.5 IU/ml (SD 1.5) respectively. The rest of the liver biochemistry at baseline was 
within normal limits.  
At follow up, the mean LSM did not significantly decline: 5.8 kPa (SD 2.1) vs 5.5 kPa (SD 2.1), p=0.156. 
However, the LSM decreased in 14/37 patients (38%), and in 9/37 (24%), the mean liver stiffness 
decreased by > 1 kPa. At follow up, only the log10HBV viral load showed a significant decline: 2.5 IU/ml 
(SD 1.5) vs 1.4 IU/ml (SD 0.5), p<0.001. Other parameters did not change significantly from baseline. A 
summary is shown in Table 46. 
In univariate analysis, the change in LSM was correlated with HBeAg seroconversion, and the change in 
GGT, ALT and AST. But in multivariate analysis, the only association with the change in LSM was the 
change in ALT levels (r=0.455, p<0.002). This relationship is shown in the scatterplot below (see Figure 
37 ). The analysis is shown in Table 47.  
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Table 46: Clinical characteristics of patients at baseline and follow up of Group 4 patients 
Patient Characteristic Baseline Follow up  P value 
Maleb 26/37 (70.3) n/a n/a 
Agea (years) 49.2 (9.5) n/a n/a 
LSM (kPa)a 5.8 (2.1) 5.5 (2.1) 0.156 
IQR/M ratioa 0.17 (0.14) 0.18 (0.13) 0.754 
Reliable scansa 36/37 (97.2) 36/37 (97.2) 1.000 
Success rate (%)a 90.6 (17.5) 84.9 (20.9) 0.200 
HBeAg +b 20/37 (54%) 15/37 (40%) 0.352 
BR (umol/L)a 14 (7) 13 (6) 0.298 
ALB (g/L)a 45 (2) 45 (2) 0.556 
ALP (IU/L)a 74 (20) 75 (22) 0.642 
GGT  (IU/L)a 27 (14) 25 (17) 0.339 
ALT (IU/L)a 35 (21) 34 (20) 0.812 
AST (IU/L)a 28 (9) 26 (8) 0.377 
LogHBV viral load 
(IU/ml)a 
2.5 (1.5) 1.4 (0.5) <0.001 
a. Continuous variables: The mean and (standard deviation) are shown. Paired samples T-test 
was performed where applicable 
b. Categorical variables: The proportions of total patients are shown. Fisher’s exact test and Chi-
square test was performed where applicable 
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Y-axis is the LSM change (kPa), while x-axis is the change in ALT between TE assessments. A line of best 
fit is drawn. 
 
  
Figure 37: Scatterplot of the change in LSM and change in ALT in group 4 patients 
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Table 47: Correlation of the change in clinical parameters with the change in liver stiffness for group 4 patients 
 
Patient Characteristic Change at follow up Correlation to Change 
in LSM (r) 
P value 
Maleb n/a 0.144 0.197 
Duration between LSMa 
(months) 
38.6 (13.3) -0.104 0.270 
HBeAg +b (# cases) -5 -0.244 0.073 
LogHBV viral load 
(IU/ml)a 
1.03 (1.43) 0.181 0.142 
BR (umol/L)a -1 (6) -0.070 0.340 
ALB (g/L)a 0 (3) 0.024 0.443 
ALP (IU/L)a -1 (14) 0.077 0.325 
GGT  (IU/L)a -2 (10) 0.304 0.034 
ALT (IU/L)a -1 (23) 0.455 0.002c 
AST (IU/L)a -1 (10) 0.453 0.002 
a. Continuous variables: The mean (standard deviation) is shown.  
b. Categorical variables: A dummy continuous variable was assigned for the multiple regression 
c.  Significant in multivariate analysis  
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6.3.7 Patients in study cohort with persistently normal ALT 
 
To clarify whether the LSM decline is influenced by other factors other than the ALT, patients who have 
persistently normal ALT (PNALT) were identified from the entire study cohort, irrespective of whether 
they were treated or not treated with antivirals. The level of ALT taken as the upper limits of normal was 
30 IU/L for males and 19 IU/L for females. A total of 43 subjects were identified as having PNALT.  Of 
these, 21/43 (49%) patients did not require therapy and remained treatment naïve (group 1 – see 6.2.3), 
2/43 were started on antiviral therapy (group 2), 2/43 had past antiviral treatment for a finite duration 
(group 3) and 18/43 were treated with long term antiviral therapy started before baseline (group 4).  
There was no difference in the LSM at baseline compared to the LSM at follow up: 5.3 kPa (SD 1.8) vs 5.1 
kPa (SD 1.7), p=0.353.  There were small clinically insignificant differences in the following parameters:  
ALT 21 U/L (SD 5) vs 27 U/L (SD 12), p = 0.002; AST 21 U/L (SD 4) vs 25 U/L (SD 4), p < 0.001; and 
log10HBV DNA viral load 2.7 IU/ml (SD 1.5) vs 2.4 IU/ml (SD 1.4), p = 0.028. No other factors showed any 
significant change. The findings are presented in Table 48. 
Although, the overall mean liver stiffness between baseline and follow up was not significantly different 
(mean difference LSM = 0.3 kPa, SD 1.6, p=0.353), the mean liver stiffness decreased in 19/43 cases, and 
by > 1 kPa in 15/43 patients. 
The only variable found to be associated with the change in the LSM was the duration of monitoring (r=-
0.381, p = 0.008). The scatterplot diagram with the line of best fit to demonstrate this relationship is 
shown in  
 
 
 
 
 
 
 
 
 
 
 
Figure 38. 
No significant association was found with the change in any of the other clinical parameters. A summary 
of the analysis is shown in Table 49. 
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Table 48: Clinical characteristics of normal ALT patients at baseline and follow up and analysis of the difference 
 
Patient characteristic Baseline Follow up  P value 
Maleb 33/43 n/a n/a 
Age (yrs) 49.4 (10.6) n/a n/a 
LSM (kPa)a 5.3 (1.8) 5.1 (1.7) 0.353 
IQR 1.1 (0.9) 0.8 (0.9) 0.068 
Reliable scansa    
Success rate (%)a 88.6 (15.2) 93.3 (10.4) 0.120 
HBeAg +b 10/43 (23%) 9/43 (21%) 1.000 
Antiviral treatment b 21/43 23/43 0.829 
BR (umol/L)a 13 (6) 12 (6) 0.202 
ALB (g/L)a 45 (3) 45 (2) 0.232 
ALP (IU/L)a 70 (20) 70 (17) 0.682 
GGT  (IU/L)a 20 (10) 21 (14) 0.269 
ALT (IU/L)a 21 (5) 27 (12) 0.002 
AST (IU/L)a 21 (4) 25 (4) <0.001 
LogHBV viral load 
(IU/ml)a 
2.7 (1.5) 2.4 (1.4) 0.028 
a. Continuous variables: The mean and (standard deviation) are shown. Independent samples T-
test was performed where applicable 
b. Categorical variables: The proportions of total patients are shown. Chi-square test was 
performed where applicable 
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Table 49: Correlation of the change in clinical parameters with the change in liver stiffness in persistently normal ALT 
patients 
Patient characteristic Change at follow up Correlation to change 
 in LSM (r)  
P value 
Malec n/a -0.121 0.228 
Duration between LSMa 
(months) 
30.7 (14.1) -0.381 0.008 
HBeAg +b (#cases) -1 -0.191 0.119 
Log10HBV viral load 
(IU/ml)a 
0.4 (1.0) -0.184 0.128 
Antiviral treatment b (# 
cases) 
+2 -0.161 0.143 
BR (umol/L)a -1 (5) 0.084 0.303 
ALB (g/L)a -1 (3) 0.045 0.392 
ALP (U/L)a -1(12) -0.067 0.341 
GGT  (U/L)a 1 (7) 0.248 0.061 
ALT (U/L)a 6 (12) 0.093 0.284 
AST (U/L)a 3 (5) 0.139 0.197 
a. Continuous variables: The mean (standard deviation) is shown.  
b. Categorical variables: A dummy continuous variable was assigned for multiple regression  
c. Baseline was compared to LSM change 
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Figure 38: Scatterplot of LSM change and duration for PNALT patients 
Y-axis is the LSM change (kPa), while x-axis is the duration (months) between TE assessments. A 
line of best fit is drawn. 
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6.3.8 Change in liver stiffness at follow up according to specific antiviral therapy  
 
The mean LSM at baseline and follow-up according to the type of antiviral therapy is shown in Table 50. 
Only entecavir use was associated with a statistically significant decline in LSM from 6.6 (2.7) kPa to 5.7 
(1.6) kPa (p=0.030). Pegylated interferon and tenofovir treated patients had a numerical decline in LSM 
that approached statistical significance.   
 
 
Table 50: Antiviral therapy and LSM change between baseline and follow up 
Antiviral N* Baseline LSM (kPa) Follow up LSM (kPa) P value 
pegylated interferon 14 6.9 (2.7) 5.7 (2.2) 0.081 
lamivudine 28 5.7 (2.2) 5.5 (2.1) 0.369 
adefovir 17 5.7 (2.4) 5.4 (2.4) 0.538 
entecavir 33 6.6 (2.7) 5.7 (2.3) 0.030 
tenofovir 22 5.6 (1.7) 5.1 (1.6) 0.084 
Paired samples t-test was performed. The standard deviation is shown in the parentheses. 
* Some patients had received more than 1 form of antiviral therapy 
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6.3.9 Change in liver stiffness at follow up according to hepatitis B e antigen for entire study 
cohort 
The mean LSM at baseline and follow up according to HBeAg status is shown in Table 51. HBeAg positive 
patients who underwent seroconversion had a significant decline in LSM at follow up: 8.6 (SD 3.7) kPa vs 
5.4 (SD 2.8) kPa, p=0.007. Patients who were persistently HBeAg negative also had a significant 
decrease: 5.6 (SD 2.3) kPa to 5.1 (SD 2.0) kPa, p=0.004. Patients who were persistently HBeAg positive 
had a decline in LSM that approached statistical significance: 5.6 (SD 1.8) kPa vs 5.0 (SD 2.0) kPa, 
p=0.054). 
 
  
Table 51: Hepatitis B e antigen status and Liver Stiffness at baseline and follow up 
HBe Antigen Status Cases Baseline LSM (kPa) Follow up (kPa) P value 
HBe Antigen Positive 
at baseline, 
seroconversion to 
negative by follow up 
9 8.6 (3.7) 5.4 (2.8) 0.007 
HBe Antigen Positive 
at baseline and follow 
up  
27 5.6 (1.8) 5.0 (1.7) 0.054 
HBe Antigen Negative 
at baseline and follow 
up 
88 5.6 (2.3) 5.1 (2.0) 0.004 
Paired samples t-test was performed. The standard deviation is shown in the parentheses. 
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6.3.10 Change in liver stiffness at follow up according to hepatitis B viral load for the entire 
study cohort 
 
The change in LSM was analysed according to the whether HBV DNA viral load was: undetectable at 
both baseline and follow up; detectable at baseline, but undetectable at follow up; detectable at 
baseline and follow up but had either decreased, unchanged or increased; or was undetectable at 
baseline, but detectable at follow up .  
The LSM significantly declined at follow up in patients where the viral load was detectable at baseline 
and subsequently became undetectable: 6.2 (SD 2.5) kPa vs 4.8 (SD 2.2) kPa, p<0.001; or if the viral load 
decreased by at least 1log10 IU/ml: 6.1 (SD 3.1) kPa vs 5.0 (SD 2.1) kPa, p=0.020.  No significant change in 
the LSM was observed if the viral load was already undetectable at baseline and remained so at follow-
up, or if detectable at baseline, had unchanged or increased.  The findings are shown in Table 52.  
 
Table 52: Hepatitis B viral load and Liver Stiffness at baseline and follow up 
Baseline viral load 
detectable? a 
Follow up viral load 
detectable? a 
Number of 
patients 
Baseline 
LSM (kPa) 
Follow up 
LSM (kPa) 
P 
value 
N N 29 6.1 (2.4) 5.8 (1.9) 0.326 
Y N 38 6.2 (2.5) 4.8 (2.2) <0.001 
Y Y: viral load decreased b 13 6.1 (3.1) 5.0 (2.1) 0.020 
Y Y: viral load unchanged c 37 5.2 (2.0) 4.8 (1.7) 0.206 
Y Y: viral load increased b 5 5.9 (2.8) 5.5 (0.9) 0.714 
N Y 2 5.8 (0.0) 6.1 (2.4) 0.889 
a. Detectable viral load defined as > 100 IU/ml 
b. Viral load decrease and increase defined as < or > 1log10 from baseline respectively 
c. Viral load unchanged defined as <1log10 change from baseline 
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6.3.11 Cases of interest: Hepatitis B surface antigen seroconversion (2 cases) and HCC (1 
case) 
 
Only two patients during the monitoring period underwent seroconversion from surface antigen to 
surface antibody.  
Patient 1 was a 61-year-old male who at baseline was HBeAg negative, HBV DNA undetectable, ALT 19 
IU/L and LSM 9.4 kPa. He was treated with entecavir, which started four years prior. At follow up 15 
months later, his LSM was 5.6 kPa, ALT 23 IU/L and HBV DNA undetectable. 
Patient 2 was a 63-year-old male who at baseline was HBeAg negative, HBV DNA undetectable, ALT 17 
IU/L and LSM 5.7 kPa. He was treated with pegylated interferon 3 years prior to the start of the study 
period.  At 51 month follow up, his LSM was 2.6 kPa, ALT 26 IU/L and HBV DNA undetectable.  
There was only 1 patient who developed HCC during the study period. No other patients developed any 
other form of liver related morbidity (eg. varices, ascites, and hepatic encephalopathy). The patient was 
52-year-old female with a baseline LSM 8.8 kPa. A liver biopsy was performed six years prior to her 
baseline LSM which showed Metavir fibrosis stage 3. Her HBeAg was negative, ALT 32 IU/l and an 
undetectable viral load. Entecavir treatment was started at the time of her liver biopsy 6 years prior to 
the study period. During the monitoring period, she was diagnosed with locally advanced hepatocellular 
carcinoma and received transarterial chemo embolization. At 49 months follow up, her LSM was 6.4 kPa, 
ALT 33 IU/L and an undetectable HBV DNA viral load. 
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6.3.12 Summary of Results 
 
A graphical representation of the LSM decline in patients according to their clinical characteristic is 
shown in Figure 39 
• The mean LSM decline was the greatest in the following  (a, b and c in figure 36) 
o Group 2 patients (newly treated with antivirals): 7.4 (SD 3.0) kPa vs 5.9 (SD 2.5) kPa, 
p=0.009  
o Patients who experienced HBeAg seroconversion: 8.6 (SD 3.7) kPa vs 5.4 (SD 2.8) kPa, 
p=0.007. 
o Patients who had a detectable viral load at baseline which became undetectable at 
follow up: 6.2 (SD 2.5) kPa vs 4.8 (SD 2.2) kPa, p<0.001 
• The mean LSM declined minimally or not significantly at follow up for (d, e, f, g and h in figure 
36) 
o Group 1 patients (treatment naïve): 5.2 (SD 2.0) kPa vs 4.6 kPa (SD 1.4) kPa, p=0.006. 
There were 67% of subjects who had an LSM decline, and 39% who had a decline > 1 
kPa. 
o Patients with PNALT did not have a significant change in LSM: 5.3 kPa (SD 1.8) vs 5.1 kPa 
(SD 1.7), p=0.353. However 44% experienced a decline in LSM and 35% had a decline of 
> 1 kPa. 
o Group 4 patients (long term treatment started before study), however 38% experienced 
a decline, and 24% had a decline of > 1 kPa. 
o Patients whose  viral load did not change, even for those who viral load remained 
undetectable at baseline and follow up, and for those whose viral load increased (are 
you saying that if viral load went up, LSM did not change??) 
o Patients with persistently HBeAg negative: 5.6 (SD 2.3) kPa to 5.1 (SD 2.0) kPa, p=0.004. 
The parameters correlated strongest with the change in LSM at follow up were 
• HbeAg seroconversion in the overall cohort (r=0.377, p<0.001) and in the sub-cohort of group 2 
patients (r=0.668, p<0.001) 
• Change in ALT in the overall cohort (r=0.489, p<0.001) and in the sub-cohorts of group 1 
(r=0.256, p=0.027) and group 4 (r=0.455, P=0.002).  
• Duration between baseline and follow up in those who were PNALT (r=0.381, p=0.008), 
and in. group 1 (r=0.321, p=0.007)  
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Figure 39: LSM decline between baseline and follow up in patients according to clinical features 
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6.4 DISCUSSION 
 
6.4.1 Decline in LSM occurs mostly in patients with active disease who are newly treated 
with antivirals (group 2)  
 
In our study cohort, group 2 patients had the greatest reduction in LSM (1.5 kPa). This cohort of patients 
had a high baseline ALT (mean 114 IU/L) and viral load (5.2 log IU/L), and had the greatest decline in the 
mean ALT (63 IU/L decline), viral load (3 log IU/L decline) and HBeAg seroconversion rate (16% patients).  
Patients with active disease and who were treated with antiviral therapy experienced the largest 
decrease in LSM. This is associated with ALT decline, viral load suppression and HBeAg seroconversion.  
Our results differ from findings in 2 studies (334, 335). In a study of 41 patients initiated on antivirals, 
Kim et al. reported significant decline in LSM values and DNA levels, while ALT decline occurred but did 
not reach statistical significance after year 12 months (p=0.063) or 24 months (p=0.086) (334). This 
study was also limited by small numbers. Enomoto et al. also concluded there was no correlation 
between the LSM with histological inflammatory activity or rate of ALT decline in 20 CHB patients 
receiving entecavir (335). However, this was a small study, and paired biopsies were not performed and 
so strong conclusions cannot be drawn.  
Although our study did not include liver biopsy, it has the advantage of directly comparing and 
statistically correlating the change in LSM with the change in clinical parameters at follow up, which 
allowed for a rigorous analysis for whether the change in ALT was associated.  Two other studies have 
shown a relation between LSM change and ALT levels. In a study of 71 newly treated CHB patients with 
liver biopsy performed at baseline and at 48 week follow up, the main cause of LSM decline was found 
to be due to the degree of change in histological necroinflammation and ALT (336). In a study of 426 
CHB patients, a significant LSM decline was observed in patients who received antiviral therapy and had 
a decline in ALT over a 3 year follow up (333).  
The ALT level has been consistently found to affect the LSM in CHB patients. Earlier in this thesis, we 
reported that elevated ALT increases the LSM (see 5.4.3). Higher ALT tends to reflect more severe 
hepatic necroinflammation. There is an increase in inflammatory cell infiltrate and oedema in the liver, 
which causes liver stiffness to increase. This effect has been observed in other studies and shown to be 
independent of the stages of liver fibrosis (81, 280). 
 
6.4.2 Mild or not significant decline in LSM occurs in patients with quiescent disease, 
correlating strongest with time  
 
Patients who did not require antiviral treatment and were monitored (group 1 -treatment naïve), and 
patients with persistently normal ALT (PNALT) irrespective of treatment (49% were treatment naïve, 
51% on past or current treatment) predominantly had quiescent disease with minimal liver 
inflammation. These patients were mostly HBeAg negative (79-93%), had minimal decline in ALT (0- 4 
IU/L) and minimal decline in viral load (0.2-0.4 log10) over the follow up period. These cohorts had a 
mean LSM decline that was very mild (0.2-0.6 kPa), and statistically significant only for the treatment 
 238 
 
naïve (group 1) and not for those with PNALT. Although, the mean LSM decline for these subgroups was 
minimal, some individual patients experienced a marked decline, with 39% and 35% of group 1 and 
PNALT patients respectively had a marked LSM decline of > 1 kPa.  
In the PNALT group, duration between scans was the only correlating factor with the change in LSM at 
follow up. In group 1, the duration between scans had greater correlation with decline in LSM compared 
with ALT (Group 1: LSM decline correlation with duration r=0.321, p=0.007 vs correlation with ALT 
r=0.256, p=0.027). Thus the duration between scans was the most important factor for these patients.  
Fibrosis is a bidirectional dynamic process that changes with the function of time. The degree of fibrotic 
change depends not only on the degree of inflammation and tissue damage to the liver, but also on the 
duration of injury. Conversely, a longer duration with the absence of, or lesser degrees of injury and 
inflammation (as represented by ALT normalization), would expect to result in the regenerative 
capabilities of the liver enabling fibrosis regression over time.  
Fibrosis regression over time has been well demonstrated by a study that examined liver histology at 
baseline, year 1 and year 5 in CHB patients treated with tenofovir (15). At baseline, 38% of participants 
had bridging fibrosis or worse, but this proportion declined to 28% at year 1 and 12% at year 5 – see 
Figure 40. Our findings are consistent with the current understanding that liver fibrosis regresses as a 
function of time after removal of the injurious agent.   
We were able to elucidate the correlation between LSM and duration of monitoring because the follow 
up interval was not fixed unlike in other studies (333-336). It allowed us to observe that the time 
between scans was in itself a critical factor in LSM decline. Prospective studies involving serial 
measurements of the LSM at regular fixed time intervals for each patient would be useful in confirming 
the findings.    
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Figure 40: Histology results over 5-year treatment phase  
(A) Distribution of Knodell necroinflammatory scores in 348 patients with results available at each time 
point. (B) Distribution of Ishak fibrosis scores in 348 patients with baseline and year 5 data, and 344 with 
data for all three time points. (C) Histological response at year 5 according to baseline Ishak fibrosis 
scores for 348 patients with data available at baseline and year 5. (D) Change from baseline to year 5 in 
Ishak fibrosis scores for the subset of 96 patients with cirrhosis (Ishak score ≥5) at baseline; each cell 
represents an individual patients’ response. For 24 of 96 patients no changes were noted in Ishak score 
from baseline. Figure adopted from Marcellin (15) 
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6.4.3 Limitations of the study 
 
This study is limited by the lack of comparison to liver biopsy.  LSM decline in patients with persistently 
normal ALT was presumed to reflect fibrosis regression. This is a reasonable assumption, but without 
liver histology, the findings should be interpreted with care.  
The study was also limited by the relatively mild liver disease of the study cohort, with low baseline LSM 
in the study population so that there is very little room for further decline. This may be the reason why a 
significant decline in LSM was not observed for patients who were on long-term NAs (group 4). The 
greatest reduction in LSM occurred in those with active disease requiring antiviral therapy (group 2). 
Presumably, group 4 patients have already experienced biochemical resolution and viral suppression at 
some stage prior to the study, similar to what group 2 patients experienced during the study period. 
Hence they may have already undergone most of the potential decline in LSM, thus resulting in the 
minimal improvement observed during the study.  
Another consequence of the study population having low baseline LSM meant that LREs were less likely 
to occur. Subsequently, there was only one incident case of HCC, and no other liver related morbidities 
in the patients during the study period. Conclusions about the prognostic significance of the severity of 
the LSM could not be drawn. 
There is a paucity of literature regarding the LSM for patients who obtain favorable clinical end points. 
Unfortunately, small study numbers prevented any generalisations about the change of the LSM in 
patients who experienced HBsAg loss (only 2 cases) and patients who achieved a durable response on 
finite antiviral therapy (group 3 – only 5 cases).  
The study examines a retrospective cohort vulnerable to selection bias. Not all chronic hepatitis B 
patients seen in the outpatient clinic had Fibroscan routinely performed. At the time of the study, the 
role of Fibroscan had not been completely defined for chronic hepatitis B, and variation in the clinical 
application of Fibroscan existed between clinicians. One of the perceived uses of Fibroscan is that it is 
more sensitive in diagnosing compensated cirrhosis that is otherwise not clinically apparent. Patients 
with obvious clinical features of decompensation would therefore not be scanned, based on the 
perception that clinical management would not be any different since cirrhosis is already established. 
This perception lead to cases of overt cirrhosis being excluded, causing a selection bias and probably 
contributed to our study population overall having low baseline LSM scores. Other issues related to the 
retrospective aspects of the study include patients who received an initial Fibroscan were often not 
available for a follow up scan, and clinical data often being incomplete.   
This study is the first to describe the correlation between LSM change and length of time in CHB patients 
with quiescent disease. There is very little data regarding longitudinal LSM monitoring in the treatment 
of chronic hepatitis B patients. Fibroscans were performed with a high rate of reliability and validity. This 
also is the first longitudinal study of Fibroscan in Australian CHB patients.  
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6.4.4 Future directions and the case for LSM to be a stand-alone marker 
 
Our results demonstrate the difficulty in determining whether LSM changes reflected more of fibrosis or 
inflammation. LSM is influenced by the combination of these factors over the function of time. Our data 
is unable to objectively quantify to what degree changes in the LSM reflect change in fibrosis or change 
in the level of inflammatory activity.  
The importance of showing LSM change to be reflective of fibrosis is because the fibrosis stage is 
traditionally perceived as being one of the most important prognostic indicators in CHB (259, 332). 
Further prospective studies with serial liver biopsies compared with LSM may be able to shed more light 
on this subject. However, large studies involving liver biopsies are difficult to perform. The poor 
correlation of LSM decline with fibrosis regression demonstrated by Wong et al (336) from the 48 week 
study of paired liver biopsies in 71 CHB patients also suggests larger long term studies may not be 
worthwhile.    
A possible better use of the LSM is to perceive it as a stand-alone variable that indicates disease 
severity. We have demonstrated that the decline in LSM is correlated with decline in ALT, HBeAg 
seroconversion, HBeAg negativity and viral suppression of which each has been shown to be important 
in prognosis (260). Perhaps rather than being strictly thought of as a marker for fibrosis, the LSM may be 
used more meaningfully if that by itself has prognostic implications?  
There is a strong rationale for attempting to demonstrate the LSM has use as a standalone variable 
when considering the problems with using it as an indicator for fibrosis stage as highlighted in chapter 
5.4.  In brief, histological staging of fibrosis is subject to error from sampling and interobserver 
variability. Furthermore, histological stage is not a proportionate correlation to fibrosis quantity as each 
stage represents a morphologic description of the distribution of fibrosis. The correlation with liver 
stiffness, which presumably measures extracellular matrix components that determine fibrosis quantity, 
is therefore an imperfect comparison. LSM probably correlates better to a quantifiable marker of liver 
fibrosis, such as the collagen proportion area (CPA) – see discussion in 5.4.11. 
Other studies have already shifted the focus of TE towards prediction of LREs such as HCC (326, 337), 
and thus there is a growing recognition that TE actually has additional use beyond being limited to 
measuring the classical end point of liver fibrosis, in which the role is to simply lessen the need for liver 
biopsy. We attempted to further evaluate the roles of TE in the prediction of long-term disease 
prognosis. However, the low incidence of HBsAg seroconversion, low numbers of patients who 
experienced a durable response after finite antiviral treatment and low numbers of LREs (discussed in 
6.4.3) prevented meaningful generalisations to be made from our findings on this aspect. Further 
longitudinal studies that correlate long term outcomes with the LSM cut-offs, while comparing it against 
currently used clinical parameters and prognostic scoring systems (eg Childs Pugh Score, MELD score) 
will help determine the usefulness of LSM as a standalone marker that has prognostic significance.  
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6.5 CONCLUSION 
 
CHB patients, who have active disease and subsequently treated with antivirals, have the greatest 
decline in LSM. This is associated with ALT normalization, HBeAg seroconversion and viral suppression.  
CHB patients who do not require antiviral treatment and/or who have persistently normal ALT 
irrespective of treatment, have a mild or non-significant decline in LSM. The LSM change is most strongly 
correlated with length of time and may suggest fibrosis regression.  
It is difficult to attribute to what extent the degree of LSM decline is reflective of a reduction in 
inflammation versus fibrosis regression. The LSM may not be an ideal tool to monitor fibrosis regression. 
Future studies on the use of the LSM should focus on its potential in being a prognostic tool for liver 
related morbidity and mortality. 
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CHAPTER 7:   ASSESSMENT OF LIVER FIBROSIS 
USING TRANSIENT ELASTOGRAPHY AND 
ASPARTATE AMINOTRANSFERASE PLATELET 
RATIO IN PATIENTS TREATED WITH 
METHOTREXATE FOR CHRONIC INFLAMMATORY 
DISEASE   
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7.0 CHAPTER SUMMARY 
 
Background: Long term use of methotrexate is considered a risk factor for liver fibrosis. Most of this 
observation is based on small biopsy series. Guidelines suggest close monitoring and liver biopsy when 
cumulative doses of 1.0-4.0g are reached (338, 339). The emergence of non-invasive modalities in the 
evaluation of liver fibrosis have allowed further assessment, and so far do not demonstrate  correlation 
with cumulative methotrexate dose. Using Transient Elastography (TE), we sought that to determine the 
relationship between liver fibrosis and methotrexate dose, and to identify any other factors associated 
with fibrosis. We also compared to liver stiffness measurement (LSM) between patients on 
methotrexate and healthy controls who were not taking methotrexate. 
Methods: Patients who had been on methotrexate therapy for at least 6 months were recruited 
consecutively from outpatient clinics. Total cumulative dose of methotrexate and other relevant data 
was recorded. Transient Elastography was performed as per the manufacturer’s instructions. At least 10 
successful measurements were required for a valid Liver Stiffness Measurement (LSM). A reliable scan 
was defined by having an interquartile range to median ratio of ≤ 30% if the LSM≥7.1 kPa. The LSM 
cutoff of ≥ 7.1 kPa was used to define Metavir F≥2 from the landmark study by Foucher (see 1.9) (84). 
Results: Thirty nine patients on long term methotrexate therapy were recruited. LSM identified 7/39 
cases of F≥2 (17.9%). No correlation was found between LSM and methotrexate cumulative dose 
(r=0.044, p=0.394) or duration of treatment (r=0.018, p=0.457). There was no difference in the mean 
LSM of patients who had taken a cumulative dose of methotrexate < 1.5g compared with ≥ 1.5g: 5.0 (SD 
1.5) kPa vs 6.4 (SD  4.5) kPa, p=0.214; or <4.0g compared with ≥4.0g: 5.9 (SD 2.3) kPa vs 6.7 (SD 5.9) kPa, 
p=0.618. Independent predictors of LSM included albumin (r = -0.350, p=0.014) and platelet count (r= -
0.357, p=0.013). The LSM cutoff indicative F≥2 was significantly associated with BMI≥30: LR 4.442, 
p=0.029. No difference was found in the mean LSM of methotrexate subjects and a matched population:  
6.3 (SD 4.2) kPa vs 4.8 (SD 1.3) kPa, p=0.090.  
Conclusions: In this cohort of 39 patients on at least 6 months of methotrexate therapy, dose and 
duration were not associated with liver stiffness. The only independent predictors of LSM were lower 
albumin, lower platelet counts and BMI>30. LSM was not increased in methotrexate subjects when 
compared to controls. Fibroscan appears to be a useful tool in monitoring long term methotrexate 
induced liver fibrosis. Longitudinal studies with in larger numbers that can account for intercurrent 
chronic liver disease are needed to further evaluate the risk of fibrosis and the exact role of TE.    
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7.1 BACKGROUND and AIMS 
7.1.1 Introduction 
 
Methotrexate is a folate antimetabolite that inhibits DNA synthesis, repair, and cellular replication. 
Methotrexate irreversibly binds to dihydrofolate reductase, inhibiting the formation of reduced folates, 
and thymidylate synthetase. Purine and thymidylic acid synthesis are blocked, resulting in cellular 
replication halting in the S phase (340). This medication has been used for over 40 years as an oncologic 
therapy, and for the treatment of other pathologies, mainly in chronic inflammatory diseases such as 
rheumatoid arthritis, juvenile polyarthritis, corticoid-dependent asthma, severe cases of psoriasis, and 
inflammatory bowel disease (IBD).  
 
7.1.2 Evidence of methotrexate-induced hepatotoxicity and guidelines for monitoring 
 
Hepatotoxicity is well recognized adverse effect of methotrexate. Liver histological changes that occur 
include steatosis, cellular hypertrophy, anisonucleosis, and liver fibrosis (341). The exact mechanism of 
injury remains poorly understood (342).  Concomitant folate supplementation has been shown to 
reduce the incidence of abnormal transaminases, but folate depletion has never been directly 
demonstrated in hepatotoxicity (343).  
Studies from the 1970s reported high rates of liver fibrosis (up to 50%) and cirrhosis (up to 25.6%) in 
psoriasis patients on long term methotrexate, which appeared to be associated with higher cumulative 
doses (2, 3). Hence, early dermatology guidelines recommended a liver biopsy at a cumulative dose of 
1.5 g and then for every additional 1g (2). Although methotrexate had been observed to cause ALT and 
AST abnormalities when used in high doses for oncologic conditions (344), liver biochemistry was not 
recommended in these early guidelines. These early dermatological guidelines however, were drawn 
from studies that were limited by a lack of longitudinal data and proper controls for hepatotoxins such 
as alcohol, vitamin A and arsenic (5). 
Longitudinal data on methotrexate hepatotoxicity became available when its use became popularized 
for treating inflammatory arthropathies. AST levels were reported to be predictive of liver fibrosis in 
rheumatoid arthritis (345, 346) and subsequent rheumatology guidelines suggested dose reduction 
according to AST levels. A liver biopsy was recommended if there was persistent elevation or if there 
were other risk factors for liver disease (347). In contrast, dermatological society guidelines 
recommended biopsies without monitoring of liver biochemistry.  However, the data in which these 
recommendations were based had limitations as there were only small studies that did not account for 
alcohol consumption.  
More recent data suggests that methotrexate hepatotoxicity is less prevalent than was previously 
thought. A retrospective study of 125 patients who had a liver biopsy and who had taken a median 
cumulative dose of 2.1g found only 4% of subjects developed moderate fibrosis or cirrhosis (4). Fibrosis 
was not related to cumulative dose, but was associated with diabetes and obesity.  
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In response to new data and the growing recognition of the limitations of early studies (5), the latest 
guidelines from the National (US) Psoriasis foundation (339) have recommended adoption of some 
aspects of the monitoring protocol of the American College of Rheumatology (338), which is traditionally 
less stringent and do not advocate liver biopsies as routine practice.  
Patients who are at high risk (ie. pre-existing liver disease), the National Psoriasis foundation still 
recommends liver biopsy performed at the beginning of methotrexate therapy, and then a repeat biopsy 
for every additional cumulative dose of 1.0-1.5 g (339).  
For low risk patients, the National Psoriasis foundation suggests monitoring as per the American College 
of Rheumatology guidelines. Monitoring is recommended every 1 month during the first year of 
treatment, and then every 1-3 months.  A liver biopsy is recommended when there is a persistent 
elevation in transaminases or if there are any clinical or biochemical signs of decompensated liver 
disease.  When a cumulative dose of 3.5 - 4.0g is reached and patients remain asymptomatic with 
normal biochemistry, the following 3 options are recommended: (a) return to monthly clinical 
monitoring, (b) liver biopsy or (c) switch to alternate therapy (338).  
 
7.1.3 Recent studies of methotrexate-induced hepatotoxicity using transient elastography  
 
There has been increased research in methotrexate induced liver fibrosis with the availability of 
Transient Elastography (TE), as previously studies were limited by the need for liver biopsy to accurately 
assess liver fibrosis. In studies using TE, long-term methotrexate use has been reported to have a 
prevalence of advanced fibrosis of 4.4 - 8.5% (89, 90, 348-350), which is much lower than early biopsy 
studies and more in line with recent biopsy studies (4). The other common finding is that liver stiffness 
was not correlated with the cumulative dose of methotrexate, but instead associated with risk factors 
for metabolic syndrome, suggesting liver injury is caused by concomitant nonalcoholic fatty liver disease 
(NAFLD). 
 
7.1.4 Hypothesis and specific objectives 
 
The main hypothesis is that the moderate fibrosis as determined by the LSM is not associated with the 
cumulative dose of methotrexate consumed, but with risk factors for NAFLD such as type II diabetes and 
obesity. The specific objectives are: 
1. To determine whether the relationship between LSM and methotrexate dose and duration 
2. To identify those with moderate fibrosis F≥2 and determine the factors associated, specifically 
examining the relationship with cumulative doses of methotrexate greater than 1.5g and 4.0g 
that have been implicated in guidelines.  
3. To compare the LSM of patients on methotrexate with a matched control group  
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7.2 METHODS 
 
7.2.1 Patient Selection and data collection 
 
Patients treated with methotrexate long term and attending the Rheumatology outpatient clinic at 
Concord Repatriation Hospital (Concord Sydney, Australia) and private specialist rooms were identified. 
Criteria for recruitment included: age older than 18yrs, minimum 6 months of methotrexate treatment, 
and no previously documented history of liver disease. All patients gave informed written consent. A 
total of 46 patients were enrolled from July 2009 to October 2009. 
Clinical Assessment was performed using a standardized questionnaire. Age, gender, height, weight, 
BMI, methotrexate cumulative dose, indication for methotrexate, other anti-inflammatory and immune-
modulating therapy (steroids, leflunomide, sulphasalazine, cyclosporine, and abatacept), alcohol intake, 
presence of co-morbid liver disease and other co-morbid medical history was recorded.  
Recent laboratory data (within 2 weeks) in relation to the date of the patient having a Fibroscan was 
recorded. These were: bilirubin (BR), alkaline phosphatase (ALP), gamma-glutamyl transpeptidase (GGT), 
alanine aminotransferase (ALT), aspartate aminotransferase (AST), albumin (ALB), and platelet count.  
Controls were recruited from healthy volunteers (staff and accompanying persons with patients) who 
were not taking methotrexate.  After matching for age, sex, height, weight, body mass index (BMI) and 
weekly alcohol intake, 28 controls were included in the analysis.  
 
7.2.2 Liver Stiffness assessment 
 
The performance of the Fibroscan has been described in detail earlier in this thesis (refer to section 1.7). 
In brief, scans were taken on the right lobe of the liver. The probe is placed in the intercostal space along 
the axillary line with the subject lying supine and the right arm at maximum abduction. A minimum of 
ten successful measurements was required, with the median score taken as the LSM. The success rate is 
the percentage of successful scans out of total number of attempts. The LSM is expressed in kilopascals 
(kPa). The LSM was considered reliable if the interquartile range/median ratio (IQR/M ratio) was less 
than 30% when the result is ≥ 7.1 kPa (55). All scans were performed by trained operators.     
The LSM cut-off values used for moderate fibrosis (F≥2) was ≥ 7.1 kPa (sensitivity 67%, specificity 89%), 
and for cirrhosis (F=4) ≥ 17.6 kPa (sensitivity 87%, specificity 91%). These were derived from the 
landmark study by Foucher et al (84), which has been described previously in section 1.9.   
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7.2.3 Sample size determination 
The null hypothesis (H0) is that the mean LSM of healthy controls (µc) is lower compared to the mean 
LSM of patients on long term methotrexate (µm) by a clinically significant amount (d).  
That is:  
H0: µc + d ≤ µm 
The mean LSM in healthy controls in our study was found to be 4.8 kPa and standard deviation 1.3 kPa 
(see Table 58). The LSM cut-off for F1 was 6.5 kPa in chronic hepatitis B patients from our earlier studies 
(see Table 23).  Extrapolating LSM cut-offs is unavoidable as there is no literature for LSM cut-offs for 
methotrexate induced liver fibrosis. Thus, the mean LSM of methotrexate patients would need to be at 
least 6.5 kPa to be a clinically significant difference. The difference (d) would therefore need to be 1.7 
kPa.  
Based on these assumptions, if there truly is no difference between the control group and methotrexate 
group, a total sample size of 16 subjects (8 in each cohort) will be required to achieve 80% power with a 
95% confidence interval.   
 
7.2.4 Statistical analysis 
 
Statistical analysis was performed using the Statistical package for Social Sciences (SPSS) version 21.0. 
Continuous variables were expressed as the mean (standard deviation) where appropriate. Scale 
variables between groups were compared using Independent samples T-test. Categorical variables were 
compared using the chi-square test.  
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7.3 RESULTS 
 
7.3.1 Transient Elastography assessment in the methotrexate cohort 
Forty six subjects were recruited into the study. Clinical records were incomplete for 3 subjects and so 
43 subjects had TE attempted. A valid TE was unable to be obtained in 4 subjects which left 39/43 
(90.7%) for the final analysis. Reliable scans were obtained in 37/39 (94.8%). The mean liver stiffness for 
the methotrexate group was 6.3 kPa (SD 4.2). T There were 7/39 (17.9%) and 1/39 (2.6%) subjects with 
LSM cut-offs predictive of moderate fibrosis and cirrhosis respectively. The results are summarised in 
Table 53.  
 
Table 53: Transient Elastrography results of methotrexate subjects 
Valid Liver Stiffness Measurement 39/43 subjects (90.7%) 
Reliable Liver Stiffness Measurement 37/39 subjects (94.8%) 
Liver Stiffness (kPa) 6.3 (4.3) 
Interquartile range/Median ratio 0.27 (0.15) 
Success rate (%) 76.4 (24.0) 
Subjects (n) LSM ≥ 7.1 kPa 7/39 subjects (17.9%) 
Subjects (n) LSM ≥ 17.6 kPa 1/39 subjects (2.6%) 
Values represent the mean with standard deviation in parentheses unless otherwise indicated 
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7.3.2 Clinical and anthropometric characteristics of the methotrexate study population 
 
Females comprised 27/39 (69.2%) of total methotrexate group subjects. The mean age was 59.0 (SD 
10.5) yrs, mean alcohol intake 30.8 (SD 55.6) g/week and mean BMI 27.9 (SD 6.2) kg/m2. The mean 
methotrexate treatment duration was 5.9 (SD 3.4) yrs, while the mean methotrexate cumulative dose 
was 5.3 (SD 3.5) g. The indication for methotrexate was rheumatoid arthritis for 30/39 (76.9%), psoriasis 
5/39 (12.8%) and other inflammatory arthropathies in remaining 4/39 (10.3%) subjects. Rheumatoid 
factor was found in 21/39 (53.8%). Use of other disease modifying anti-rheumatoid drugs and NSAIDs 
are described in Table 54.  The means of the liver biochemistry and platelet count were within normal 
range. Diabetes was present in 3/39 (7.7%) of subjects.  The results are summarised in Table 54. 
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Table 54: Anthropometric and clinical characteristics of study subjects 
 
  
Anthropometric and clinical characteristics of study subjects 
Female 27/39 (69.2%) 
Age 59.0 (10.5) 
Alcohol (grams/week) 30.9 (51.6) 
Height (m) 1.65(0.10) 
Weight (kg) 75.8 (19.4) 
BMI (kgm-2) 27.85 (6.17) 
Methotrexate Duration (yrs) 5.95 (3.39) 
Methotrexate cumulative dose (g) 5.29 (3.48) 
Indication for Methotrexate  Rheumatoid Arthritis 30/39 (76.9%)  
 Psoriasis 5/39 (12.8%) 
 Other inflammatory arthropathy 4/39 (10.3%) 
Rheumatoid Factor 21/39 (53.8%)   
Other DMARDS/anti-inflammatory agents  Prednisone 15/39 (38.5%) 
 Leflonomide 5/39 (12.8%) 
 NSAIDS 17/39 (43.6%) 
 Anti-TNF alpha 4/39 (10.3%) 
 Hydroxychloroquine 6/39 (15.4%) 
 Sulphasalazine 4/35 (10.3%) 
 Cyclosporine 1/39 (2.6%) 
 Intramuscular Gold 1/39 (2.6%) 
 Abatacept 2/39 (5.1%) 
Bilirubin (umol/L) 
9 (4) 
 
Albumin (g/L) 44 (3) 
Alkaline Phosphatase (IU/L) 83 (21) 
Gamma Glutamyl Transpeptidase (IU/L) 36 (39) 
Alanine Aminotransferase (IU/L) 
30 (14) 
 
Aspartate Aminotransferase (IU/L) 26 (9) 
Platelet count (x10^9/L) 262 (59) 
Type II Diabetes 3/39 (7.7%) 
Values represent the mean with standard deviation in parentheses except where there is a “/” which represents number of 
cases/total cases with percentage in parentheses. 
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7.3.3 Relationship between methotrexate and liver stiffness  
 
A scatterplot diagram was plotted for liver stiffness compared to the cumulative dose of methotrexate 
(Figure 41), and the duration of methotrexate treatment (Figure 42). Logical regression performed for 
liver stiffness found no significant correlation to methotrexate cumulative dose (r=0.044, p=0.394) and 
duration of treatment (r=0.018, p=0.457). There was no significant difference in the mean liver stiffness 
of those who had taken a cumulative dose of methotrexate < 1.5g compared with ≥ 1.5g:  5.0 (SD 1.5) 
kPa vs 6.4 (SD 4.5) kPa, p=0.214; or < 4.0g compared with ≥ 4.0g: 5.9 (SD 2.3) kPa vs 6.7 (SD 5.9) kPa, 
p=0.618. 
 
Figure 41: Scatterplot of methotrexate cumulative dose and liver stiffness with a line of best fit 
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Figure 42: Scatterplot of methotrexate treatment duration and liver stiffness with a line of best fit 
  
 255 
 
7.3.4 Relationship between Liver Stiffness and other clinical variables 
 
The relationship between liver stiffness and other clinical variables apart from methotrexate was 
examined. Continuous variables were correlated against the LSM. Categorical variables; the mean LSM 
of each level within the category was compared.  Multivariate analysis of the continuous variables 
showed significant correlations with albumin (r = -0.350, p=0.014) and platelet count (r= -0.357, 
p=0.013), see Table 55. Age was significantly associated in univariate analysis, but not in multivariate 
analysis. No significant differences were found in the mean LSM between the levels for each categorical 
factor that was examined – see Table 56. 
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Table 55: Correlation of continuous variables with liver stiffness 
  
 Correlation coefficient (r)  P-value 
Age 0.283 0.041b 
Alcohol (grams/week) -0.073 0.330 
BMI (kgm-2) 0.064 0.349 
Methotrexate Duration (yrs) -0.018 0.457 
Methotrexate cumulative dose (g) -0.044 0.394 
Bilirubin (umol/L) 0.007 0.484 
Albumin (g/L) -0.350 0.014a 
Alkaline Phosphatase (IU/L) -0.061 0.357 
Gamma Glutamyl Transpeptidase (IU/L) 0.053 0.374 
Alanine Aminotransferase (IU/L) 0.044 0.396 
Aspartate Aminotransferase (IU/L) 0.076 0.323 
Platelet count (x10^9/L) -0.357 0.013a 
a. ALB and PLT significant after multivariate analysis 
b. Age was not significant in multivariate analysis 
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Table 56: Comparison of Categorical Variables and Liver Stiffness 
Variable N Liver Stiffness (kpa) a p-value 
Gender Male 12 7.9 (6.6) 0.262 
 Female 27 5.6 (2.5)  
Methotrexate 
Cumulative Dose (g) 
< 1.5 4 5.0 (1.5) 0.214 
 > 1.5 35 6.4 (4.5)  
Methotrexate 
Cumulative Dose (g) 
> 4.0 21 5.9 (2.3) 0.618 
 < 4.0 18 6.7 (5.9)  
Rheumatoid Factor  Positive 21 5.4 (1.8) 0.174 
 Negative 18 7.3 (5.9)  
Type II Diabetes? Yes 3 12.5 (13.5) 0.478 
 No 36 5.8 (2.4)  
Known Liver Disease? Yes 4 11.2 (11.2) 0.401 
 No 35 5.7 (2.5)  
Prednisone Yes 15 5.4 (2.1) 0.236 
 No 24 6.8 (5.2)  
Leflonomide Yes 5 5.2 (2.0) 0.325 
 No 34 6.4 (4.5)  
NSAIDs Yes 17 6.2 (3.0) 0.900 
 No 22 6.4 (5.1)  
Anti-TNF alpha agent Yes 4 8.0 (4.3) 0.404b 
 No 35 6.1 (4.3)  
Hydroxychloroquine Yes 6 4.7 (1.2) 0.052 
 No 33 6.6 (4.6)  
Sulphasalazine Yes 4 6.2 (2.0) 0.959 
 No 35 6.3 (4.5)  
Cyclosporine Yes 1 9.8 0.412 
 No 38 6.2 (4.3)  
Intramuscular Gold Yes 1 6.8 0.904 
 No 38 6.3 (4.3)  
Abatacept Yes 2 5.1 (0.4) 0.124 
 No 37 6.3 (4.3)  
BMI (kgm2) <25 14/39 6.9 (6.5) N/Ac 
 25-30 13/39 4.6 (1.0)  
 >30 12/39 7.3 (2.8)  
Methotrexate 
Indication 
Psoriasis 5/39 11.4 (10.2) N/Ac 
 Rheumatoid 
Arthritis 
30/39 5.6 (2.0)  
 Other 
Inflammatory 
Arthropathy 
4/39 5.2 (1.6)  
a. Mean LSM with standard deviation in parentheses. 
b. Independent sample T-tests performed for all variables with 2 levels. Equal variances were not 
assumed except anti-tnf alpha agent  
c. One way ANOVA attempted for BMI and Methotrexate indication. Tests of homogeneity failed and so 
p-value cannot be interpreted.  
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7.3.5 Characteristics of subjects with LSM ≥ 7.1 kPa (indicative of moderate fibrosis) 
 
The characteristics of subjects with LSM ≥ 7.1 kPa were compared in those with LSM < 7.1 kPa. This cut-
off was chosen to be indicative of moderate fibrosis as discussed in section 7.2.2.  BMI ≥ 30 was the only 
significantly associated variable in subjects with an LSM ≥ 7.1 kPa. The corresponding likelihood ratio 
(LR) of having an LSM ≥ 7.1 kPa when the BMI≥ 30 compared to BMI < 30 was:  4.442 (p=0.029). No 
other characteristic, including the methotrexate cumulative dose and duration, was found to increase 
the likelihood of having LSM ≥ 7.1 kPa – see Table 57. 
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Table 57: Comparison of variables for LSM <7.1kpa and LSM ≥7.1kpa 
 
LSM <7.1 kPa 
Mean (SD) 
LSM≥7.1 kPa 
Mean (SD) 
P value 
Scale Variablesab    
Age 58.3 (10.7) 61.8 (9.9) 0.413 
Methotrexate Duration (yrs) 5.7 (3.5) 7.0 (3.1)  0.331 
Methotrexate cumulative dose (g) 4.842 (3.396) 6.822 (3.565) 0.154 
Alcohol (grams/week) 33.4 (56.6) 21.3 (24.2) 0.560 
BMI (kgm-2) 27.7 (6.2) 28.5 (6.3) 0.762 
Bilirubin (µmol/L) 8 (4) 10 (5) 0.268 
Albumin (g/L) 45 (3) 43 (4) 0.207 
Alkaline Phosphatase (IU/L) 83 (23) 84 (14) 0.938 
Gamma Glutamyl Transpeptidase (IU/L) 37 (44) 30 (13) 0.638 
Alanine Aminotransferase (IU/L) 29 (14) 34 (15) 0.346 
Aspartate Aminotransferase (IU/L) 25 (9) 28 (6) 0.384 
Platelet count (x10^9/L) 271 (57) 227 (57) 0.063 
 LSM <7.1 kPa LSM ≥ 7.1 kPa P value 
Categorical Variablesab N cases (%)  N cases (%)  
Gender (male) 8/31 (25.8%) 4/8 (50%) 0.186 
Type II Diabetes 2/31 (6.5%) 1/8 (12.5%) 0.567 
BMI ≥25 20/31 (64.5%) 5/8 (62.5%) 0.916 
BMI ≥30 
 
7/31 (22.6%) 
 
5/8 (62.5%) 0.029  
LRd 4.442 
BMI ≥35 4/31 (12.9%) 1/8 (12.5%) 0.976 
Rheumatoid factor 18/31 (58.1%) 3/8 (37.5%) 0.298 
Methotrexate Indicationc    
Rheumatoid Arthritis 25/31 (80.6%) 5/8 (62.5%) 0.476 
Psoriasis 3/31 (9.7%) 2/8 (25.0%)  
Other Inflammatory Arthropathy 3/31 (9.7%) 1/8 (12.5%)  
Prednisone 13/31 (41.9%) 2/8 (25.0%) 0.380 
Leflonomide 4/31 (12.9%) 1/8 (12.5%) 0.976 
NSAIDS 12/31 (38.7%) 5/8 (62.5%) 0.226 
Anti-TNF alpha agent 3/31 (9.7%) 1/8 (12.5%) 0.815 
Hydroxychloroquine 6/31 (19.4%) 0/8 (0%) 0.176 
Sulphasalazine 3/31 (9.7%) 1/8 (12.5%) 0.815 
Cyclosporine 0/31 (0%) 1/8 (12.5%) 0.205  
Intramuscular Gold 1/31 (3.2%) 0/8 (0%) 0.795 
Abatacept  2/31 (6.5%) 0/8 (0%) 0.628 
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a. Independent T-test applied for scale variables, while Chi-square and Fisher’s tests applied to 
categorical variables 
b. Values reported for scale variables represent the mean and standard deviation in parentheses. 
Values reported for categorical variables are proportions with percentages in parentheses.  
c. Chi Square statistic was applied across all levels within the categorical variable of Methotrexate 
indication and BMI. Null hypothesis being no difference in proportion of moderate fibrosis across 
all levels.  
d. Likelihood ratio of having Moderate Fibrosis if BMI > 30.  
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7.3.6 Comparison of LSM between methotrexate subjects and matched controls 
 
Methotrexate were compared with controls matched for gender, age, alcohol use and BMI (see Table 
58). There was no significant difference between methotrexate subjects and controls for mean LSM: 6.3 
(SD 4.2) kPa vs 4.8 (SD 1.3) kPa, p=0.090; or frequency of LSM ≥ 7.1 kPa (7/39 subjects vs 1/28, p=0.126). 
There was also no difference in the mean IQR/median ratio, proportion of reliable scans, proportion of 
valid scans, number of valid scans obtained or the mean scan success rate (see Table 58).   
  
 262 
 
Table 58: Comparison of between methotrexate and control subjects 
 
 
Compared variables Methotrexate  Control P- value 
Subjects 39 28  
Women 27 (69.2%) 16 (57.1%) 0.448 
Age (yrs) 59.0 (10.5) 55.0 (12.5) 0.165 
ETOH(g/wk) 30.9 (51.6) 24.5 (57.6) 0.633 
BMI kgm-2 27.9 (6.2) 27.6 (6.4) 0.897 
LSM (kpa) 6.3 (4.3) 4.8 (1.3) 0.090 
LSM≥7.1kpa (F≥2)  7/39 (17.9%) 1/28 (3.6%) 0.126 
IQR/M ratio 0.27 (0.15) 0.25 (0.15) 0.589 
Reliable scans 37/39 (94.5%) 28/28 (100%) 0.506 
Total Valid scans 10.9 (3.0) 11.3 (4.2) 0.589 
Success Rate (%) 76.4 (24.0) 69.1 (30.6) 0.277 
Independent T tests applied to scale variables while Fisher’s exact test applied to categorical variables.  
Values represent the mean for scale variables with standard deviation in parentheses and proportions 
for categorical variables with percentages In parentheses.  
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7.3.7 Summary of main findings 
 
• No correlation was found in subject’s LSM and methotrexate cumulative dose (r=0.044, 
p=0.394) or duration of methotrexate treatment (r=0.018, p=0.457) 
• No difference was found in the mean LSM of patients who had taken a cumulative dose 
methotrexate < 1.5g vs ≥ 1.5g: 5.0 (SD 1.5) kPa vs 6.4 (SD 4.5) kPa, p=0.214 
• No difference was found in the mean LSM of patients who had taken a cumulative dose 
methotrexate  <4.0g vs ≥ 4.0g: 5.9 (SD 2.3) kPa vs 6.7 (SD 5.9) kPa, p=0.618 
• LSM identified 7/39 cases (17.9%) of LSM ≥7.1 kPa – the chosen cut-off to indicate moderate 
fibrosis 
• An LSM≥7.1 kPa was significantly associated with BMI≥30: LR 4.442, p=0.029. Albumin (r = -
0.350, p=0.014) and platelet count (r= -0.357, p=0.013) were also independent predictors of 
LSM 
• No difference in the mean LSM of methotrexate subjects and matched controls:  6.3 (SD 4.2) kPa 
vs 4.8 (SD 1.3) kPa, p=0.090.  
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7.4 DISCUSSION 
 
7.4.1 BMI ≥ 30 kgm-2 is associated with LSM ≥7.1 kPa, but not methotrexate duration or dose. 
 
In our study there was no evidence of any association between the LSM and the methotrexate cumulative 
dose or treatment duration. Instead an LSM ≥7.1 kPa (cut-off chosen for Metavir F2) was associated with 
BMI ≥30 kgm-2 (LR 4.44, p=0.029). The LSM being associated with obesity rather than methotrexate 
suggests the predominant aetiology for liver stiffness is more likely to be NAFLD in this particular study 
population.  
Similar findings have been reported in recent studies that have assessed the LSM in methotrexate subjects.  
The largest study to date investigated 518 patients treated with methotrexate for a variety of chronic 
inflammatory conditions. Advanced liver fibrosis (determined by Fibroscan or Fibrotest) was not 
associated with methotrexate dose or length of treatment duration, but was predicted by BMI > 28 and 
excessive alcohol consumption (350). Three smaller studies of 46, 53 and 54 patients also found no 
association with methotrexate dose and liver stiffness (90, 348, 349).  In these cohorts, a total of 7 subjects 
were found to have significant fibrosis, in which 4 were attributed to morbid obesity and alcohol abuse 
(348, 349).   
Furthermore, a liver biopsy study of 125 patients who had taken a median cumulative dose of 2.1g 
methotrexate reported that fibrosis was not related to cumulative dose, but diabetes and obesity (4). Our 
data and recent literature consistently indicate that fibrosis is unrelated to the methotrexate dose, and 
that metabolic syndrome risk factors are more important.  
In our study, liver stiffness was also correlated by lower albumin levels and platelet count.  The capability 
for diagnosing LSM≥7.1 kPa was further explored in a side analysis (not shown in results). The platelet 
count AUROC= 0.750 (95% CI 0.549-0.951, p=0.031) while for albumin, results were not statistically 
significant. The best sensitivity and specificity for predicting LSM≥7.1 kPa was 74.2% and 87.5%, at a 
platelet level of 253 x 109/L. This moderate level of accuracy is unsurprising, as it is well recognized that 
lower platelet levels can indicate progressive liver damage, but not at a high enough accuracy as a stand-
alone marker. Hence the frequent inclusion of platelet count in combination with other markers as part 
of fibrosis predicting panels, such as the FIB4-I, APRI and API which have been discussed in earlier chapters.  
 
7.4.2 The prevalence of fibrosis in methotrexate patients is lower in recent studies 
 
Earlier studies had suggested rates of fibrosis up to 50% and cirrhosis up to 26% (2).  Our study results 
show that LSM ≥ 7.1 kPa (cut-off for Metavir F2) occurred in 17.9%, while LSM ≥ 17.6 kPa (cut-off for 
Metavir F4) occurred in 2.6% of the study population. Other studies using Fibroscan or Fibrotest have 
shown similar prevalence rates. The rate of moderate fibrosis or worse (Metavir F≥2), advanced fibrosis 
or worse (Metavir F≥3), and cirrhosis (Metavir F4) have been reported to be 17.4%, 6.5-8.5% and 0-2.1% 
respectively (90, 348-350). In studies that assessed liver biopsy, moderate fibrosis and cirrhosis were each 
described in only 2% of patients (4).   
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Furthermore there have also been studies that have compared the prevalence of fibrosis amongst patients 
with chronic inflammatory disorders who are on methotrexate treatment versus methotrexate naïve. The 
largest study which comprised of 518 patients with a variety of chronic inflammatory conditions, reported 
no difference in the median LSM between cases and controls (350). Another study of 54 patients with 
Crohn’s disease also found no difference in the median LSM (90).   
Overall, these results suggest that methotrexate is associated with a low risk for developing fibrosis. It 
would appear that early studies probably overestimated the prevalence of liver fibrosis in methotrexate 
users. Experts have increasingly recognized that early studies lacked proper controls for hepatotoxins such 
as alcohol and pre-existing liver disease (5, 351), lending support to the findings in more recent studies. 
We reported the comparison of the LSM between methotrexate subjects and population controls who 
were not on methotrexate. By showing that the mean LSM and the rate of Metavir F≥2 (as determined by 
LSM ≥ 7.1 kPa) is no different to healthy controls, this raises the question of whether methotrexate really 
is a significant risk factor for liver fibrosis at all. Possibly, a more appropriate comparison would be to 
assess the prevalence in methotrexate users against the general population. While the rate of fibrosis in 
the general population is unknown, the rate of cirrhosis is estimated to be at 0.8% (352). Our data and 
other recent studies so far indicate the rate of cirrhosis in methotrexate users is around 2%, which is in 
contrast with early studies reporting rates of up to 26% (2). 
The pathological features of methotrexate induced liver toxicity have been described to closely resemble 
NASH (353). While it is suggested that methotrexate aggravates pre-existing NASH (338, 354), this is based 
on expert opinion and has not been substantiated with data. There is a possibility that the observation of 
liver fibrosis in methotrexate is coincidental, and is actually mostly due to NAFLD because it is so common 
(95, 133). Further prospective studies would be helpful in evaluating this area.  
 
7.4.3 Cautious interpretation of results, implications for guidelines and use of Fibroscan in 
monitoring methotrexate patients  
 
The findings in our study should be interpreted with caution due to the small size of the study population 
limiting generalizability. In addition, although in population controls the age, gender, BMI and alcohol 
intake were adequately controlled, NALFD was not able to be directly assessed and controlled for. The 
Fibroscan model at the time of the study had yet to feature the CAP score for diagnosing steatosis, and 
other forms of imaging such as ultrasound was available for only a few subjects. The exclusion of chronic 
viral hepatitis and other liver disease was based on clinical history and medical records alone, as the 
relevant confirmatory laboratory tests were unavailable. However, it is unlikely this last issue led to any 
significant impact on the findings as the prevalence of these conditions combined is estimated be only 
2.5% in the local population (113-115). Another criticism may be that Fibroscan has yet to be widely 
validated by liver biopsy for its use in methotrexate induced liver fibrosis. One study assessed the accuracy 
of Fibroscan against liver biopsy in 24 methotrexate patients, and reported that the ≥ 7.1 kPa cut-off had 
88% specificity for identifying F≥2 (89). This suggests extrapolating the cut-offs from the landmark study 
by Foucher et al (84) is a reasonable strategy.  
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Current guidelines maintain very careful and strict recommendations regarding the monitoring of 
hepatotoxicity. Until there are rigorous longitudinal studies that assess liver fibrosis pre and post 
methotrexate treatment, it is remains prudent to adopt a vigilant approach. Such studies must account 
comprehensively for intercurrent liver diseases.   
Lastly, in this study Fibroscan was demonstrated to be feasible for the assessment of liver stiffness in 
methotrexate patients, with valid measurements obtained in 90.7%, and reliable measurements in 94.8% 
of subjects.   The reliability, reasonable accuracy, high acceptance and noninvasive nature of Fibroscan 
suggest that it can be used in place of liver biopsy when monitoring for hepatic fibrosis in long term users 
of methotrexate. This may also allow for more frequent monitoring of hepatic fibrosis where repeated 
liver biopsy is undesirable. In cases where liver biopsy is contraindicated, Fibroscan is likely to be a 
sufficient alternative.  
 
  
7.5 CONCLUSION 
 
In long-term users of methotrexate, dose and duration are not associated with liver stiffness. 
Cumulative doses of 1.5g and 4.0g, where current guidelines suggest liver biopsy, was not associated 
with a high LSM indicative of F≥2. Instead obese range BMI was found to be a risk factor for high LSM. 
The rate of F≥2 and F4 (as assessed with Fibroscan) are lower than reports from early studies, and 
consistent with more recent data. The mean LSM in methotrexate treated patients was no different to 
healthy population controls who were not on methotrexate. Further studies that adequately account for 
NAFLD and other liver diseases are required to accurately establish the risk of developing methotrexate 
induced fibrosis.  
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GENERAL CONCLUSION 
 
The goals of research were to further explore the clinical utility of transient elastography, targeting the 
liver disease populations which had a paucity of literature at the time. These were patients with NAFLD, 
chronic hepatitis B and long term users of methotrexate.    
In a pilot study, we established that a significant proportion of diabetes patients had high liver stiffness 
suggestive of advanced fibrosis. However, the usefulness of TE was somewhat limited because of the 
high rate of invalid or unreliable scans in obese patients. Our review and meta-analysis confirmed the 
accuracy and widespread validation of using TE to assess fibrosis in NAFLD, and that the XL probe 
ameliorates concerns over its usefulness in obese patients.  Thus we proceeded to examine a much 
larger group of diabetes patients. TE was performed validly and reliably in 98.2% of 1918 diabetes 
patients using the M or XL probes. NAFLD was diagnosed in 72.7% using the CAP, and advanced fibrosis 
was found in 17.7% using indicative LSM cut-offs. Diabetic patients with high BMI and dyslipidaemia 
were at particularly high risk. Our data supports liver assessment to be incorporated as part of routine 
screening for complications in diabetes patients.     
We demonstrated that TE is an accurate and reliable noninvasive tool for assessing fibrosis stage in 
chronic hepatitis B. TE especially has excellent accuracy for advanced fibrosis and cirrhosis, and is 
superior to FIB 4, APRI, AAR, API and FI. Our results are consistent with more recent validation studies. 
Different LSM cut-offs have been reported because of variability in study populations. This can make 
deciding which LSM cut-offs to apply in the local setting difficult.  Our study on local CHB patients was 
thus able to provide LSM cut-offs that would most accurately reflect and can be applied in our local 
patient population.  TE is most rationally applied by determining high and low cut-offs that can “rule in” 
or “rule out” fibrosis with very high degree of specificity or sensitivity respectively. Higher LSM cut-offs 
for high ALT patients are needed to maintain the accuracy of TE. Our study showed that by incorporating 
TE into the assessment of CHB patients, liver biopsy can be avoided in the majority of patients.  
Two distinct patterns of LSM decline in CHB patients were described in our 31 month longitudinal study. 
Patients with active disease and subsequently treated with antivirals have the largest decline in LSM, 
while those with quiescent disease have only a mild or negligible decline in LSM. ALT normalization, 
HBeAg seroconversion and viral suppression are important factors that are associated with LSM decline 
in those with active disease. Hence the level of inflammatory activity has a strong influence on the LSM 
in those with active disease.  In those with quiescent disease, length of time is the most important 
influence to LSM decline. A longer period of time allows for the regenerative ability of the liver to 
regress fibrosis to a greater capacity. Hence, LSM decline may be more reflective of fibrosis regression in 
patients with quiescent CHB infection.   
Performing TE in long term methotrexate users revealed that cumulative dose and duration are not 
associated with liver fibrosis. The dose thresholds of 1.5g and 4.0g whereby liver biopsy is 
recommended were not found to be associated, but instead, obese BMI was the only risk factor. The 
rate of moderate fibrosis and cirrhosis is low, which contrasts with early studies, but consistent with 
recent data. The mean LSM is not significantly different in methotrexate users compared population 
controls. The risk of liver fibrosis in methotrexate users is likely to be low and may not be much higher 
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than non-methotrexate users from the general population. More studies that assess the pre and post 
methotrexate liver fibrosis are required to clarify this issue further.  
One of the recurrent discussion themes was the potential use of the LSM as a standalone marker.  There 
are a number of problems with using the LSM to assess fibrosis stage.  Liver biopsy has several 
limitations, one of which is interobserver variability. This was demonstrated by our findings of 44% 
biopsies being staged differently upon a second assessment. The variability in histological assessment 
subsequently limits evaluation of the diagnostic accuracy of TE and any other non-invasive markers that 
are compared against liver biopsy. Furthermore, fibrosis stage is a morphological description of the 
distribution of fibrosis. Evaluating it against the liver stiffness, which best reflects fibrosis quantity, is an 
awkward comparison.  
Thus LSM may be better considered as a standalone variable, but it needs to have prognostic value. We 
attempted to correlate the LSM in chronic hepatitis B patients with important clinical outcomes such as 
HbsAg loss and cirrhotic complications. Due to small study numbers and relative infrequency of these 
events, we were not able to make any useful generalisations. The future of Fibroscan will be to 
determine the prognostic significance of the LSM values. Our large study of diabetes patients in chapter 
4 was only the report of the baseline assessment. Prospective follow-up is planned for another 10 years. 
The prognostic implications of liver stiffness measurement will be unraveled in the near future.   
In conclusion, transient elastography is a valuable tool for the noninvasive diagnosis of fibrosis in 
nonalcoholic fatty liver disease, chronic hepatitis B and liver fibrosis in patients who use methotrexate.  
We showed that TE has a high level of diagnostic accuracy for CHB in our validation study and for NAFLD 
in our meta-analysis. CAP and TE are useful for screening NAFLD and advanced fibrosis in diabetes 
patients. TE is useful for establishing the baseline level of fibrosis and may also be a useful marker in the 
monitoring the progress of CHB patients. As long-term study results become available, the LSM may be 
considered a standalone variable that has prognostic implications rather than simply being an 
estimation of the fibrosis stage.  
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